Objection Deadline: September 14, 2021 @ 12:00 p.m. (ET)

UNITED STATES BANKRUPTCY COURT FOR THE SOUTHERN DISTRICT OF NEW YORK

In re:	Chapter 11
PURDUE PHARMA L.P., et al., 1	Case No. 19-23649 (RDD)
Debtors.	(Jointly Administered)

TWENTY-THIRD MONTHLY FEE STATEMENT OF ALIXPARTNERS, LLP, FINANCIAL ADVISOR TO THE CHAPTER 11 DEBTORS, FOR ALLOWANCE OF COMPENSATION FOR PROFESSIONAL SERVICES RENDERED AND REIMBURSEMENT OF EXPENSES FOR THE PERIOD OF JULY 1, 2021 THROUGH JULY 31, 2021

Name of Applicant:	ALIXPARTNERS, LLP			
Applicant's Role in Case:	Financial Advisor to the Chapter 11 Debtors			
Date Order of Employment Signed:	November 21, 2019 [Docket No. 528], Nunc Pro Tunc September 15, 2019			
Time named account by this statement.	Beginning of Period	End of Period		
Time period covered by this statement:	July 1, 2021	July 31, 2021		
Summary of Total	Fees and Expenses Requested:			
Total fees requested in this statement:	\$1,068,913.20 (80% of \$1,336,14	11.50)		
Total expenses requested in this statement:	\$64,512.00			
Total fees and expenses requested in this statement: \$1,133,425.20				
This is a(n): X Monthly Application Interim Application Final Application				

The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

ALIXPARTNERS, LLP

SUMMARY OF HOURS AND FEES BY PROFESSIONAL FOR THE PERIOD JULY 1, 2021 THROUGH JULY 31, 2021 ESSIONAL TITLE RATE HOURS

PROFESSIONAL	TITLE	RATE	HOURS	FEES
Lisa Donahue	Managing Director	\$1,295	8.7	\$ 11,266.50
Richard Collura	Managing Director	\$1,125	50.6	56,925.00
Jesse DelConte	Managing Director	\$1,055	133.7	141,053.50
Mark F Rule	Director	\$980	62.7	61,446.00
Kevin M McCafferty	Director	\$980	189.9	186,102.00
Joon H Hyun	Director	\$980	173.9	170,422.00
Gabe J Koch	Director	\$865	113.7	98,350.50
Jamey Hamilton	Director	\$865	14.4	12,456.00
Nate P Janysek	Director	\$865	9.2	7,958.00
HS Bhattal	Director	\$865	150.1	129,836.50
Sam K Lemack	Senior Vice President	\$665	174.0	115,710.00
Charles C Nweke	Vice President	\$650	163.5	106,275.00
Julia Gutierrez	Vice President	\$625	6.0	3,750.00
Andrew D DePalma	Vice President	\$625	193.7	121,062.50
Lan T Nguyen	Vice President	\$530	176.2	93,386.00
Julia Caitlin Hardy	Vice President	\$530	8.7	4,611.00
Tammy Brewer	Vice President	\$465	1.1	511.50
Lisa Marie Bonito	Associate	\$465	32.3	15,019.50
Total Professional Hou	rs and Fees		1,662.4	\$ 1,336,141.50
Less 20% Holdback				(267,228.30)
Total Professional Fees	3			\$ 1,068,913.20
		Averag	ge Billing Rate	\$ 803.74

ALIXPARTNERS, LLP

SUMMARY OF HOURS AND FEES BY MATTER CATEGORY FOR THE PERIOD JULY 1, 2021 THROUGH JULY 31, 2021

CODE	MATTER CATEGORY HOURS			FEES
101	Chapter 11 Process/Case Management	77.6	\$	60,954.50
103	Cash Management	60.8	34,730.50	
104	Communication with Interested Parties	90.7		66,454.50
105	U.S. Trustee / Court Reporting Requirements	58.9		34,560.50
106	Business Analysis & Operations	268.8		218,108.00
107	POR Development	240.4		215,636.50
108	Executory Contracts	86.7		60,340.50
109	Claims Process	3.7		2,577.50
110	Special Projects	665.7		552,384.50
113	Fee Statements and Fee Applications	43.5		26,186.50
114	Court Hearings	4.0		3,840.00
115	Forensic Analysis	61.6		60,368.00
	Total Hours and Professional Fees by Matter Category	1,662.4	\$ 1	,336,141.50
	Averag	e Billing Rate	\$	803.74

ALIXPARTNERS, LLP

SUMMARY OF EXPENSES FOR THE PERIOD JULY 1, 2021 THROUGH JULY 31, 2021

EXPENSE CATEGORY	<u> </u>	EXPENSE		
Hosting Fees (GB)	\$	64,512.00		
Total	\$	64,512.00		

AlixPartners, LLP ("AlixPartners"), as financial advisor to the Debtors, hereby submits this twenty-third monthly fee statement seeking compensation for professional services rendered and reimbursement of out-of-pocket expenses for the period July 1, 2021 through July 31, 2021 (the "Compensation Period"), pursuant to the *Order Establishing Procedures For Interim Compensation and Reimbursement of Expenses for Retained Professionals* [Docket No. 529] and the *Order Authorizing Debtors to Retain and Employ AlixPartners, LLP as its Financial Advisor Nunc Pro Tunc to the September 16, 2019* [Docket No. 528].

Detailed time descriptions of the services performed by each professional, organized by discrete project and by day is attached hereto as **Exhibit A**. Exhibit A (a) identifies the individuals that rendered services in each subject matter; (b) describes each activity or service that each individual performed; and (c) states the number of hours (in tenths of an hour) spent by each individual providing the services during the Compensation Period.

A detailed analysis of the out-of-pocket expenses showing the amount incurred by each professional in each expense category by day is attached hereto as **Exhibit B**.

[Remainder of page intentionally left blank.]

19-23649-shl Doc 3730 Filed 09/02/21 Entered 09/02/21 21:49:51 Main Document

Pg 6 of 157

WHEREFORE, AlixPartners respectfully requests that it be granted an allowance of

compensation for professional services rendered during the Compensation Period in the amount

of \$1,336,141.50, without prejudice to a final allowance of compensation, plus reimbursement of

out-of-pocket expenses incurred in the amount of \$64,512.00, and that the Court grant

AlixPartners such other and further relief as is just and proper. Pursuant to the Interim

Compensation Order, AlixPartners seeks payment of professional fees in the amount of

\$1,068,913.20 (80% of \$1,336,141.50) and expenses in the amount of \$64,512.00, for a total

amount of \$1,133,425.20.

Dated: August 31, 2021

ALIXPARTNERS, LLP 909 Third Avenue, 28th Floor New York, NY 10022

/s/ Lisa Donahue

By: Lisa Donahue Managing Director

Exhibit A

AlixPartners, LLP

Detailed Description of AlixPartners' Fees and Hours by Matter Category

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Chapter 11 Process/Case Management Re:

Date	Consultant	Description of Services	Hours
07/01/21	SKL	Participate in meeting with D. McGuire, D. Fogel, R. Aleali, K. McCarthy, S. Hoffman, Z. Haseeb, J. Doyle, M. Kroese, J. Northington, B. Evans, V. Manicinelli (all Purdue), W. McConagha, M. Florence, J. Bragg (all Skadden) and G. Koch (AlixPartners) to discuss FDA talking points re: inventory sell-through process.	1.20
07/01/21	SKL	Meeting with R. Aleali, K. McCarthy, Z. Haseeb (all Purdue), C. Robertson, E. Turay, A. Lele (all Davis Polk) and G. Koch (AlixPartners) re: change of control/transfer work plan update.	0.50
07/01/21	SKL	Finalize updates to the weekly change of control PMO tracker and prepare updated agenda for today's weekly update meeting.	2.20
07/01/21	SKL	Continue to review latest feedback provided re: change of control process, and update transfer work plans and PMO tracker accordingly.	1.20
07/01/21	GJK	Update and coordinate on weekly change of control working group call.	0.50
07/01/21	GJK	Participate in meeting with D. McGuire, D. Fogel, R. Aleali, K. McCarthy, S. Hoffman, Z. Haseeb, J. Doyle, M. Kroese, J. Northington, B. Evans, V. Manicinelli (all Purdue), W. McConagha, M. Florence, J. Bragg (all Skadden) and S. Lemack (AlixPartners) to discuss FDA talking points re: inventory sell-through process.	1.20
07/01/21	GJK	Meeting with R. Aleali, K. McCarthy, Z. Haseeb (all Purdue), C. Robertson, E. Turay, A. Lele (all Davis Polk) and S. Lemack (AlixPartners) re: change of control/transfer work plan update.	0.50
07/01/21	GJK	Review ongoing change of control workstream priorities.	0.70
07/06/21	SKL	Finalize updates to the weekly change of control PMO tracker and prepare updated agenda for tomorrow's	2.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Chapter 11 Process/Case Management Re:

Date	Consultant	Description of Services weekly update meeting.	Hours
07/06/21	LJD	Call with C. Robertson (Davis Polk), J.Turner, J.Arsic, R.Schnitzler, T. Melvin (all PJT), L.Donahue, H. Bhattal, J.DelConte (both AlixPartners) re: update and planning.	0.50
07/06/21	JD	Call with C. Robertson (Davis Polk), J.Turner, J.Arsic, R.Schnitzler, T. Melvin (all PJT), L.Donahue, H. Bhattal, J.DelConte (both AlixPartners) re: update and planning.	0.50
07/06/21	HSB	Call with C. Robertson (Davis Polk), J.Turner, J.Arsic, R.Schnitzler, T. Melvin (all PJT), L.Donahue, H. Bhattal, J.DelConte (both AlixPartners) re: update and planning.	0.50
07/07/21	JD	Create agenda for weekly call with advisors and management tomorrow.	0.30
07/07/21	SKL	Prepare additional updates to the PMO tracker based on the latest feedback received and circulate accordingly for today's change of control update call.	1.40
07/07/21	SKL	Finalize updates to the latest consolidated contract listing and circulate to the IP working group following our weekly update call.	0.50
07/07/21	SKL	Call with C. Robertson (Davis Polk), J. DelConte, S. Lemack, H. Bhattal (all AlixPartners), J. Lowne, S. Daniel, J. Lauriat, C. Russo (all Purdue) re: contract rejection and assumption.	0.80
07/07/21	SKL	Weekly change of control/transfer work plan update meeting with R. Aleali (Purdue), K. McCarthy (Purdue), Z. Haseeb (Purdue), C. Robertson (Davis Polk), E. Turay (Davis Polk) and A. Lele (Davis Polk).	0.70
07/07/21	SKL	Call with G. Koch (AlixPartners) to discuss updated PMO tracker and change of control process.	0.10
07/07/21	SKL	Meeting with J. Doyle, B. Koch, R. Krappel, R. Inz, K. McCarthy, Z. Haseeb and S. Hoffman (all Purdue) to	1.00

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Chapter 11 Process/Case Management Re:

Date	Consultant	Description of Services	Hours
		discuss the IP transfer work plan	
07/07/21	GJK	Call with S. Lemack (AlixPartners) to discuss updated PMO tracker and change of control process.	0.10
07/07/21	GJK	Review change of control updates for IP, FDA, IT.	1.70
07/07/21	GJK	Update and coordinate on weekly Change of Control call.	0.40
07/08/21	GJK	Call with M.Kesselman, J.Lowne, R.Aleali (all Purdue), C. Robertson, A.Libby (Davis Polk), J.Turner, J.Arsic, R.Schnitzler, T. Melvin (all PJT), J.DelConte, G.Koch (both AlixPartners) re: update and planning.	0.80
07/08/21	GJK	Call with S. Lemack(AlixPartners) to touch base on the latest updates re: change of control process.	0.30
07/08/21	SKL	Call with G. Koch (AlixPartners) to touch base on the latest updates re: change of control process.	0.30
07/08/21	JD	Participate in weekly update call with C. Landau, M. Kesselman, R. Aleali, J. Lowne (all Purdue), C. Robertson, E. Vonnegut, W. Taylor (all Davis Polk), J. O'Connell, J. Turner, T. Melvin, J. Arsic (all PJT), J. DelConte, H. Bhattal G. Koch (all AlixPartners) re: weekly update and planning call.	0.80
07/08/21	HSB	Call with M.Kesselman, J.Lowne, R.Aleali (all Purdue), C. Robertson, A.Libby (Davis Polk), J.Turner, J.Arsic, R.Schnitzler, T. Melvin (all PJT), J.DelConte, G.Koch (both AlixPartners) re: update and planning.	0.80
07/09/21	HSB	Prepare agenda and list of open items for discussion prior to meeting with Purdue advisory team	0.50
07/09/21	HSB	Call with J.DelConte, K.McCafferty G.Koch, S.Lemack, A.DePalma, L.Nguyen (all AlixPartners) re: weekly update	0.60
07/09/21	LTN	Weekly team update call with J. DelConte, K. McCafferty, H. Bhattal, G. Koch, A. DePalma, S. Lemack, L. Nguyen (all AlixPartners)	0.60

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Chapter 11 Process/Case Management Re:

Date	Consultant	Description of Services	Hours
07/09/21	JD	Call with J.DelConte, K.McCafferty G.Koch, S.Lemack, A.DePalma, L.Nguyen (all AlixPartners) re: weekly update	0.60
07/09/21	KM	Weekly team update call with J. DelConte, K. McCafferty, H. Bhattal, G. Koch, A. DePalma, S. Lemack, L. Nguyen (all AlixPartners)	0.60
07/09/21	ADD	Weekly team update call with J. DelConte, K. McCafferty, H. Bhattal, G. Koch, A. DePalma, S. Lemack, L. Nguyen (all AlixPartners)	0.60
07/09/21	SKL	Call with J. DelConte, K. McCafferty, H. Bhattal, A. DePalma, G. Koch, S. Lemack, L. Nguyen, (all AlixPartners) re: weekly team update call.	0.60
07/09/21	SKL	Call with G. Koch (AlixPartners) to discuss latest updates re: change of control process.	0.10
07/09/21	GJK	Call with S. Lemack (AlixPartners) to discuss latest updates re: change of control process.	0.10
07/09/21	GJK	Weekly team update call with J. DelConte, K. McCafferty, H. Bhattal, G. Koch, A. DePalma, S. Lemack, L. Nguyen (all AlixPartners)	0.60
07/12/21	SKL	Call with G. Koch (AlixPartners) to touch base on the latest updates re: change of control process.	0.40
07/12/21	SKL	Meeting with H. Ghnaimeh, K. McCarthy, S. Hoffman and Z. Haseeb (all Purdue) to discuss latest IT transfer work plan and provide/receive update accordingly.	0.70
07/12/21	SKL	Meeting with J. Doyle, D. Fogel, K. McCarthy, R. Aleali, S. Hoffman, Z. Haseeb, B. Evans, J. Northington, M. Krosse (all Purdue), J. Bragg (Skadden), B. McConagha (Skadden), M. Florence (Skadden) to discuss latest inventory sell-through talking points and FDA process.	1.00
07/12/21	SKL	Review latest notes and feedback provided on the IT transfer work plan and began making updates to the	1.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Chapter 11 Process/Case Management Re:

Date	Consultant	Description of Services	Hours
		upcoming IT meeting accordingly.	
07/12/21	GJK	Call with S Lemack (AlixPartners) to discuss change of control process workstream.	0.40
07/13/21	SKL	Review latest notes and feedback provided on the change of control workstream and prepare updated PMO tracker and weekly agenda accordingly.	2.50
07/13/21	SKL	Review latest notes and feedback from today's weekly update call and circulate updates notes and action items accordingly for this week.	0.80
07/13/21	SKL	Weekly IP change of control update meeting with K. McCarthy, Z. Haseeb, S. Hoffman, R. Inz, B. Koch, J. Doyle, R. Kreppel (all Purdue).	0.50
07/13/21	SKL	Multiple calls with H. Bhattal (AlixPartners) to discuss plan matters.	0.40
07/13/21	SKL	Weekly change of control/transfer work plan update meeting with R. Aleali (Purdue), K. McCarthy (Purdue), Z. Haseeb (Purdue), C. Robertson (Davis Polk), E. Turay (Davis Polk), and A. Lele (Davis Polk).	0.50
07/13/21	JD	Participate in weekly professionals catch up meeting with J. O'Connell, J. Turner, T. Melvin (all PJT), E. Vonnegut, C. Robertson, W. Taylor (all Davis Polk), J. DelConte, H. Bhattal (both AlixPartners).	0.40
07/13/21	HSB	Call with E.Vonnegut, C. Robertson, W.Taylor (all Davis Polk), J.Turner, J.Arsic, R.Schnitzler, T. Melvin (all PJT), J.DelConte (AlixPartners) re: update and planning.	0.40
07/16/21	HSB	Call with L.Donahue, G.Koch, H. Bhattal, S.Lemack, A.DePalma, L.Nguyen (all AlixPartners) re: weekly update	0.50
07/16/21	HSB	Prepare agenda and list of open items for discussion prior to meeting with Purdue advisory team	0.60
07/16/21	LTN	Call with L.Donahue, G.Koch, H. Bhattal, S.Lemack,	0.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Chapter 11 Process/Case Management Re:

Date	Consultant	Description of Services	Hours
		A.DePalma, L.Nguyen (all AlixPartners) re: weekly update	
07/16/21	ADD	Call with L.Donahue, G.Koch, H. Bhattal, S.Lemack, A.DePalma, L.Nguyen (all AlixPartners) re: weekly update	0.50
07/16/21	SKL	Call with Z. Haseeb (Purdue) and G. Koch (AlixPartners) to discuss latest employee change of control questions.	0.50
07/16/21	SKL	Call with L.Donahue, G.Koch, H. Bhattal, S.Lemack, A.DePalma, L.Nguyen (all AlixPartners) re: weekly update	0.50
07/16/21	SKL	Meeting with Z. Haseeb (Purdue) and G. Koch (AlixPartners) to discuss employee matters open items.	0.50
07/16/21	LJD	Call with L.Donahue, G.Koch, H. Bhattal, S.Lemack, A.DePalma, L.Nguyen (all AlixPartners) re: weekly update	0.50
07/16/21	GJK	Review change of control planning and open items following discussion with S Lemack (AlixPartners).	1.30
07/16/21	GJK	Call with Z Haseeb (Purdue) and S Lemack (AlixPartners) to walk through employee resources questions.	0.50
07/16/21	GJK	Call with L.Donahue, G.Koch, H. Bhattal, S.Lemack, A.DePalma, L.Nguyen (all AlixPartners) re: weekly update	0.50
07/16/21	GJK	Call with Z. Haseeb (Purdue) and S. Lemack (AlixPartners) to discuss latest employee change of control questions.	0.50
07/18/21	GJK	Review IT Agreement Chart from B Trost (Davis Polk).	0.20
07/19/21	SKL	Weekly IT catch-up meeting with H. Ghnaimeh, K. McCarthy, Z. Haseeb and S. Hoffman (all Purdue).	0.40
07/20/21	SKL	Meeting with H. Bhattal (AlixPartners) to discuss plan related matters.	0.10
07/20/21	SKL	Review latest notes and feedback provided by the change of control subgroups and prepare updated PMO tracker accordingly.	2.30
07/20/21	SKL	Call with A. DePalma (AlixPartners) to discuss latest	0.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Chapter 11 Process/Case Management Re:

Date	Consultant	Description of Services	Hours
		diligence request and next steps.	
07/20/21	SKL	Weekly change of control/transfer work plan update meeting with R. Aleali (Purdue), K. McCarthy (Purdue), Z. Haseeb (Purdue), C. Robertson (Davis Polk), E. Turay (Davis Polk), and A. Lele (Davis Polk).	0.60
07/20/21	LJD	Prepare for weekly meeting with advisors, PJT and Davis Polk	0.30
07/20/21	SKL	Call with Purdue Legal, Davis Polk and G. Koch (AlixPartners) to update and coordinate on weekly change of control call.	0.50
07/20/21	GJK	Follow-up on open change of control issues from working team call.	0.40
07/20/21	GJK	Call with Purdue Legal, Davis Polk and S. Lemack (AlixPartners) to update and coordinate on weekly change of control call.	0.50
07/20/21	GJK	Prepare for contract and change of control discussions.	0.80
07/20/21	JD	Call with M. Huebner, C. Robertson, E. Vonnegut, A. Libby (all Davis Polk), J. DelConte, H. Bhattal (all AlixPartners), J. O'Connell, T. Melvin, J. Turner, R. Schnitzler (all PJT) re: weekly professionals catch up and planning call.	0.40
07/20/21	HSB	Call with M.Huebner, E.Vonnegut, C. Robertson, W.Taylor (all Davis Polk), J.Turner, J.Arsic, R.Schnitzler, T. Melvin (all PJT), J.DelConte (AlixPartners) re: update and planning.	0.40
07/21/21	JD	Prepare agenda for biweekly call with management and advisors tomorrow.	0.30
07/21/21	GJK	Review current status of change of control work streams.	1.30
07/21/21	GJK	Calls with S Lemack (AlixPartners) to coordinate on change of control process.	0.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Chapter 11 Process/Case Management Re:

Date	Consultant	Description of Services	Hours
07/21/21	GJK	Weekly IP change of control update meeting with S. Lemack (AlixPartners) K. McCarthy, Z. Haseeb, S. Hoffman, R. Inz, B. Koch, J. Doyle, (all Purdue).	0.50
07/21/21	SKL	Weekly IP change of control update meeting with G. Koch (AlixPartners) K. McCarthy, Z. Haseeb, S. Hoffman, R. Inz, B. Koch, J. Doyle, (all Purdue).	0.50
07/21/21	SKL	Call with A. DePalma (AlixPartners) to discuss latest diligence request and next steps.	0.20
07/21/21	SKL	Call with H. Bhattal (AlixPartners) to discuss plan related matters.	0.40
07/21/21	SKL	Review latest feedback and notes provided by Purdue IP and prepare updated agenda and talking points accordingly.	0.60
07/21/21	SKL	Calls with G. Koch (AlixPartners) to provide update on the change of control process and discuss open items.	0.40
07/21/21	SKL	Meeting with C. Robertson and S. Brecher (both Davis Polk) to discuss latest Ceridian questionnaire.	0.30
07/22/21	SKL	Meeting with Z. Haseeb (Purdue), C. Robertson (Davis Polk), S. Brecher (Davis Polk) and G. Koch (AlixPartners) to discuss latest Ceridian questionnaire.	0.30
07/22/21	SKL	Meeting with G. Koch (AlixPartners) to debrief following employee change of control call.	0.10
07/22/21	LJD	Participate in weekly call with J. Lowne, M. Kesselman, R. Aleali (all Purdue), J. O'Connell, J. Turner, T. Melvin (all PJT), J. DelConte, H. Bhattal, L. Donahue (all AlixPartners), M. Huebner, C. Robertson, E. Vonnegut, A. Libby (all Davis Polk) re: catch up and go forward planning.	1.10
07/22/21	GJK	Meeting with Z. Haseeb (Purdue), C. Robertson (Davis Polk), S. Brecher (Davis Polk) and S. Lemack	0.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Chapter 11 Process/Case Management Re:

Date	Consultant	Description of Services	Hours
		(AlixPartners) to discuss latest Ceridian questionnaire.	
07/22/21	GJK	Call with S Lemack to discuss change of control process.	0.10
07/22/21	GJK	Review change of control deck and potential updates for AHC advisors.	0.60
07/22/21	JD	Participate in weekly call with J. Lowne, M. Kesselman, R. Aleali (all Purdue), J. O'Connell, J. Turner, T. Melvin (all PJT), J. DelConte, H. Bhattal, L. Donahue (all AlixPartners), M. Huebner, C. Robertson, E. Vonnegut, A. Libby (all Davis Polk) re: catch up and go forward planning.	1.10
07/22/21	HSB	Call with M.Kesselman, J.Lowne, R.Aleali (all Purdue), M.Huebner, C. Robertson, A.Libby (Davis Polk), J.Turner, J.Arsic, R.Schnitzler, T. Melvin (all PJT), L.Donahue, J.DelConte (AlixPartners) re: update and planning.	1.10
07/23/21	GJK	Call with S Lemack (AlixPartners) to discuss change of control planning.	0.10
07/23/21	GJK	Review potential transition issues in emergence.	1.40
07/23/21	SKL	Calls with G. Koch (AlixPartners) to provide update on the change of control process and discuss open items.	0.10
07/23/21	SKL	Meeting with R. Aleali, L. Kusinski, K. Laurel, C. DeStefano, D. Cabral, Z. Haseeb (all Purdue), C. Robertson (Davis Polk) and S. Brecher (Davis Polk) to discuss open questions from Ceridian.	1.00
07/27/21	SKL	Update Project Change Intralinks exchange with new Davis Polk users and update access.	0.30
07/27/21	SKL	Weekly change of control/transfer work plan update meeting with R. Aleali (Purdue), K. McCarthy (Purdue), Z. Haseeb (Purdue), C. Robertson (Davis Polk), E. Turay (Davis Polk), and A. Lele (Davis Polk).	0.80
07/27/21	SKL	Meeting with K. McCarthy, J. Doyle, R. Kreppel, B. Koch,	0.80

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Chapter 11 Process/Case Management Re:

Date	Consultant	Description of Services	Hours
		R. Inz, S. Hoffman and Z. Hasseb (all Purdue) to discuss latest updates re: the IP change of control process.	
07/27/21	SKL	Review latest notes and feedback provided by the change of control subgroups and prepare updated PMO tracker accordingly.	2.40
07/27/21	SKL	Call with C. Robertson (Davis Polk) to discuss latest change of control IP items and questions related to contract assumptions.	0.20
07/27/21	SKL	Multiple calls with A. DePalma (AlixPartners) to discuss various case related matters.	0.20
07/27/21	SKL	Review latest Project Change inquiry provided by Davis Polk and update Intralinks site accordingly.	0.40
07/27/21	SKL	Review latest updates to the IP transfer workplan and prepare updates accordingly prior to IP change of control call.	0.90
07/27/21	SKL	Call with G. Koch (AlixPartners) to discuss the change of control process.	0.10
07/27/21	GJK	Call with S Lemack (AlixPartners) re: change of control employee matters and working group call.	0.10
07/27/21	GJK	Review change of control working group PMO tracker.	0.20
07/27/21	ADD	Multiple calls with S. Lemack (AlixPartners) to discuss various case related matters.	0.20
07/28/21	SKL	Multiple calls & working session to discuss Purdue due diligence related analysis with H. Bhattal (AlixPartners).	2.00
07/29/21	HSB	Call with H. Bhattal, L. Nguyen (AlixPartners) re: new MOR format update	0.20
07/29/21	JD	Call with M. Kesselman, C. Landau, J. Lowne, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), J.	0.60

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Chapter 11 Process/Case Management Re:

Date Cons	Description of Services DelConte, G. Koch, H. Bhattal (all AlixPartners) re: weekly catch up and planning call.	Hours
07/30/21 JD	Call with L. Donahue, J. DelConte, H. Bhattal, A. DePalma, G. Koch, S. Lemack, L. Nguyen, (all AlixPartners) re: weekly team update call.	0.80
07/30/21 KM	Call with H. Bhattal, J. DelConte, A. DePalma, G. Koch, S. Lemack, K. McCafferty, L. Nguyen (all AlixPartners) re: weekly team update call.	0.80
07/30/21 HSB	Call with H. Bhattal, L. Nguyen (AlixPartners) re: new MOR format update	0.10
07/30/21 HSB	Call with L. Donahue, J. DelConte, H. Bhattal, A. DePalma, G. Koch, S. Lemack, L. Nguyen, (all AlixPartners) re: weekly team update call.	0.80
07/30/21 HSB	Prepared agenda and list of open items for team meeting in connection with various Purdue plan related items	0.40
07/30/21 SKL	Call with L. Donahue, J. DelConte, H. Bhattal, A. DePalma, G. Koch, S. Lemack, L. Nguyen, (all AlixPartners) re: weekly team update call.	0.80
07/30/21 LJD	Weekly team update call with J. DelConte, H. Bhattal, G. Koch, L. Donahue, K. McCafferty, S. Lemack, L. Nguyen (all AlixPartners)	0.80
07/30/21 GJK	Call with L. Donahue, J. DelConte, H. Bhattal, A. DePalma, G. Koch, S. Lemack, L. Nguyen, (all AlixPartners) re: weekly team update call.	0.80
07/30/21 LTN	Weekly team update call with J. DelConte, H. Bhattal, G. Koch, L. Donahue, K. McCafferty, S. Lemack, L. Nguyen (all AlixPartners)	0.80
	Total	77.60

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Chapter 11 Process/Case Management

Client/Matter # 012589.00101

Fee Recap:

Consultant	Hours	Rate	Amount
Lan T Nguyen	1.90	530.00	1,007.00
Andrew D DePalma	1.30	625.00	812.50
Sam K Lemack	39.30	665.00	26,134.50
HS Bhattal	6.90	865.00	5,968.50
Gabe J Koch	17.80	865.00	15,397.00
Kevin M McCafferty	1.40	980.00	1,372.00
Jesse DelConte	5.80	1,055.00	6,119.00
Lisa Donahue	3.20	1,295.00	4,144.00
Total Hours & Fees	77.60	-	60,954.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Cash Management Re: Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
07/01/21	LTN	Reconcile and update Adlon and Avrio Health financials section of the May 2021 PEO monthly flash report	1.40
07/01/21	LTN	Reconcile and update the Purdue and Rhodes financials section of the May 2021 PEO monthly flash report	1.70
07/01/21	LTN	Review May 2021 Financial statement deck and update Consolidated financials section for May PEO monthly flash report	2.10
07/01/21	HSB	Review Purdue weekly cash report prepared by L.Nguyen (AlixPartners)	0.80
07/01/21	JD	Provide comments on last week's forecast to actual cash report.	0.40
07/07/21	LTN	Prepare a list of open items to R. Brown, T. Gabriele, C. Hobbick, M. Santonastaso (Purdue) and update week ended 07.02 cash report based on their feedback	0.50
07/07/21	LTN	Reconcile and categorize the latest Paysource cash transactions and updated the week ended 07.02 cash report	1.70
07/07/21	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 07.02 cash report	2.00
07/08/21	LTN	Prepare the latest Purdue forecast to actuals variance analysis for week ended 07.02 and update the weekly cash report deck	1.60
07/08/21	LTN	Prepare the latest Rhodes forecast to actuals variance analysis for week ended 07.02 and update the weekly cash report deck	1.10
07/08/21	HSB	Review Purdue cash forecast prepared by L.Nguyen (AlixPartners)	0.80
07/08/21	JD	Review and provide comments on the latest forecast to actual cash report.	0.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Cash Management Re: Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
07/12/21	LTN	Prepare a list of open items to R. Brown, T. Gabriele, C. Hobbick, M. Santonastaso (Purdue) and update week ended 07.09 cash report based on their feedback	0.40
07/12/21	LTN	Reconcile and categorize the latest Paysource cash transactions and updated the week ended 07.09 cash report	1.80
07/12/21	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 07.09 cash report	1.70
07/13/21	LTN	Prepare the latest Purdue forecast to actuals variance analysis for week ended 07.09 and update the weekly cash report deck	1.20
07/13/21	LTN	Prepare the latest Rhodes forecast to actuals variance analysis for week ended 07.09 and update the weekly cash report deck	0.80
07/14/21	HSB	Review Purdue financial forecasts prepared by L.Nguyen (AlixPartners)	0.70
07/15/21	LTN	Finalize the May PEO monthly flash report and circulate for internal review	1.70
07/16/21	LTN	Review the latest fee applications from the docket filed by Restructuring professionals and update the tracker	2.20
07/16/21	LTN	Review the latest fee applications from the docket filed by Retained professionals and update the tracker	1.30
07/19/21	JD	Review and provide comments on latest weekly cash forecast to actual report.	0.40
07/21/21	LTN	Reconcile and categorize the latest Paysource cash transactions and updated the week ended 07.16 cash report	1.80
07/21/21	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 07.16 cash report	1.60

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Cash Management Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
07/23/21	LTN	Prepare the latest Purdue forecast to actuals variance analysis for week ended 07.16 and update the weekly cash report deck	1.40
07/23/21	LTN	Prepare a list of open items to R. Brown, T. Gabriele, C. Hobbick, M. Santonastaso (Purdue) and update week ended 07.16 cash report based on their feedback	0.60
07/23/21	LTN	Call among J. DelConte, S. Lemack, H. Bhattal, L. Nguyen (AlixPartners), J. Lowne, L. Scheinbach (Purdue) to discuss Newco Cashflow breakdown.	0.30
07/23/21	LTN	Prepare the latest Rhodes forecast to actuals variance analysis for week ended 07.16 and update the weekly cash report deck	0.90
07/23/21	SKL	Meeting with J. Lowne (Purdue), E. Ruiz (Purdue), E. Nowakowski (Purdue), L. Scheinbach (Purdue), T. Melvin (PJT), J. DelConte (AlixPartners) and H. Bhattal (AlixPartners) to discuss NewCo CF projections.	0.30
07/27/21	JH	Correspondence with C. Oluwole (Davis Polk) re confidentiality designations.	0.20
07/28/21	JD	Review and provide comments on latest weekly cash forecast to actual report.	0.50
07/28/21	JD	Correspondence with J. Tran (Purdue) re: Avrio performance.	0.20
07/28/21	HSB	Review Purdue weekly cash forecast prepared by L.Nguyen (AlixPartners)	0.70
07/28/21	HSB	Review Purdue MOR draft prepared by L.Nguyen (AlixPartners)	0.40
07/28/21	LTN	Prepare the Customer rebates section of Purdue 13-week cash forecast beginning 07.23	1.50
07/28/21	LTN	Download AP data from SAP, categorize the operating expense section of Purdue & Rhodes 13-week cash	2.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Cash Management Re: Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		forecast beginning 07.23	
07/28/21	LTN	Download AR data from SAP, categorize Account Receivables section of Purdue & Rhodes 13w cash forecast beginning 07.23	2.00
07/29/21	LTN	Prepare the customer receipts section of Purdue 13 week cash forecast beginning 07.23 based on the latest sales forecast provided by J. Knight (Purdue)	1.00
07/29/21	LTN	Reconcile and categorize the latest Paysource cash transactions and updated the week ended 07.23 cash report	2.00
07/29/21	LTN	Update the latest EastWest cash transaction report and categorized for the week ended 07.23 cash report	1.80
07/29/21	LTN	Review the latest rebates tracker provided by D. Krishnan (Purdue) as of Jul 2021 and updated the 13-week cash forecast	1.00
07/29/21	LTN	Prepare the IAC receipts and IAC disbursements section of Purdue 13-week cash forecast beginning 07.23	0.70
07/29/21	LTN	Prepare the updated weekly sales reports as of 07.23 for Rhodes provided by P. Phouthasone (Purdue) and circulated for CFO review	0.80
07/29/21	LTN	Prepare the updated weekly sales reports as of 07.23 for Purdue provided by E. Nowakowski (Purdue) and circulated for CFO review	0.50
07/29/21	LTN	Revise OCP report for June 2021 invoices based on updated data from C. MacDonald (Purdue) and circulate to DavisPolk	1.50
07/30/21	LTN	Update the Restructuring and retained professional fee section to the latest 13w cash forecast beginning week 07.23	2.00
07/30/21	LTN	Review Professional fee forecast prepared by J. DelConte	0.80

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Cash Management Re: Client/Matter # 012589.00103

Date	Consultant	Description of Services (AlixPartners) and update the latest 13 week cash forecast beginning week 07.23	Hours
07/30/21	JD	Review and update the latest case professional fee tracker for the next version of the 13 week cash flow forecast.	0.50
07/31/21	LTN	Prepare the Customer Receipts and Operating Expenses section of Rhodes 13 week cash forecast beginning period 07.23	2.00
07/31/21	LTN	Prepare the customer rebates section of Rhodes 13 week cash forecast beginning period 07.23	1.20
07/31/21	LTN	Prepare the Professional fees, IACs and the remaining sections of Rhodes 13-week cash forecast beginning 07.23	1.40
07/31/21	LTN	Prepare the latest Rhodes forecast to actuals variance analysis for week ended 07.23 and update the weekly cash report deck	0.80
07/31/21	LTN	Prepare the latest Purdue forecast to actuals variance analysis for week ended 07.23 and update the weekly cash report deck	1.50
		Total =	60.80

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Cash Management Client/Matter # 012589.00103

Fee Recap:

Consultant	Hours	Rate	Amount
Lan T Nguyen	54.50	530.00	28,885.00
Sam K Lemack	0.30	665.00	199.50
HS Bhattal	3.40	865.00	2,941.00
Jamey Hamilton	0.20	865.00	173.00
Jesse DelConte	2.40	1,055.00	2,532.00
Total Hours & Fees	60.80		34,730.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Communication with Interested Parties Re:

Date	Consultant	Description of Services	Hours
07/01/21	LTN	Review indemnification data in MOR reports and correspondence with C. MacDonald (Purdue)	0.80
07/01/21	ADD	Review and compile materials in response to diligence request.	2.30
07/01/21	ADD	Review documents for third party confidentiality and other sensitivity in preparation for production.	2.40
07/01/21	JD	Correspondence with Davis Polk and AlixPartners team re: indemnification details request from the UCC.	0.30
07/02/21	ADD	Review list agreements and compile documents in response to diligence requests.	2.90
07/02/21	ADD	Review materials previously produced in response to diligence request.	1.70
07/02/21	ADD	Review documents for third party confidentiality and other sensitivity in preparation for production.	0.80
07/02/21	LTN	Compile January - May MOR data and provide to R. Aleali (Purdue).	0.30
07/03/21	ADD	Prepare and upload materials provided by Davis Polk's eDiscovery team for upload to the data room.	3.10
07/06/21	HSB	Call with M. Diaz, B. Bromberg, I. Turner, C. Kim, E. Kurtz (all FTI), G. Coutts, H. Schenk, A. Benjamin, H. Sun (all Houlihan), J. Turner, T. Melvin (both PJT), J. DelConte, H. Bhattal (both AlixPartners) re: plan documents.	0.70
07/06/21	JD	Call with B. Bromberg (FTI) re: plan documents.	0.20
07/06/21	JD	Review latest long term business plan for underlying long- term compensation assumptions per request from the UCC.	1.20
07/06/21	JD	Call with M. Diaz, B. Bromberg, I. Turner, C. Kim, E. Kurtz (all FTI), G. Coutts, H. Schenk, A. Benjamin, H. Sun	0.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Communication with Interested Parties Re:

Date	Consultant	Description of Services	Hours
		(all Houlihan), J. Turner, T. Melvin (both PJT), J. DelConte, H. Bhattal (both AlixPartners) re: plan documents.	
07/06/21	LTN	Call among G. Koch, L. Nguyen (AlixPartners), J. Finelli, A. Libby (Davis Polk) and other advisors to discuss A-Side multipod credit support Annex	2.90
07/06/21	HSB	Call with R. Aleali, J. Lowne (Purdue), E. Vonnegut, C. Robertson, S. Massman, Z. Levine, W. Taylor (all Davis Polk), J. DelConte, H. Bhattal (both AlixPartners), J. Turner, T. Melvin, J. Arsic (all PJT) re: supplemental plan documents.	0.80
07/07/21	LTN	Reconcile the cumulative indemnification payments based on data provided by C. MacDonald (Purdue)	0.60
07/07/21	LTN	Call with C. MacDonald (Purdue) to discuss indemnification fees	0.60
07/07/21	LTN	Prepare the indemnification payments report by firm based on data provided by C. MacDonald (Purdue)	1.80
07/07/21	LTN	Continue to prepare the indemnification payments report by Case Type based on data provided by C. MacDonald (Purdue)	1.30
07/07/21	JD	Create updated analysis of incentive compensation in the long term business plan per UCC diligence request.	0.80
07/07/21	JD	Create summary analysis of breakdown of changes to emergence distributions to share with AHC advisors.	0.80
07/07/21	JD	Call with G. Coutts (Houlihan) re: plan document negotiations.	0.60
07/07/21	JD	Call with J. Turner (PJT) and G. Coutts (Houlihan) re: plan document negotiations.	0.40
07/07/21	JD	Correspondence with FTI and Houlihan re: proposed changes to plan document language.	0.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Communication with Interested Parties Re:

Date	Consultant	Description of Services	Hours
07/07/21	JD	Correspondence with AHC and UCC advisors re: open diligence questions on the KEIP/KERP.	0.60
07/08/21	ADD	Review outstanding diligence request and compile responsive materials.	1.20
07/08/21	LTN	Correspondence with C. MacDonald (Purdue) re indemnification fees	0.30
07/08/21	HSB	Review Purdue diligence materials updated by L.Nguyen (AlixPartners) based on info from Purdue	0.30
07/09/21	HSB	Review email with Purdue diligence request received	0.10
07/09/21	HSB	Review Purdue cash forecasts in connection with diligence request	0.40
07/09/21	JD	Review and provide comments on the indemnification payment breakdown analysis per UCC diligence request.	0.50
07/10/21	SKL	Call with H. Bhattal (AlixPartners) to discuss latest KEIP/KERP inquiry provided by the AHC.	0.20
07/10/21	SKL	Continue to review latest AHC inquiry re: KEIP/KERP, and prepare and circulate update accordingly.	0.60
07/10/21	HSB	Call with S.Lemack (AlixPartners) to discuss Purdue keip/kerp	0.20
07/12/21	HSB	Call with E.Vonnegut, (Davis Polk), J.Turner, T. Melvin (both PJT), J.DelConte (AlixPartners), G. Coutts, A. Benjamin, H.Sun, A.Benjamin, O.Cohen (all HL), B. Bromberg, M.Diaz (both FTI), M.Kesselman, R.Aleali (both Purdue) re: plan related negotiations	0.70
07/12/21	LTN	Call with G. Koch, L. Nguyen (both AlixPartners) to discuss model scenarios provided by FTI	0.20
07/12/21	SKL	Review latest AHC inquiry re: sales to IACs and begin preparing update accordingly.	1.40
07/12/21	JD	Call with E.Vonnegut, (Davis Polk), J.Turner, T. Melvin	0.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Communication with Interested Parties Re:

Date	Consultant	Description of Services (both PJT), H. Bhattal (AlixPartners),G. Coutts, A. Benjamin, H.Sun, A.Benjamin,O.Cohen (all HL), B. Bromberg, M.Diaz (both FTI), M.Kesselman, R.Aleali (both Purdue) re: plan related negotiations	Hours
07/12/21	JD	Call with M. Diaz (FTI) re: KEIP/KERP.	0.10
07/12/21	JD	Call with S. Burian, G. Coutts, H. Schenk (all Houlihan), M. Kesselman, R. Aleali (both Purdue), J. Turner, T. Melvin (both PJT), M. Diaz, B. Bromberg (both FTI) re: PBM discussions.	1.00
07/12/21	ADD	Compile files from productions for document reserve.	2.10
07/13/21	JD	Call with G. Coutts (Houlihan) re: PBM discussions.	0.20
07/13/21	JD	Call with M. Diaz, B. Bromberg (both FTI), J. Turner (PJT) re: open diligence questions.	0.70
07/13/21	LTN	Call among J. Finelli, A. Libby (Davis Polk), J. Ball, C. Rosekans (Debevoise) and other advisors to discuss open items on the multipod credit support Annex	1.70
07/13/21	HSB	Call among L. Nguyen (AlixPartners), J.Finelli, A. Libby, J.Weiner (all Davis Polk), J. Ball, C.Rosekrans, J.Rosen (both Debevoise), G. Coutts, H. Schenk, A. Benjamin (all Houlihan), M. Atkinson (Province), J.Rosenbaum, R. Ringer (Kramer Levin), S. Gilbert (Gilbert), E.Miller (Akin Gump), M. Diaz, B.Bromberg (FTI) re: A-side family group credit support proposal	1.70
07/14/21	LTN	Call with G. Koch, L. Nguyen (both AlixPartners) to discuss settlement agreement matters	0.20
07/14/21	LTN	Call among G. Koch, L. Nguyen (AlixPartners), J. Finelli, A. Libby (Davis Polk), G. Gooding, J. Ball, C. Rosekans (Debevoise) and other advisors to discuss open Settlement Agreement issues, including materiality/breaches and remedies.	1.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Communication with Interested Parties Re:

Date	Consultant	Description of Services	Hours
07/14/21	ADD	Compile vendor data in response to Committee request.	0.50
07/14/21	SKL	Finalize updated analysis of IAC sales and circulate to FTI accordingly.	0.60
07/15/21	LTN	Call with B. Bromberg (FTI) to discuss model examples	0.50
07/16/21	HSB	Call with S. Burian, G. Coutts, H. Shenk (all Houlihan), M. Diaz, B. Bromberg (both FTI), R. Aleali (Purdue), J. Turner, T. Melvin (both PJT), E. Vonnegut, C. Robertson (both Davis Polk), J. DelConte, H. Bhattal (both AlixPartners), M. Florence, J. Bragg (both Skadden) re: PBMs.	0.80
07/16/21	ADD	Compile agreements in response to monitor request.	0.90
07/16/21	JD	Call with S. Burian, G. Coutts, H. Shenk (all Houlihan), M. Diaz, B. Bromberg (both FTI), R. Aleali (Purdue), J. Turner, T. Melvin (both PJT), E. Vonnegut, C. Robertson (both Davis Polk), J. DelConte, H. Bhattal (both AlixPartners), M. Florence, J. Bragg (both Skadden) re: PBMs.	0.80
07/16/21	JD	Review and provide comments on draft responses to UCC cash flow analysis questions.	0.60
07/17/21	GJK	Review contract assumption information sent to UCC and AHC advisors from S Lemack (AlixPartners) and comments from C Robertson (Davis Polk) and B Bromberg (FTI).	0.40
07/19/21	JD	Correspondence with FTI, Davis Polk and Purdue management re: KEIP/KERP proposal and counterproposal.	0.80
07/19/21	JD	Correspondence with Davis Polk and Houlihan re: pharmacy benefit manager analysis.	0.40
07/19/21	ADD	Call with J. Hyun and A. DePalma (AlixPartners) re: to review and analyze vendor data.	0.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Communication with Interested Parties Re:

Date	Consultant	Description of Services	Hours
07/19/21	ADD	Review and follow up with outstanding diligence requests.	1.50
07/19/21	HSB	Call among H. Bhattal, L. Nguyen (AlixPartners), J. Lowne, E. Ruiz (Purdue), T. Melvin (PJT) to discuss Newco Cashflow breakdown	0.20
07/19/21	LTN	Call among A. Libby (Davis Polk), E. (Akin) and other advisors re: updates to breach fees	0.70
07/20/21	HSB	Call with M. Diaz, B. Bromberg, E. Kurtz, I. Turner (all FTI), M. Atkinson (Province), J. DelConte, G. Koch, H. Bhattal, S. Lemack (all AlixPartners), D. Consla, C. Robertson (both Davis Polk) re: contract assumptions and rejections.	0.70
07/20/21	ADD	Upload documents submitted in response to diligence requests to the data room for creditor committee review.	2.30
07/20/21	ADD	Call with S. Lemack (AlixPartners) to discuss latest diligence request and next steps.	0.20
07/20/21	JD	Call with G. Coutts, H. Schenk, A. Benjamin (all Houlihan), J. Turner (PJT) re: PBM analysis.	0.50
07/20/21	JD	Call with M. Diaz, B. Bromberg (both FTI) re: KEIP/KERP.	0.50
07/20/21	JD	Call with M. Diaz, B. Bromberg, E. Kurtz, I. Turner (all FTI), M. Atkinson (Province), J. DelConte, G. Koch, H. Bhattal, S. Lemack (all AlixPartners), D. Consla, C. Robertson (both Davis Polk) re: contract assumptions and rejections.	0.70
07/20/21	SKL	Call with M. Diaz, B. Bromberg, E. Kurtz, I. Turner (all FTI), M. Atkinson (Province), J. DelConte, G. Koch, H. Bhattal, S. Lemack (all AlixPartners), D. Consla, C. Robertson (both Davis Polk) re: contract assumptions and rejections.	0.70
07/20/21	GJK	Call with M. Diaz, B. Bromberg, E. Kurtz, I. Turner (all FTI), M. Atkinson (Province), J. DelConte, G. Koch, H.	0.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Communication with Interested Parties Re:

Date	Consultant	Description of Services	Hours
		Bhattal, S. Lemack (all AlixPartners), D. Consla, C. Robertson (both Davis Polk) re: contract assumptions and rejections.	
07/21/21	JD	Review and provide comments on cash flow by product analysis per UCC diligence request.	0.40
07/21/21	JD	Call with G. Coutts (Houlihan) re: open diligence requests.	0.20
07/21/21	ADD	Call with S. Lemack (AlixPartners) to discuss latest diligence request and next steps.	0.20
07/22/21	ADD	Review outstanding diligence request.	0.40
07/22/21	JD	Call with E. Vonnegut (Davis Polk), R. Ringer (Kramer Levin), M. Diaz (FTI) re: KEIP/KERP.	0.30
07/22/21	JD	Call with C. Robertson, D. Klein, E. Vonnegut (all Davis Polk), M. Florence, J. Bragg (both Skadden), R. Aleali (Purdue) re: PBM analysis.	0.60
07/22/21	SKL	Finalize review of latest info provided by J. Carlisle and E. Nowakowski (both Purdue) and provide update to FTI and Province accordingly.	1.50
07/23/21	SKL	Continue to review latest notes and feedback re: contract assumptions, and begin preparing updates per FTI/Province request.	2.30
07/23/21	SKL	Call with A. DePalma (AlixPartners) to discuss latest diligence requests.	0.50
07/23/21	ADD	Call with S. Lemack (AlixPartners) to discuss latest diligence request and next steps.	0.50
07/24/21	JD	Review incoming diligence requests from Houlihan re: operations.	0.20
07/24/21	JD	Call with M. Diaz (FTI) re: KEIP/KERP.	0.20
07/25/21	JD	Correspondence with Purdue management re: open	0.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Communication with Interested Parties Re:

Date	Consultant	Description of Services diligence requests from the government and from the ad hocs.	Hours
07/25/21	JD	Correspondence with the AHC and UCC advisors re: KEIP/KERP counterproposal.	0.40
07/26/21	JD	Correspondence with FTI, Davis Polk and Purdue management re: KEIP counterproposals.	0.60
07/26/21	JD	Review operational materials and correspondence with Davis Polk re: AHC operational diligence requests.	0.50
07/26/21	JD	Meeting with J. DelConte, H. Bhattal, S. Lemack, A. DePalma (all AlixPartners) re: status of various inbound diligence requests.	0.70
07/26/21	HSB	Meeting with J. DelConte, H. Bhattal, S. Lemack, A. DePalma (all AlixPartners) re: status of various inbound diligence requests.	0.70
07/26/21	ADD	Meeting with J. DelConte, H. Bhattal, S. Lemack, A. DePalma (all AlixPartners) re: status of various inbound diligence requests.	0.70
07/26/21	ADD	Compile and format documents provided by the client in response to diligence requests for processing and upload for creditor review.	2.40
07/26/21	ADD	Review outstanding diligence request and compile responsive materials.	0.90
07/26/21	SKL	Meeting with J. DelConte, H. Bhattal, S. Lemack, A. DePalma (all AlixPartners) re: status of various inbound diligence requests.	0.70
07/27/21	ADD	Compile and format documents provided by the client in response to diligence requests for processing and upload for creditor review.	2.40
07/27/21	JD	Correspondence with Davis Polk and Purdue management re: open AHC operating agreement diligence requests.	0.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Communication with Interested Parties Re:

Date	Consultant	Description of Services	Hours
07/27/21	JD	Correspondence with management, Davis Polk and FTI re: KEIP/KERP proposals.	0.40
07/28/21	ADD	Compile list of board materials in response to diligence request.	1.30
07/28/21	ADD	Review outstanding diligence request and compile responsive materials.	1.20
07/28/21	HSB	Call with J.DelConte (AlixPartners), J.O'Connell, J.Turner, T.Melvin (both PJT), K.Benedict, M.Tobak (Davis Polk) re: plan related discussions	0.80
07/29/21	HSB	Call with M. Kesselman, C. Landau, J. Lowne, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: weekly catch up and planning call.	0.60
07/29/21	ADD	Compile list of board materials in response to diligence request.	0.80
07/29/21	SKL	Continue to prepare updates to the latest product-by- product RALP sales revenue file and work through the AHC open item list accordingly.	1.80
07/29/21	SKL	Review latest lease details on the Intralinks site and prepare consolidated breakdown of all leases per AHC request.	1.40
07/29/21	JD	Correspondence with M. Atkinson (Province) and R. Collura (AlixPartners) re: open UCC tax diligence questions.	0.30
07/30/21	SKL	Consolidate latest AHC diligence materials and prepare for distribution and signoff.	2.20
07/30/21	ADD	Compile list of board materials in response to diligence request.	1.10

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Communication with Interested Parties

Client/Matter # 012589.00104

Date Consultant **Description of Services Hours Total**

90.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Communication with Interested Parties Re:

Client/Matter # 012589.00104

Fee Recap:

Consultant	Hours	Rate	Amount
Lan T Nguyen	13.80	530.00	7,314.00
Andrew D DePalma	34.20	625.00	21,375.00
Sam K Lemack	13.90	665.00	9,243.50
HS Bhattal	8.70	865.00	7,525.50
Gabe J Koch	1.10	865.00	951.50
Jesse DelConte	19.00	1,055.00	20,045.00
Total Hours & Fees	90.70		66,454.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

U. S. Trustee / Court Reporting Requirements Re:

Date	Consultant	Description of Services	Hours
07/01/21	LTN	Correspondence with R. Robbins (AlixPartners) re: new MOR format	0.30
07/08/21	LTN	Prepare the bank account balances section of the June 2021 monthly operating report	1.70
07/08/21	LTN	Prepare the cash activity section of the June 2021 monthly operating report	1.90
07/08/21	LTN	Finalize the indemnification report based on feedback from C. MacDonald (Purdue) and circulate for internal review	1.10
07/08/21	LTN	Call with S. Lemack (AlixPartners) to discuss MOR preparation	0.30
07/08/21	SKL	Call with L. Nguyen (AlixPartners) to discuss MOR preparation.	0.30
07/09/21	SKL	Call with L. Nguyen (AlixPartners) to discuss latest MOR updates.	0.30
07/09/21	LTN	Call with S. Lemack (AlixPartners) to discuss latest MOR updates	0.30
07/12/21	LTN	Submit data requests to various Purdue teams to prepare the June 2021 MOR	0.40
07/15/21	LTN	Pull SAP data and calculate a Purdue director's total compensation requested by the examiner	1.10
07/15/21	LTN	Prepare a template for cash receipts / disbursements for the new MOR format	1.90
07/16/21	LTN	Prepare the Insider payments section of June 2021 monthly operating report	2.30
07/16/21	LTN	Prepare the professional fee payments section of the June 2021 monthly operating report and circulated to C. MacDonald (Purdue) for review	1.20
07/19/21	LTN	Prepare schedule of cash receipts/ disbursements for June	2.10

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

U. S. Trustee / Court Reporting Requirements Re:

Date	Consultant	Description of Services	Hours
		MOR for 24 debtors and upload to the automation toll	
07/19/21	LTN	Call with A. DePalma, L. Nguyen (AlixPartners) to discuss new MOR form	0.20
07/19/21	LTN	Call with H. Bhattal, L. Nguyen (AlixPartners) to discuss Newco cash flows	0.40
07/19/21	LTN	Reconcile schedule of cash receipts/ disbursements for June MOR for individual entities vs consolidated cash balances	1.70
07/19/21	ADD	Call with A. DePalma, L. Nguyen (AlixPartners) re: MOR	0.20
07/19/21	JD	Review latest trustee guidance and correspondence with L. Nguyen (AlixPartners) re: MOR reporting requirements.	0.40
07/19/21	JD	Review draft June financials for the upcoming MOR.	0.20
07/22/21	JD	Correspondence with Purdue HR re: updated MOR reporting requirements.	0.20
07/22/21	JD	Correspondence with Davis Polk and Purdue management re: KEIP/KERP negotiations.	0.40
07/22/21	HSB	Attend part of call with J.Horgan and L.Nguyen (both AlixPartners) re: MOR	0.30
07/22/21	SKL	Call with J. Clarrey (AlixPartners) to discuss latest MOR templates and updating the June MOR accordingly.	0.30
07/22/21	SKL	Review latest feedback and prepare updates to MOR format accordingly.	1.90
07/22/21	SKL	Meeting with L. Nguyen (AlixPartners) to discuss MOR format and preparation.	0.50
07/22/21	SKL	Calls with J. Muskovich (AlixPartners) to discuss latest MOR templates and updating the June MOR accordingly.	1.40
07/22/21	LTN	Revise the Part 1- cash receipts and disbursement for individual debtors and reconcile against schedule MOR 1a,1b	2.80

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

U. S. Trustee / Court Reporting Requirements Re:

Date	Consultant	Description of Services	Hours
07/22/21	LTN	Call with J. Horgan, H. Bhattal, L. Nguyen (AlixPartners) to discuss part 1 - cash schedule for the new MOR process	0.30
07/22/21	LTN	Prepare employee counts for individual debtors for the new MOR process	1.60
07/22/21	LTN	Revise the MOR template for individual debtors and upload to the automation form	2.50
07/22/21	LTN	Correspondence with J. Nadkarni (UST) re new MOR requirement	0.90
07/23/21	LTN	Review errors in the MOR template for individual debtors and re-upload to the automation form	1.00
07/26/21	LTN	Prepare debtor questionnaire section of the June 2021 MOR	0.50
07/26/21	LTN	Call with A. DePalma, L. Nguyen (AlixPartners) to discuss MOR	0.20
07/26/21	LTN	Prepare a reconciliation between Part 1 - Cash schedule MOR vs intercompany transfers and correspondence with J.DelConte, H. Bhattal (AlixPartners)	2.50
07/26/21	LTN	Review financial statements provided by J. Lowne (Purdue) and consolidate to June 2021 MOR	1.40
07/26/21	LTN	Update Coverpage and signature page of the new MOR form for all individual debtors	1.00
07/26/21	LTN	Draft a list of issues re: automation template for uploading MOR to B. Young (AlixPartners)	1.00
07/26/21	LTN	Call with B. Young (AlixPartners) re: automation tool for the new MOR process	0.20
07/26/21	LTN	Draft a list of new MOR form issues and correspondence with J. Nadkarni (USTP)	1.20
07/26/21	ADD	Call with A. DePalma, L. Nguyen (AlixPartners) to discuss	0.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

U. S. Trustee / Court Reporting Requirements Re:

Date	Consultant	Description of Services MOR	Hours
07/26/21	JD	Review and provide comments on the updated draft MOR form for May.	0.40
07/27/21	HSB	Review draft of Purdue MOR prepared by L.Nguyen (AlixPartners) based on new reporting requirements for multiple debtor entities and provided comments	1.80
07/27/21	LTN	Correspondence with J. Nadkarni (USTP) re: open items on the new MOR form	0.80
07/27/21	LTN	Correspondence with D. Consla, C. Robertson (DavisPolk) re: MOR new requirement	0.50
07/27/21	LTN	Finalize reconciliation for calculated cash balances vs actual ending balances for 24 debtors and summarize findings to internal team	1.80
07/27/21	LTN	Update Part 7- questionaire of the new MOR form for all individual debtors	1.30
07/27/21	LTN	Calculate Q2 2021 US Trustee fee and circulate to H. Benson (Purdue) for processing payment	0.90
07/28/21	LTN	Consolidate new MOR report for PPLP and individual debtors and circulate for internal review	1.70
07/28/21	LTN	Review the latest OCP data provided by C. MacDonald (Purdue) and prepared OCP report for June 2021 invoices	1.70
07/28/21	LTN	Call with H. Bhattal, L. Nguyen (AlixPartners) re: new MOR format update	0.20
07/28/21	LTN	Call among J. DelConte, S. Lemack, H. Bhattal, L. Nguyen (AlixPartners), J. Lowne (Purdue) to discuss new MOR format	0.20
07/28/21	LTN	Correspondence to J. Lowne (Purdue) re: new MOR format requirement	0.40
07/28/21	HSB	Call with L.Nguyen (AlixPartners) to discuss Purdue MOR	0.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

U. S. Trustee / Court Reporting Requirements Re:

Date	Consultant	Description of Services	Hours
07/28/21	HSB	Call with J. Lowne, E. Nowakowski (both Purdue), J. DelConte, H. Bhattal, S. Lemack, L. Nguyen (all AlixPartners) re: new MOR form.	0.20
07/28/21	JD	Correspondence with H. Bhattal and L. Nguyen (both AlixPartners) re: MOR edits.	0.30
07/28/21	JD	Call with J. Lowne, E. Nowakowski (both Purdue), J. DelConte, H. Bhattal, S. Lemack, L. Nguyen (all AlixPartners) re: new MOR form.	0.20
07/28/21	SKL	Meeeting with J. Lowne, E. Nowakowski (both Purdue), J. DelConte, H. Bhattal and L. Nguyen (all AlixPartners) to discuss new MOR format.	0.20
07/30/21	SKL	Call with J. DelConte and H. Bhattal (both AlixPartners) to touch base on latest diligence requests.	0.40
07/30/21	JD	Meeting with J. DelConte, H. Bhattal, S. Lemack (all AlixPartners) re: open diligence requests.	0.40
07/30/21	HSB	Review MOR prepared by L.Nguyen (AlixPartners) and prepared related writeup	0.50
07/30/21	HSB	Call with J.DelConte and S.Lemack (both AlixPartners) re: diligence materials requested	0.40
07/30/21	HSB	Call with C. Robertson, D.Consla (both Davis Polk) and LNguyen (AlixPartners) re: MOR	0.30
07/30/21	ADD	Call with A. DePalma, L. Nguyen (both AlixPartners) to update MOR	0.40
07/30/21	LTN	Call with H. Bhattal, L. Nguyen (AlixPartners), C. Robertson, D. Consla (both DavisPolk) re: new MOR format update	0.30
07/30/21	LTN	Call with H. Bhattal, L. Nguyen (AlixPartners) re: new MOR format update	0.10
07/30/21	LTN	Call with A. DePalma, L. Nguyen (both AlixPartners) to	0.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

U. S. Trustee / Court Reporting Requirements Re:

Date	Consultant	Description of Services update MOR	Hours
07/30/21	LTN	Insert notes and finalize the consolidated June MOR report and circulate to C. Robertson, D. Consla (DavisPolk) for review	2.30
		Total	58.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

U. S. Trustee / Court Reporting Requirements

Client/Matter # 012589.00105

Fee Recap:

Consultant	Hours	Rate	Amount
Lan T Nguyen	46.60	530.00	24,698.00
Andrew D DePalma	0.80	625.00	500.00
Sam K Lemack	5.30	665.00	3,524.50
HS Bhattal	3.70	865.00	3,200.50
Jesse DelConte	2.50	1,055.00	2,637.50
Total Hours & Fees	58.90		34,560.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Re: **Business Analysis & Operations**

Date	Consultant	Description of Services	Hours
07/01/21	JD	Correspondence with Davis Polk re: wind down budget estimates.	0.20
07/01/21	LJD	Call with R. Aleali, J. Lowne (both Purdue), C. Robertson, A. Libby (both Davis Polk), J. Turner, T. Melvin, J. Arsic (all PJT), L. Donahue, J. DelConte, G. Koch (all AlixPartners) re: weekly catch up and go forward planning call.	0.60
07/01/21	GJK	Call with Z. Haseeb, R. Aleali, J. Lowne, E. Ruiz, K. McCarthy, R. Kreppel, R. Inz (all Purdue), E. Vonnegut, A. Libby, C. Robertson, D. Bauer (all Davis Polk), J. DelConte, G. Koch (both AlixPartners) re: IAC agreements.	0.80
07/01/21	GJK	Review of updated draft of IAC Rider to Settlement Agreement.	1.50
07/01/21	GJK	Call with R. Aleali, J. Lowne (both Purdue), C. Robertson, A. Libby (both Davis Polk), J. Turner, T. Melvin, J. Arsic (all PJT), L. Donahue, J. DelConte, G. Koch (all AlixPartners) re: weekly catch up and go forward planning call.	0.60
07/01/21	JD	Call with R. Aleali, J. Lowne (both Purdue), C. Robertson, A. Libby (both Davis Polk), J. Turner, T. Melvin, J. Arsic (all PJT), L. Donahue, J. DelConte, G. Koch (all AlixPartners) re: weekly catch up and go forward planning call.	0.60
07/01/21	JD	Call with Z. Haseeb, R. Aleali, J. Lowne, E. Ruiz, K. McCarthy, R. Kreppel, R. Inz (all Purdue), E. Vonnegut, A. Libby, C. Robertson, D. Bauer (all Davis Polk), J. DelConte, G. Koch (both AlixPartners) re: IAC agreements.	0.80
07/01/21	GJK	Review of revised draft of Pod 4 Annex to Settlement Agreement.	1.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Business Analysis & Operations Re:

Date	Consultant	Description of Services	Hours
07/01/21	GJK	Scan through proposed revisions to Articles 1 & 2 of the Settlement Agreement as related to prepayments, including email explaination from B Kennedy (Debevoise).	0.70
07/02/21	GJK	Review of updated draft and redlines of Articles 1 and 2 of the Settlement Agreement (ongoing).	2.10
07/02/21	GJK	Review creditor edits and comments to draft of Article 1 and 2 of the Settlement Agreement.	0.90
07/02/21	GJK	Review model scenario example issue re: prepayment from B Bromberg (FTI) and respond to M. Atkinson (Province) on outeach approach to Sackler advisors.	0.50
07/02/21	GJK	Review IAC entity infomation including Germay tax example from Norton Rose.	0.40
07/02/21	GJK	Respond to M. Atkinson (Province) on outeach approach to Sacker advisors.	0.20
07/02/21	JD	Correspondence with Purdue PR team re: insider payments and inbound requests for comment from a reporter.	0.50
07/02/21	JD	Meeting with J. Lowne (Purdue), C. Nweke, A. DePalma, J. DelConte, K. McCafferty (AlixPartners) re: weekly stand-up meeting.	0.50
07/02/21	LTN	Review the latest settlement model provided by B. Olson (Kokino), test scenarios and summarize finding for G. Koch (AlixPartners).	2.20
07/03/21	GJK	Review prepayment model example email from B. Bromberg (FTI) to B. Olson (Sackler Family Office).	0.30
07/03/21	GJK	Track document updates from various parties for Settlement Agreement, rider and annexes.	0.60
07/05/21	GJK	Review of Creditor and Davis Polk updates to IAC Provisions rider of Settlement Agreement (ongoing).	0.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Business Analysis & Operations Re:

Date	Consultant	Description of Services	Hours
07/05/21	GJK	Review redlines of Pod 4 rider to Settlement Agreement from Creditors and Davis Polk.	0.90
07/05/21	GJK	Review of updates to IAC Provisions rider of Settlement Agreement (ongoing).	2.20
07/05/21	JD	Call with T. Melvin (PJT) re: NOAT distribution forecast.	0.40
07/05/21	JD	Review and provide comments on the updated distribution waterfall analysis from PJT.	0.70
07/06/21	JD	Review and provide comments on the updated cash flow distribution analysis from PJT.	0.30
07/06/21	JD	Call with J. DelConte, H. Bhattal (both AlixPartners), J. Lowne (Purdue), J. Turner, T. Melvin, J. Arsic, L. Schwarzmann (all PJT) re: distribution breakdown.	0.20
07/06/21	JD	Correspondence with Purdue management, Davis Polk and PJT re: governance and plan document negotiations with the AHC.	0.60
07/06/21	JD	Update analysis of emergence date cash flow payments for the governance term sheet and plan supplements.	1.00
07/06/21	GJK	Call among G. Koch, H. Bhattal, L. Nguyen (AlixPartners), J. Finelli, A. Libby (Davis Polk), J. Ball, C. Rosekans (Debevoise) and other advisors to discuss A-Side multipod credit support Annex	1.40
07/06/21	GJK	Calls with L Nguyen (AlixPartners) to discuss breach fee model and content for the collar deck	1.10
07/06/21	GJK	Call among G. Koch, L. Nguyen (AlixPartners), J. Finelli, A. Libby (Davis Polk) and other advisors to discuss A-Side multipod credit support Annex	2.90
07/06/21	GJK	Review and comment on Financial Statement Template for reporting.	0.90
07/06/21	GJK	Review Settlement Agreement Material Issues List from E	1.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Business Analysis & Operations Re:

Date	Consultant	Description of Services Hwang (Davis Polk)	Hours
07/06/21	GJK	Review Breach Fee language and analysis by L Nguyen (AlixPartners).	0.90
07/06/21	LJD	Review May fee statement	0.40
07/06/21	LTN	Prepare breach fee model for B-side family groups	1.50
07/06/21	LTN	Review the prepayment issue analysis provided by B. Bromberg (FTI) and provide feedback to G. Koch (AlixPartners)	0.60
07/06/21	LTN	Review outstanding settlement issue list before the call	0.50
07/06/21	LTN	Review definition and collateral matters section in the Aside multipod credit support annex	1.00
07/06/21	LTN	Call with G. Koch (AlixPartners) to work on N168	1.10
07/06/21	LTN	Call among G. Koch, H. Bhattal, L. Nguyen (AlixPartners), J. Finelli, A. Libby (Davis Polk), J. Ball, C. Rosekans (Debevoise) and other advisors to discuss A-Side multipod credit support Annex	1.40
07/06/21	LTN	Prepare breach fee model for A-side family groups	0.80
07/06/21	LTN	Finalize breach fee model based on internal feedback and circulate to J. Weiner (DavisPolk)	1.00
07/06/21	HSB	Call with J.Lowne (Purdue), J.Turner, J.Arsic, R.Schnitzler, T. Melvin (all PJT), J.DelConte (AlixPartners) re: Purdue projections	0.20
07/07/21	GJK	Follow-up on Financial Reporting template email from M Atkinson (Province).	0.60
07/07/21	GJK	Review Milbank revisions to Article 1 and Article 2 rider for Settlement Agreement.	1.30
07/07/21	GJK	Review of edits to Settlement Agreement (ongoing).	2.20
07/07/21	GJK	Review of updates and revisions of Settlement Agreement	2.10

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Business Analysis & Operations Re:

Date	Consultant	Description of Services	Hours
07/07/21	JD	for filing. Review settlement agreement diligence responses to date and correspondence with Davis Polk re: same.	0.50
07/07/21	ADD	Update liabilities subject to compromise calculation for June month end.	2.30
07/07/21	ADD	Compile supplementary materials for state license applications.	1.70
07/07/21	ADD	Update outstanding state license applications and incorporate comments from Purdue legal team.	2.30
07/08/21	JD	Call with R. Aleali (Purdue) re: plan documents and emergence planning.	0.40
07/08/21	JD	Prepare latest month end fee accruals for Purdue accounting.	0.30
07/08/21	GJK	Review Breach Documents from E Hwang (Davis Polk).	0.80
07/08/21	GJK	Review open items list for Settlement Agreement including model outputs for illustrative examples.	1.00
07/08/21	GJK	Review Annex B credit support from A Romero-Wagner (Davis Polk).	0.70
07/09/21	GJK	Call with L Nguyen to coordinate on diligence requests.	0.10
07/09/21	GJK	Review Group 4 Annex draft revisions from J Finelli (Davis Polk).	0.70
07/09/21	GJK	Review FTI model and proposed scenarios for Illustrative Examples for Settlement Agreement.	1.30
07/09/21	GJK	Call with C. Robertson, L. Altus, T. Matlock (all Davis Polk), J. DelConte, G. Koch (both AlixPartners) re: PPI assets.	0.50
07/09/21	GJK	Review files for information on Purdue Research Associates (PRA) and if information on value.	0.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Re: **Business Analysis & Operations**

Date	Consultant	Description of Services	Hours
07/09/21	SKL	Review latest approved vendor requests and update/run latest accounts payable release files.	1.00
07/09/21	JD	Call with J. Turner (PJT) and J. Lowne (Purdue) re: PHI business plan.	0.30
07/09/21	JD	Meeting with J. Lowne (Purdue); J.DelConte, K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence project weekly stand-up meeting.	0.80
07/09/21	JD	Review updated interim business plan for PHI.	0.50
07/09/21	JD	Review updated retention plan payments from Purdue HR.	0.20
07/09/21	JD	Call with C. Robertson, L. Altus, T. Matlock (all Davis Polk), J. DelConte, G. Koch (both AlixPartners) re: PPI assets.	0.50
07/09/21	JD	Correspondence with PJT re: distribution cash flow projections in the operating agreement.	0.30
07/09/21	JD	Analyze historical sales to Mundipharma and respond to diligence questions from FTI re: same.	0.70
07/09/21	ADD	Update outstanding state license applications and incorporate comments from Purdue legal team.	1.90
07/09/21	ADD	Call with Z.Haseeb (Skadden) and H. Bhattal (AlixPartners) re: Purdue state license process update	0.40
07/09/21	HSB	Call with Z.Haseeb (Skadden) and A.DePalma (AlixPartners) re: Purdue state license process update	0.40
07/09/21	LTN	Review the latest markup in the consolidated Settlement Agreement	1.70
07/09/21	LTN	Review the Settlement payment model and test scenarios provided by B. Bromberg (FTI)	1.70
07/09/21	LTN	Continue to test scenarios analysis based on examples from B. Bromberg (FTI) and provide comments to G.	0.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Re: **Business Analysis & Operations**

Date	Consultant	Description of Services Koch (AlixPartnerts)	Hours
07/09/21	LTN	Call with G. Koch (AlixPartners) to discuss diligence requests	0.10
07/09/21	LTN	Call with J. Weiner (DavisPolk) to discuss breach fee model	0.40
07/09/21	LTN	Revise the breach fee model based on feedback from J. Weiner (DavisPolk) and circulate to DavisPolk	1.20
07/10/21	HSB	Review Purdue keip/kerp related details and related analysis	0.50
07/10/21	JD	Correspondence with H. Bhattal, S. Lemack (AlixPartners), Davis Polk and Purdue management re: public insider compensation data in response to a reporter request.	0.40
07/12/21	JD	Call with E. Vonnegut (Davis Polk) re: KEIP/KERP discussions.	0.20
07/12/21	JD	Call with M. Kesselman, R. Aleali (both Purdue), E. Vonnegut (Davis Polk), J. Turner (PJT) re: discussion with HL on PBM's.	0.40
07/12/21	GJK	Call with G. Koch, L. Nguyen (both AlixPartners), M. Atkinson, C. Klawunder (Province), M. Diaz, B. Bromberg (both FTI) re: model scenarios	0.30
07/12/21	GJK	Call with G. Koch, L. Nguyen (both AlixPartners) to discuss model scenarios provided by FTI	0.20
07/12/21	GJK	Review revisions to B-Side Family annex to Settlement Agreement from Davis Polk.	1.80
07/12/21	GJK	Review of FDA talking points draft from D McGuire (Purdue).	0.60
07/12/21	GJK	Follow-up on China and Consumer Health Munidpharma businesses.	0.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Re: **Business Analysis & Operations**

Date	Consultant	Description of Services	Hours
07/12/21	GJK	Follow-up on B-Side asset values with L Nguyen (AlixPartners) for A Romero-Wagner (Davis Polk).	0.10
07/12/21	GJK	Review and comment on proposed email to B Kennedy (Milbank) and B Olson (Family Office) from B Bromberg (FTI) re: illustrative model examples.	0.70
07/12/21	GJK	Follow-up planning and coordination for open Settlement Agreement and annex issues for AlixPartners.	0.40
07/12/21	GJK	Review model updates from Brian Olson.	1.40
07/12/21	GJK	Update on correspondence and discussions between counsel for Sackler Family, Debtor, UCC and AHC.	0.70
07/12/21	LTN	Analyze payment examples re provision 2.07 provided by B. Olson (Kokino) and summarize findings to G. Koch (AlixPartners)	0.80
07/12/21	LTN	Call with G. Koch, L. Nguyen (both AlixPartners), M. Atkinson, C. Klawunder (Province), M. Diaz, B. Bromberg (both FTI) re: model scenarios	0.30
07/12/21	LTN	Correspondence with A. Romero (DavisPolk) re: B-side asset data	0.20
07/12/21	LTN	Analyze the latest model v07.10 provided by B. Olson (Kokino) and summarize feedback to G. Koch (AlixPartners)	1.20
07/13/21	LTN	Prepare meeting notes from the multi-pod credit support Annex call with lawyers / advisors and circulate to G. Koch (AlixPartners)	0.90
07/13/21	LTN	Review three illustrative examples based on the latest model and payment write-up, provide feedback to FTI	1.10
07/13/21	LTN	Review markup on the multi-pod credit support Annex before the call	1.50
07/13/21	HSB	Attended Purdue Board Special Committee meeting with	0.60

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Business Analysis & Operations Re:

Date	Consultant	Description of Services board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, J.Turner, T.Melvin (all PJT), S.Birnbaum (Dechert)	Hours
07/13/21	GJK	Review of Side B Annex proposed final draft from A Romero-Wagner (Davis Polk).	0.70
07/13/21	GJK	Review Settlement Agreement scenario examples with walkthrough langauge from B Bromberg (FTI).	0.80
07/13/21	GJK	Review updates to Breach & Remedies Chart from E Hwang (Davis Polk).	1.40
07/13/21	SKL	Review latest feedback provided by J. Carlisle (Purdue) re: IAC sales and prepare updated analysis accordingly.	1.00
07/13/21	JD	Call with E. Vonnegut (Davis Polk) re: KEIP/KERP.	0.20
07/13/21	JD	Call with M. Kesselman (Purdue) re: KEIP/KERP.	0.30
07/13/21	JD	Correspondence with Davis Polk and Purdue management re: KEIP/KERP negotiations.	0.70
07/13/21	JD	Correspondence with Purdue management re: historic formulary coverage.	0.40
07/13/21	JD	Review projections to be provided for renewal discussions with various insurers.	0.30
07/13/21	JD	Review attrition analysis prepared by Purdue management for Davis Polk and the KEIP/KERP filings.	0.70
07/13/21	JD	Review IAC special committee presentation from R. Aleali (Purdue).	0.60
07/13/21	JD	Review unsecured claims analyses files to be shared through the discovery process.	0.30
07/14/21	JD	Attended Purdue Board meeting with board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis	1.10

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Re: **Business Analysis & Operations**

Date	Consultant	Description of Services	Hours
		Polk), J. Turner (PJT), H. Bhattal, L. Donahue (both AlixPartners), S.Birnbaum (Dechert)	
07/14/21	JD	Call with J. DelConte and L. Donahue (both AlixPartners) re: staffing and strategic planning going forward.	0.30
07/14/21	JD	Meeting with J. Lowne (Purdue); J. DelConte, K. McCafferty and C. Nweke (AlixPartners) re: organization roles and structure scenario evaluation (partial participation).	0.30
07/14/21	JD	Review report 1B reliance materials prior to providing for confirmation data room.	0.80
07/14/21	JD	Review analysis of retention payments by EC member.	0.40
07/14/21	JD	Correspondence with Davis Polk and Purdue management re: L/C's and surety bonds.	0.40
07/14/21	LJD	Attended Purdue Board meeting with board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. Turner (PJT), J. DelConte, H. Bhattal (AlixPartners), S.Birnbaum (Dechert) (partial participation)	0.80
07/14/21	LJD	Call with J. DelConte and L. Donahue (both AlixPartners) re: staffing and strategic planning going forward.	0.30
07/14/21	GJK	Review updates to Articles 1 $\&$ 2 of Settlement Agreement from J Weiner (Davis Polk).	0.40
07/14/21	GJK	Review settlement agreement model illustrative examples.	0.80
07/14/21	GJK	Call among G. Koch, L. Nguyen (AlixPartners), J. Finelli, A. Libby (Davis Polk), G. Gooding, J. Ball, C. Rosekans (Debevoise) and other advisors to discuss open Settlement Agreement issues, including materiality/breaches and remedies.	1.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Business Analysis & Operations Re:

Date	Consultant	Description of Services	Hours
07/14/21	GJK	Call with J Weiner (Davis Polk) to discuss Settlement Agreement open issues.	0.20
07/14/21	GJK	Call with L Nguyen (AlixPartners) to discuss Settlement Agreement model scenarios.	0.20
07/14/21	GJK	Follow-up on tax question from T Matlock (Davis Polk) re: Huron valuation of assets.	0.40
07/14/21	HSB	Attended Purdue Board meeting with board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. Turner (PJT), J. DelConte, L. Donahue (both AlixPartners), S.Birnbaum (Dechert)	1.10
07/14/21	LTN	Review breach charts for the Settlement agreement	0.80
07/14/21	LTN	Review breach charts for A side and B side credit support annexes	1.60
07/14/21	LTN	Review the latest changes of Article 1 & 2 in the Settlement Agreement	1.00
07/15/21	LTN	Call among G. Koch, L. Nguyen (AlixPartners), J. Finelli, A. Libby (Davis Polk) and other advisors to discuss breach fee	2.00
07/15/21	LTN	Review B. Bromberg (FTI) feedback re Article 2 language and provide feedback	1.00
07/15/21	LTN	Call with G. Koch, L. Nguyen (both AlixPartners) to discuss updates on breach fee	0.10
07/15/21	GJK	Call wwith J DelConte (AlixPartners) to discuss Settlement Agreement progress.	0.20
07/15/21	GJK	Calls with L Nguyen (AlixPartners) to discuss Settlement Agreement progress.	0.10
07/15/21	GJK	Partial attendance at call among G. Koch, L. Nguyen (AlixPartners), J. Finelli, A. Libby (Davis Polk) and other	1.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Business Analysis & Operations Re:

Date	Consultant	Description of Services advisors to discuss breach fee	Hours
07/15/21	GJK	Weekly call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), J. O'Connell, J. Turner, T. Melvin (all PJT), E. Vonnegut, W. Taylor, C. Robertson (all Davis Polk), J. DelConte, L. Donahue, G. Koch (all AlixPartners) re: catch up and go forward planning call.	0.80
07/15/21	LJD	Weekly call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), J. O'Connell, J. Turner, T. Melvin (all PJT), E. Vonnegut, W. Taylor, C. Robertson (all Davis Polk), J. DelConte, L. Donahue, G. Koch (all AlixPartners) re: catch up and go forward planning call.	0.80
07/15/21	JD	Call with E. Vonnegut (Davis Polk) re: diligence project.	0.20
07/15/21	JD	Call with R. Aleali (Purdue) re: ongoing KEIP/KERP negotiations.	0.30
07/15/21	JD	Call with C. DeStefano (Purdue) re: KEIP/KERP proposal.	0.20
07/15/21	JD	Weekly call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), J. O'Connell, J. Turner, T. Melvin (all PJT), E. Vonnegut, W. Taylor, C. Robertson (all Davis Polk), J. DelConte, L. Donahue, G. Koch (all AlixPartners) re: catch up and go forward planning call.	0.80
07/15/21	JD	Call with J. DelConte and G. Koch (both AlixPartners) re: shareholder settlement agreement negotiations.	0.20
07/15/21	JD	Review updated analysis from Purdue HR re: potential KEIP/KERP counterproposal.	0.40
07/15/21	JD	Correspondence with Purdue management and K. McCafferty (AlixPartners) re: diligence project.	0.50
07/15/21	ADD	Compile and organize monthly sales data for inventory analysis	2.50
07/16/21	ADD	Compile and organize monthly sales data for inventory analysis	2.80

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Business Analysis & Operations Re:

Date	Consultant	Description of Services	Hours
07/16/21	ADD	Review and address license application comments from Purdue Legal team.	1.90
07/16/21	JD	Call with J. Lowne (Purdue) re: KEIP/KERP.	0.30
07/16/21	JD	Call with J. Lowne, H. Ghnaimeh, J. Carlisle, H. Benson, E. Ruiz, W. Sielert (all Purdue) re: NewCo transition.	0.70
07/16/21	JD	Call with J. Lowne, M. Kesselman (both Purdue), E. Vonnegut (Davis Polk), J. DelConte, K. McCafferty (both AlixPartners) re: diligence project.	0.80
07/16/21	JD	Review analysis from Purdue management on historic OxyContin formulary coverage.	0.30
07/16/21	JD	Provide comments on draft KEIP/KERP counterproposal from Purdue management.	0.30
07/16/21	JD	Call with J. Turner and R. Schnitzler (both PJT) re: potential BD opportunity.	0.30
07/16/21	JD	Call with J. Bragg, M. Florence (both Skadden), R. Aleali (Purdue), E. Vonnegut, C. Robertson, Z. Levine (all Davis Polk), J. Turner (PJT) re: PBM discussion follow-up.	0.50
07/16/21	JD	Review preliminary diligence project flash report to be shared with management.	0.40
07/16/21	KM	Call with J. Lowne, M. Kesselman (both Purdue), E. Vonnegut (Davis Polk), J. DelConte, K. McCafferty (both AlixPartners) re: diligence project.	0.80
07/16/21	LJD	Review and comment on 5th fee app	0.80
07/16/21	HSB	Review Purdue monthly flash report prepared by L.Nguyen (AlixPartners) and related supporting document	0.90
07/16/21	HSB	Prepare file with Purdue forecast analysis	0.80
07/17/21	GJK	Review of Settlement Agreement (ongoing).	2.40
07/17/21	GJK	Review Settlement Agreement rep and covenant draft from E Hwang (Davis Polk).	1.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Re: **Business Analysis & Operations**

Date	Consultant	Description of Services	Hours
07/17/21	JD	Call with J. Lowne (Purdue) re: proposed KEIP/KERP counterproposal.	0.30
07/17/21	JD	Correspondence with Davis Polk and Purdue management re: KEIP/KERP response.	0.40
07/18/21	JD	Review KEIP/KERP counterproposal summary from J. Lowne (Purdue).	0.30
07/18/21	JD	Call with C. Landau, J. Lowne, K. Laurel (all Purdue), E. Vonnegut (Davis Polk) re: KEIP/KERP counterproposal.	0.50
07/18/21	GJK	Review revised Side B Annex from J Finelli (Davis Polk).	1.20
07/18/21	GJK	Review of blackline of Settlement Agreement from E Hwang (Davis Polk).	1.80
07/18/21	GJK	Review Settlement Agreement scenario walk throughs from B Bromberg (FTI).	0.80
07/18/21	GJK	Review Sackler redline to Scenario walkthroughts for illustrative examples of Settlement Agreement payment mechanics from B Kennedy (Milbank).	0.80
07/19/21	GJK	Respond to Davis Polk re: Financial Statement template for Settlement Agreement reporting.	0.60
07/19/21	GJK	Respond to Atkinson (Province) re: Financial Statement template for Settlement Agreement reporting.	0.30
07/19/21	GJK	Review Assistance with Litigation related language from Debtor and UCC/AHC counsel.	0.50
07/19/21	GJK	Review Creditor Comments to B-Side Annex from E Miller (Akin) and A Libby (Davis Polk).	1.30
07/19/21	GJK	Review edits and comments to Side A Multipod Annex from E Miller (Akin) and A Libby (Davis Polk).	1.10
07/19/21	GJK	Call when M Atkinson (Province) and B Bromberg (FTI) to discuss financial reporting needs from Sackler parties.	0.30
07/19/21	GJK	Draft edits to M Atkinson email for FAs to counsel re:	0.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Business Analysis & Operations Re:

Date	Consultant	Description of Services Sackler Parties reporting.	Hours
07/19/21	GJK	Call with G. Koch, L. Nguyen (AlixPartners) re: updates to reporting for credit support	0.20
07/19/21	JD	Review detailed company slides related to a potential Avrio BD opportunity.	0.80
07/19/21	JD	Call with C. Robertson (Purdue) re: outstanding diligence questions.	0.20
07/19/21	JD	Call with J. Lowne (Purdue) re: KEIP/KERP discussions and proposals.	0.30
07/19/21	JD	Call with J. Turner, R. Schnitzler (both PJT), J. Lowne, E. Ruiz, L. Scheinbach (all Purdue) re: Avrio BD opportunity.	0.70
07/19/21	JD	Correspondence with Purdue management re: royalty and license fee calculations.	0.30
07/19/21	JD	Review updated quarterly attrition analysis from Purdue management	0.30
07/19/21	JD	Review and edit pharmacy benefit manager analysis provided by management.	0.50
07/19/21	ADD	Address license application open items and incorporate comments from Purdue legal.	2.40
07/19/21	LTN	Prepare notes from the breach fee call and circulate to G. Koch (AlixPartners)	0.80
07/19/21	LTN	Review A side and B side annex markup before the call with DWP and other advisors	1.80
07/19/21	LTN	Analyze model illustrative examples and write-up provided by B. Kennedy (Milbank)	2.00
07/19/21	LTN	Call with G. Koch, L. Nguyen (AlixPartners) re: updates to reporting for credit support	0.20
07/20/21	HSB	Review updated monthly flash report prepared by L.Nguyen (AlixPartners)	0.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Re: **Business Analysis & Operations**

Date	Consultant	Description of Services	Hours
07/20/21	JD	Call with J. Bragg, M. Florence (both Skadden), R. Aleali (Purdue), D. Klein, C. Robertson (both Davis Polk) re: PBM analysis.	0.60
07/20/21	JD	Call with D. Klein (Davis Polk) re: pharmacy benefit manager analysis.	0.20
07/20/21	JD	Review PHI settlement overview deck from management.	0.40
07/20/21	JD	Correspondence with Purdue management and Davis Polk re: PBM analysis.	0.30
07/20/21	JD	Review monthly Nalmafene reporting from management prior to providing to creditors.	0.20
07/20/21	JD	Correspondence with Davis Polk re: PBM contracts.	0.30
07/20/21	JD	Correspondence with K. McCafferty (AlixPartners) re: diligence project.	0.30
07/20/21	JD	Review analysis of insurance collateral and potential future requirements.	0.40
07/20/21	GJK	Review call notes re: breaches from L Nguyen (AlixPartners).	0.30
07/20/21	SKL	Review latest feedback provided by J. Carlisle (Purdue) and follow-up on open item re: IAC royalties.	1.80
07/21/21	SKL	Review latest invoice/payment detail and review latest vendor questions re: postpetition payments.	1.00
07/21/21	GJK	Review Settlement Agreement payment mechanic scenarios and descriptions of family groups.	1.70
07/21/21	GJK	Review open Sackler Agreement issues.	1.40
07/21/21	JD	Review latest PHI overview presentation from Purdue management.	0.40
07/21/21	JD	Correspondence with Davis Polk re: KEIP/KERP negotiations.	0.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Re: **Business Analysis & Operations**

Date	Consultant	Description of Services	Hours
07/21/21	JD	Prepare professional fee payment summary per Davis Polk request.	0.30
07/21/21	JD	Review and provide comments on draft PJT operating agreement summary document.	0.50
07/21/21	JD	Call with E. Vonnegut (Davis Polk) re: KEIP/KERP.	0.30
07/21/21	JD	Call with potential post-emergence trustee.	0.80
07/21/21	JD	Call with M. Florence, J. Bragg (both Skadden), R. Aleali, M. Ronning, W. Shank, K. Christensen, D. Rosen (all Purdue), D. Klein, C. Robertson (both Davis Polk) re: PBM contracts.	0.90
07/21/21	JD	Call with J. Turner (PJT) re: PBM analysis and confirmation timing.	0.20
07/21/21	JD	Call with J. DelConte and K. McCafferty (both AlixPartners) re: diligence project.	0.40
07/21/21	JD	Call with J. DelConte, K. McCafferty (both AlixPartners), M. Diaz, B. Bromberg, P. Shafer (all FTI) re: diligence project.	0.50
07/21/21	JD	Call with J. DelConte, K. McCafferty (both AlixPartners), J. Lowne (Purdue) re: retention observations.	0.50
07/21/21	JD	Review latest transfer overview presentation provided to HL to see if there's anything that needs to be updated.	0.40
07/21/21	KM	Call with J. DelConte and K. McCafferty (both AlixPartners) re: diligence project.	0.40
07/21/21	KM	Meeting with M. Diaz, P. Shafer, B. Bromberg (FTI Consulting); J. DelConte and K. McCafferty (AlixPartners) re: diligence project.	0.50
07/22/21	ADD	Call with J. DelConte and A. DePalma (both AlixPartners) re: open diligence questions.	0.40
07/22/21	JD	Call with J. DelConte and A. DePalma (both AlixPartners)	0.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Business Analysis & Operations Re:

Date	Consultant	Description of Services	Hours
		re: open diligence questions.	
07/22/21	JD	Review Rhodes BD opportunity slides from management.	0.40
07/22/21	JD	Review latest Mundipharma royalty summary information per AHC diligence request.	0.30
07/22/21	JD	Review updated PBM analysis from the Purdue commercial team.	0.30
07/22/21	JD	Review business plan materials to provide to Davis Polk for the confirmation discovery data room.	0.40
07/22/21	GJK	Outline potential deck walking through payment mechanics of Settlement Agreement.	0.50
07/22/21	GJK	Update and coordinate on weekly Purdue exec and advisors call.	1.10
07/22/21	GJK	Review open items in Settlement Agreement including reporting options.	0.60
07/23/21	GJK	Provide update on Settlement Agreement and Change of Control work streams to J DelConte and HS Bhattal (AlixPartners).	0.20
07/23/21	GJK	Review open issues in Settlement Agreement process.	0.90
07/23/21	SKL	Review latest inquiry provided re: VA/CSP request and begin preparing updates accordingly.	2.30
07/23/21	JD	Correspondence with Davis Polk re: next KEIP/KERP proposal.	0.40
07/23/21	JD	Call with J. Lowne, M. Jack, C. Ricarte (all Purdue) re: insurance collateral requirements.	0.60
07/23/21	JD	Call with J. Lowne (Purdue) re: KEIP/KERP proposal.	0.20
07/23/21	JD	Correspondence with Purdue management and Davis Polk re: KEIP/KERP counterproposals.	0.50
07/23/21	JD	Review latest diligence report flash report update.	0.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Business Analysis & Operations Re:

Date	Consultant	Description of Services	Hours
07/23/21	JD	Call among J. DelConte, S. Lemack, H. Bhattal, L. Nguyen (AlixPartners), J. Lowne, L. Scheinbach (Purdue) to discuss Newco Cashflow breakdown.	0.30
07/23/21	JD	Correspondence with Davis Polk re: employee questions.	0.30
07/23/21	HSB	Call among J. DelConte, S. Lemack, H. Bhattal, L. Nguyen (AlixPartners), J. Lowne, L. Scheinbach (Purdue) to discuss Newco Cashflow breakdown.	0.30
07/24/21	JD	Call with E. Vonnegut (Davis Polk) re: KEIP/KERP.	0.20
07/24/21	JD	Correspondence with Purdue management and Davis Polk re: KEIP/KERP negotiations.	0.50
07/24/21	JD	Call with C. Landau (Purdue) re: KEIP/KERP negotiations.	0.20
07/26/21	JD	Call with R. Aleali (Purdue) re: KEIP/KERP.	0.50
07/26/21	JD	Call with T. Melvin (PJT) re: open diligence questions.	0.20
07/26/21	JD	Call with C. Landau (Purdue) re: KEIP/KERP.	0.40
07/26/21	JD	Review and send the Nalmafene court reporting for June to be posted.	0.20
07/26/21	JD	Call with E. Vonnegut (Davis Polk) re: KEIP/KERP.	0.20
07/26/21	JD	Call with T. Melvin, L. Schwarzmann (both PJT), J. DelConte, H. Bhattal, L. Nguyen and A. DePalma (all AlixPartners) re: cash flow forecast breakdown.	0.30
07/26/21	JD	Call with E. Nowakowski, A. Graziano, K. McCarthy (all Purdue), J. DelConte, S. Lemack, A. DePalma (all AlixPartners) re: VA GL Reconciliation.	0.60
07/26/21	JD	Review materials pulled together in response to inbound requests from the VA OIG.	0.30
07/26/21	JD	Review and provide comments on the May monthly flash report.	0.40
07/26/21	JD	Review GL data from Purdue re: open VA OIG diligence	0.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Business Analysis & Operations Re:

requests. 07/26/21 JD Review final draft cash flow forecast analysis from H. Bhattal. 07/26/21 ADD Call with E. Nowakowski, A. Graziano, K. McCarthy (all Purdue), J. DelConte, S. Lemack, A. DePalma (all AlixPartners) re: VA GL Reconcillation. 07/26/21 ADD Reconcile sales history data with G/L and identify any exceptions and items that do not reconcile. 07/26/21 SKL Call with E. Nowakowski, A. Graziano, K. McCarthy (all Purdue), J. DelConte, S. Lemack, A. DePalma (all AlixPartners) re: VA GL Reconciliation. 07/26/21 SKL Review latest info provided re: VA contract process and circulate update accordingly to Purdue team to sign-off. 07/26/21 SKL Review additional organizational info provided by the HR team and update the VA contracting deck accordingly. 07/26/21 SKL Review latest counterparty inquiry provided by C. MacDonald (Purdue) and prepare accounts payable release files. 07/26/21 GJK Follow up on Sackler Famly balance sheets and reporting requirements with Huron. 07/26/21 GJK Prep for Settlement Agreement issues list call. 07/27/21 GJK Call among G. Koch, L. Nguyen (AlixPartners), A. Libby, J. Weiner (Davis Polk) and other advisors to discuss Settlement Issues list 07/27/21 SKL Follow-up meeting with E. Nowakoski, A. Graziano (both Purdue) and A. DePalma (AlixPartners) to discuss GL account reconciliation. 07/27/21 LJD Meeting with J. O'Connell, J. Turner, T. Melvin, L.	Date	Consultant	Description of Services	Hours
Bhattal. O7/26/21 ADD Call with E. Nowakowski, A. Graziano, K. McCarthy (all Purdue), J. DelConte, S. Lemack, A. DePalma (all AlixPartners) re: VA GL Reconciliation. O7/26/21 ADD Reconcile sales history data with G/L and identify any exceptions and items that do not reconcile. O7/26/21 SKL Call with E. Nowakowski, A. Graziano, K. McCarthy (all Purdue), J. DelConte, S. Lemack, A. DePalma (all AlixPartners) re: VA GL Reconciliation. O7/26/21 SKL Review latest info provided re: VA contract process and circulate update accordingly to Purdue team to sign-off. O7/26/21 SKL Review additional organizational info provided by the HR team and update the VA contracting deck accordingly. O7/26/21 SKL Review latest counterparty inquiry provided by C. MacDonald (Purdue) and prepare accounts payable release files. O7/26/21 GJK Prollow up on Sackler Famly balance sheets and reporting requirements with Huron. O7/26/21 GJK Prep for Settlement Agreement issues list call. O7/27/21 GJK Call among G. Koch, L. Nguyen (AlixPartners), A. Libby, J. Weiner (Davis Polk) and other advisors to discuss Settlement Issues list O7/27/21 GJK Review updated Side B Net Asset report (ongoing). O7/27/21 SKL Follow-up meeting with E. Nowakoski, A. Graziano (both Purdue) and A. DePalma (AlixPartners) to discuss GL account reconciliation.			requests.	
Purdue), J. DelConte, S. Lemack, A. DePalma (all AlixPartners) re: VA GL Reconciliation. 07/26/21 ADD Reconcile sales history data with G/L and identify any exceptions and items that do not reconcile. 07/26/21 SKL Call with E. Nowakowski, A. Graziano, K. McCarthy (all Purdue), J. DelConte, S. Lemack, A. DePalma (all AlixPartners) re: VA GL Reconciliation. 07/26/21 SKL Review latest info provided re: VA contract process and circulate update accordingly to Purdue team to sign-off. 07/26/21 SKL Review additional organizational info provided by the HR team and update the VA contracting deck accordingly. 07/26/21 SKL Review latest counterparty inquiry provided by C. MacDonald (Purdue) and prepare accounts payable release files. 07/26/21 GJK Follow up on Sackler Famly balance sheets and reporting requirements with Huron. 07/26/21 GJK Prep for Settlement Agreement issues list call. 1.30 07/27/21 GJK Call among G. Koch, L. Nguyen (AlixPartners), A. Libby, J. Weiner (Davis Polk) and other advisors to discuss Settlement Issues list 07/27/21 GJK Review updated Side B Net Asset report (ongoing). 1.80 07/27/21 SKL Follow-up meeting with E. Nowakoski, A. Graziano (both Purdue) and A. DePalma (AlixPartners) to discuss GL account reconciliation.	07/26/21	JD		0.30
exceptions and items that do not reconcile. 07/26/21 SKL Call with E. Nowakowski, A. Graziano, K. McCarthy (all Purdue), J. DelConte, S. Lemack, A. DePalma (all AlixPartners) re: VA GL Reconciliation. 07/26/21 SKL Review latest info provided re: VA contract process and circulate update accordingly to Purdue team to sign-off. 07/26/21 SKL Review additional organizational info provided by the HR team and update the VA contracting deck accordingly. 07/26/21 SKL Review latest counterparty inquiry provided by C. MacDonald (Purdue) and prepare accounts payable release files. 07/26/21 GJK Follow up on Sackler Famly balance sheets and reporting requirements with Huron. 07/26/21 GJK Prep for Settlement Agreement issues list call. 1.30 07/27/21 GJK Call among G. Koch, L. Nguyen (AlixPartners), A. Libby, J. Weiner (Davis Polk) and other advisors to discuss Settlement Issues list 07/27/21 GJK Review updated Side B Net Asset report (ongoing). 1.80 07/27/21 SKL Follow-up meeting with E. Nowakoski, A. Graziano (both Purdue) and A. DePalma (AlixPartners) to discuss GL account reconciliation.	07/26/21	ADD	Purdue), J. DelConte, S. Lemack, A. DePalma (all	0.60
Purdue), J. DelConte, S. Lemack, A. DePalma (all AlixPartners) re: VA GL Reconciliation. 07/26/21 SKL Review latest info provided re: VA contract process and circulate update accordingly to Purdue team to sign-off. 07/26/21 SKL Review additional organizational info provided by the HR team and update the VA contracting deck accordingly. 07/26/21 SKL Review latest counterparty inquiry provided by C. MacDonald (Purdue) and prepare accounts payable release files. 07/26/21 GJK Follow up on Sackler Famly balance sheets and reporting requirements with Huron. 07/26/21 GJK Prep for Settlement Agreement issues list call. 1.30 07/27/21 GJK Call among G. Koch, L. Nguyen (AlixPartners), A. Libby, J. Weiner (Davis Polk) and other advisors to discuss Settlement Issues list 07/27/21 GJK Review updated Side B Net Asset report (ongoing). 1.80 07/27/21 SKL Follow-up meeting with E. Nowakoski, A. Graziano (both Purdue) and A. DePalma (AlixPartners) to discuss GL account reconciliation.	07/26/21	ADD		2.00
circulate update accordingly to Purdue team to sign-off. 07/26/21 SKL Review additional organizational info provided by the HR team and update the VA contracting deck accordingly. 07/26/21 SKL Review latest counterparty inquiry provided by C. MacDonald (Purdue) and prepare accounts payable release files. 07/26/21 GJK Follow up on Sackler Famly balance sheets and reporting requirements with Huron. 07/26/21 GJK Prep for Settlement Agreement issues list call. 1.30 07/27/21 GJK Call among G. Koch, L. Nguyen (AlixPartners), A. Libby, J. Weiner (Davis Polk) and other advisors to discuss Settlement Issues list 07/27/21 GJK Review updated Side B Net Asset report (ongoing). 1.80 07/27/21 SKL Follow-up meeting with E. Nowakoski, A. Graziano (both Purdue) and A. DePalma (AlixPartners) to discuss GL account reconciliation.	07/26/21	SKL	Purdue), J. DelConte, S. Lemack, A. DePalma (all	0.60
team and update the VA contracting deck accordingly. 07/26/21 SKL Review latest counterparty inquiry provided by C. MacDonald (Purdue) and prepare accounts payable release files. 07/26/21 GJK Follow up on Sackler Famly balance sheets and reporting requirements with Huron. 07/26/21 GJK Prep for Settlement Agreement issues list call. 1.30 07/27/21 GJK Call among G. Koch, L. Nguyen (AlixPartners), A. Libby, J. Weiner (Davis Polk) and other advisors to discuss Settlement Issues list 07/27/21 GJK Review updated Side B Net Asset report (ongoing). 1.80 07/27/21 SKL Follow-up meeting with E. Nowakoski, A. Graziano (both Purdue) and A. DePalma (AlixPartners) to discuss GL account reconciliation.	07/26/21	SKL	·	2.30
MacDonald (Purdue) and prepare accounts payable release files. 07/26/21 GJK Follow up on Sackler Famly balance sheets and reporting requirements with Huron. 07/26/21 GJK Prep for Settlement Agreement issues list call. 1.30 07/27/21 GJK Call among G. Koch, L. Nguyen (AlixPartners), A. Libby, J. Weiner (Davis Polk) and other advisors to discuss Settlement Issues list 07/27/21 GJK Review updated Side B Net Asset report (ongoing). 1.80 07/27/21 SKL Follow-up meeting with E. Nowakoski, A. Graziano (both Purdue) and A. DePalma (AlixPartners) to discuss GL account reconciliation.	07/26/21	SKL	- · · · · · · · · · · · · · · · · · · ·	1.60
requirements with Huron. 07/26/21 GJK Prep for Settlement Agreement issues list call. 1.30 07/27/21 GJK Call among G. Koch, L. Nguyen (AlixPartners), A. Libby, J. Weiner (Davis Polk) and other advisors to discuss Settlement Issues list 07/27/21 GJK Review updated Side B Net Asset report (ongoing). 1.80 07/27/21 SKL Follow-up meeting with E. Nowakoski, A. Graziano (both Purdue) and A. DePalma (AlixPartners) to discuss GL account reconciliation.	07/26/21	SKL	MacDonald (Purdue) and prepare accounts payable	1.20
07/27/21 GJK Call among G. Koch, L. Nguyen (AlixPartners), A. Libby, J. Weiner (Davis Polk) and other advisors to discuss Settlement Issues list 07/27/21 GJK Review updated Side B Net Asset report (ongoing). 1.80 07/27/21 SKL Follow-up meeting with E. Nowakoski, A. Graziano (both Purdue) and A. DePalma (AlixPartners) to discuss GL account reconciliation.	07/26/21	GJK		0.20
Weiner (Davis Polk) and other advisors to discuss Settlement Issues list 07/27/21 GJK Review updated Side B Net Asset report (ongoing). 1.80 07/27/21 SKL Follow-up meeting with E. Nowakoski, A. Graziano (both Purdue) and A. DePalma (AlixPartners) to discuss GL account reconciliation.	07/26/21	GJK	Prep for Settlement Agreement issues list call.	1.30
07/27/21 SKL Follow-up meeting with E. Nowakoski, A. Graziano (both Purdue) and A. DePalma (AlixPartners) to discuss GL account reconciliation.	07/27/21	GJK	Weiner (Davis Polk) and other advisors to discuss	3.00
Purdue) and A. DePalma (AlixPartners) to discuss GL account reconciliation.	07/27/21	GJK	Review updated Side B Net Asset report (ongoing).	1.80
07/27/21 LJD Meeting with J. O'Connell, J. Turner, T. Melvin, L. 0.40	07/27/21	SKL	Purdue) and A. DePalma (AlixPartners) to discuss GL	0.60
	07/27/21	LJD	Meeting with J. O'Connell, J. Turner, T. Melvin, L.	0.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Business Analysis & Operations Re:

Date	Consultant	Description of Services Schwarzmann (all PJT), C. Robertson (Davis Polk), J. DelConte, L. Donahue, H. Bhattal (all AlixPartners) re: weekly update and planning meeting.	Hours
07/27/21	ADD	Follow-up meeting with E. Nowakoski, A. Graziano (both Purdue) and S. Lemack (AlixPartners) to discuss GL account reconciliation.	0.60
07/27/21	ADD	Reconcile sales history data with G/L and identify any exceptions and items that do not reconcile.	2.90
07/27/21	HSB	Call with L.Nguyen (AlixPartners) to discuss Purdue MOR	0.20
07/27/21	HSB	Attended Purdue Board Special Committee meeting with board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, J.Turner, T.Melvin (all PJT), S.Birnbaum (Dechert), J.DelConte (both AlixPartners)	0.90
07/27/21	HSB	Call with C. Robertson, W.Taylor (all Davis Polk), J.O'Connell, J.Turner, J.Arsic, R.Schnitzler, T. Melvin (all PJT), L.Donahue, J.DelConte (AlixPartners) re: update and planning.	0.40
07/27/21	JD	Review draft presentation from management on potential generic business development opportunity.	0.60
07/27/21	JD	Attended Purdue Board Special Committee meeting with board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, J.Turner, T.Melvin (all PJT), S.Birnbaum (Dechert), H. Bhattal (both AlixPartners)	0.90
07/27/21	JD	Correspondence with Davis Polk re: open management KEIP/KERP questions.	0.30
07/27/21	JD	Correspondence with C. MacDonald (Purdue) re: post-	0.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Business Analysis & Operations Re:

Date	Consultant	Description of Services	Hours
		petition professional fee payments.	
07/27/21	JD	Call with J. Lowne (Purdue) re: KEIP/KERP.	0.20
07/27/21	JD	Meeting with J. O'Connell, J. Turner, T. Melvin, L. Schwarzmann (all PJT), C. Robertson (Davis Polk), J. DelConte, L. Donahue, H. Bhattal (all AlixPartners) re: weekly update and planning meeting.	0.40
07/27/21	LTN	Call with H. Bhattal, L. Nguyen (AlixPartners) re: new MOR format update	0.20
07/27/21	LTN	Finalize the B-side asset report and circulate to G. Koch (AlixPartners) for review	1.60
07/27/21	LTN	Call among G. Koch, L. Nguyen (AlixPartners), A. Libby, J. Weiner (Davis Polk) and other advisors to discuss Settlement Issues list	3.00
07/27/21	LTN	Review the updated B-side Net Asset Value July 2021 data by Huron and start updating the asset report	2.00
07/28/21	JD	Attended Purdue Full Board meeting with board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, J.Turner, T.Melvin (all PJT), S.Birnbaum (Dechert), H. Bhattal, L.Donahue, J.DelConte (both AlixPartners)	1.40
07/28/21	JD	Call on confirmation declarations with K. Benedict, E. Kim, M. Tobak (all Davis Polk), J. DelConte, H. Bhattal (both AlixPartners), J. O'Connell, J. Turner, T. Melvin (all PJT).	0.80
07/28/21	JD	Meeting with J. DelConte and K. McCafferty (both AlixPartners) RE: diligence project.	0.50
07/28/21	JD	Review draft KERP reply from Davis Polk.	0.50
07/28/21	JD	Review latest attrition calculations for the KEIP/KERP reply.	0.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Business Analysis & Operations Re:

Date	Consultant	Description of Services	Hours
07/28/21	JD	Review J. Lowne KEIP/KERP draft reply declaration.	0.40
07/28/21	KM	Meeting with J. DelConte and K. McCafferty (both AlixPartners) re: diligence project.	0.50
07/28/21	HSB	Attended Purdue Full Board meeting with board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, J.Turner, T.Melvin (all PJT), S.Birnbaum (Dechert), L.Donahue, J.DelConte (both AlixPartners)	1.40
07/28/21	ADD	Reconcile sales history data with G/L and identify any exceptions and items that do not reconcile.	2.70
07/28/21	ADD	Meeting with E. Nowakoski, A. Graziano (both Purdue) and S. Lemack (AlixPartners) to discuss GL account reconciliation.	1.00
07/28/21	ADD	Draft notes and procedures for sales history data and G/L reconciliation.	2.00
07/28/21	LJD	Attended Purdue Full Board meeting with board members, C.Landau, M. Kesselman, R. Aleali, J.Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson, A.Libby (all Davis Polk), J. O'Connell, J.Turner, T.Melvin (all PJT), S.Birnbaum (Dechert), H. Bhattal, L.Donahue, J.DelConte (both AlixPartners)	1.40
07/28/21	SKL	Meeting with E. Nowakoski, A. Graziano (both Purdue) and A. DePalma (AlixPartners) to discuss GL account reconciliation.	1.00
07/28/21	SKL	Review latest product-by-product sales revenue file provided by E. Ruiz (Purdue) and circulate updated RALP Net Sales file.	2.40
07/28/21	SKL	Review latest vendor inquiry provided by C. MacDonald (Purdue) and prepare updated release lists accordingly.	0.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Business Analysis & Operations Re:

Date	Consultant	Description of Services	Hours
07/28/21	SKL	Finalize updates to latest org. chart inquiry and circulate final update accordingly.	0.70
07/28/21	GJK	Review revisions to draft Settlement Agreement illustrative examples from B Bromberg (FTI).	1.30
07/29/21	GJK	Call with M. Kesselman, C. Landau, J. Lowne, R. Aleali (all Purdue), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), J. DelConte, G. Koch, H. Bhattal (all AlixPartners) re: weekly catch up and planning call.	0.60
07/29/21	GJK	Review of updated Settlement Agreement draft from Milbank and Debevoise.	2.20
07/29/21	SKL	Meeting with E. Nowakoski, A. Graziano (both Purdue) and A. DePalma (AlixPartners) to discuss GL account reconciliation.	0.60
07/29/21	SKL	Review latest feedback received on the latest VA material request list and prepare updates and update the tracker accordingly.	1.40
07/29/21	SKL	Finalize business model narrative for the latest VA contract material request list and circulate updates accordingly.	2.40
07/29/21	JD	Review and provide comments on org structure materials from K. McCafferty (AlixPartners) for meeting with management	0.70
07/29/21	ADD	Draft notes and procedures for sales history data and G/L reconciliation.	1.80
07/29/21	ADD	Reconcile sales history data with G/L and identify any exceptions and items that do not reconcile.	3.30
07/29/21	ADD	Meeting with E. Nowakoski, A. Graziano (both Purdue) and S. Lemack (AlixPartners) to discuss GL account reconciliation.	0.60

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Re: **Business Analysis & Operations**

Date	Consultant	Description of Services	Hours
07/29/21	HSB	Review Purdue and Rhodes weekly sales reports prepared by L.Nguyen (AlixPartners)	0.20
07/29/21	KM	Call with J. DelConte and K. McCafferty (both AlixPartners) re: diligence project.	0.60
07/29/21	JD	Call with J. DelConte and K. McCafferty (both AlixPartners) re: diligence project.	0.60
07/29/21	JD	Correspondence with FTI and Davis Polk re: KEIP/KERP proposal.	0.20
07/29/21	JD	Review details from Purdue management re: Abbot Labs payments.	0.30
07/29/21	JD	Review latest weekly sales by product details prior to sharing with creditor advisors.	0.40
07/29/21	JD	Correspondence with Purdue management and Davis Polk re: KEIP/KERP prep.	0.40
07/29/21	JD	Review and provide comments on the draft response to open VA OIG diligence request re: business narrative.	0.20
07/30/21	KM	Meeting with J. DelConte and K. McCafferty (both AlixPartners) re: diligence project.	0.60
07/30/21	HSB	Review OCP report prepared by L.Nguyen (AlixPartners)	0.40
07/30/21	ADD	Incorporate license application comments from Purdue legal team.	2.50
07/30/21	ADD	Update sales history data reconciliation and incorporate client comments.	2.80
07/30/21	ADD	Review Sales History reconciling items and draft list of open items.	1.20
07/30/21	JD	Meeting with J. Lowne (Purdue); J. DelConte, K. McCafferty and J. Hyun (AlixPartners) re: diligence project weekly stand-up meeting.	0.80
07/30/21	JD	Meeting with C. Landau, J. Lowne and M. Kesselman	0.90
1 Cedar Springs	Road T 214 647 7	500	

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Business Analysis & Operations Re:

Date	Consultant	Description of Services	Hours
		(Purdue); J. DelConte, K. McCafferty and J. Hyun (AlixPartners) re: review of G&A and organization recommendations.	
07/30/21	JD	Call with D. Consla (Davis Polk) re: KEIP/KERP diligence.	0.20
07/30/21	JD	Call with E. Vonnegut (Davis Polk) RE: diligence project.	0.20
07/30/21	JD	Meeting with J. DelConte and K. McCafferty (both AlixPartners) RE: diligence project.	0.60
07/30/21	JD	Review draft June OCP report to be filed with the court.	0.20
07/30/21	JD	Prepare employee breakdown for Davis Polk and Skadden in response to open KEIP/KERP diligence questions.	2.50
07/30/21	JD	Correspondence with Purdue management and Davis Polk re: open DOJ questions on the NewCo operating agreement.	0.30
07/30/21	JD	Email with Purdue management re: KEIP/KERP terms.	0.20
07/30/21	GJK	Review of updated Settlement Agreement draft from Milbank and Debevoise (ongoing).	1.50
07/30/21	GJK	Call with E Hwang and J Weiner (Davis Polk) to discuss net asset definition in Settlement Agreement.	0.10
07/30/21	LTN	Review changes in the latest Settlement agreement ahead of the call	2.00
		Total	268.80

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Business Analysis & Operations

Client/Matter # 012589.00106

Fee Recap:

Consultant	Hours	Rate	Amount
Lan T Nguyen	42.20	530.00	22,366.00
Andrew D DePalma	42.60	625.00	26,625.00
Sam K Lemack	22.80	665.00	15,162.00
HS Bhattal	8.70	865.00	7,525.50
Gabe J Koch	81.70	865.00	70,670.50
Kevin M McCafferty	3.40	980.00	3,332.00
Jesse DelConte	61.90	1,055.00	65,304.50
Lisa Donahue	5.50	1,295.00	7,122.50
Total Hours & Fees	268.80	_	218,108.00

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

POR Development Re: Client/Matter # 012589.00107

Date	Consultant	Description of Services	Hours
07/01/21	LTN	Multiple calls with H. Bhattal, L. Nguyen (AlixPartners) to discuss plan related matters	0.80
07/01/21	LTN	Call with E.Ruiz, L.Scheinbach (both Purdue), J.Turner, J.Arsic, R.Schnitzler, T. Melvin (all PJT), H. Bhattal (AlixPartners) re: Purdue projections	0.20
07/01/21	HSB	Review Purdue shareholder settlement agreement related materials provided by Debevoise	0.60
07/01/21	HSB	Review Purdue plan-related analysis and correspondence from S.Lemack (AlixPartners)	0.70
07/01/21	HSB	Multiple calls with L.Nguyen (AlixPartners) to discuss Purdue plan-related matters	0.80
07/01/21	HSB	Call with S.Lemack (AlixPartners) to discuss Purdue plan- related matters	0.40
07/01/21	HSB	Review draft of NewCo document in connection with Purdue work transfer plan and provided comments	1.30
07/01/21	HSB	Review Purdue emergence date cash flow forecast and related details	0.80
07/01/21	GJK	Prepare for call to discuss open economic items with Purdue Legal and Finance, Davis Polk and J.DelConte (AlixPartners).	0.40
07/01/21	SKL	Call with H. Bhattal (AlixPartners) to discuss various plan- related matters.	0.40
07/01/21	JD	Call with W. Taylor, E. Vonnegut, C. Robertson, Z. Levine, S. Massman (all Davis Polk), R. Aleali, J. Lowne (both Purdue), J. DelConte, H. Bhattal (both AlixPartners) re: governance term sheets.	0.70
07/01/21	RC	Review documents in connection with preparation for Plan Confirmation.	1.20
07/01/21	RC	Continue review of expert reports submitted in connection	1.60

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

POR Development Re: Client/Matter # 012589.00107

Date	Consultant	Description of Services	Hours
		with Plan Confirmation issues.	
07/01/21	HSB	Call with W. Taylor, E. Vonnegut, C. Robertson, Z. Levine, S. Massman (all Davis Polk), R. Aleali, J. Lowne (both Purdue), J. DelConte, H. Bhattal (both AlixPartners) re: governance term sheets.	0.70
07/01/21	HSB	Call with E.Ruiz, L.Scheinbach (both Purdue), J.Turner, J.Arsic, R.Schnitzler, T. Melvin (all PJT),L.Nguyen (AlixPartners) re: Purdue projections	0.20
07/01/21	HSB	Call with J. Lowne, C. Russo, S. Daniel, R. Aleali (all Purdue), J. DelConte, S. Lemack (all AlixPartners) re: contract assumption and rejection lists.	0.50
07/01/21	HSB	Review Purdue contract-related updates prepared by S.Lemack (AlixPartners)	0.40
07/01/21	HSB	Review Purdue plan related analysis and projections in connection with plan related discussions	1.70
07/01/21	JD	Review latest draft NewCo operating agreement versus the side-by-side agreement with the AHC in advance of call with Purdue management and other advisors.	1.80
07/01/21	JD	Correspondence with Davis Polk, PJT and Purdue management re: comments on the latest NewCo operating agreement.	0.30
07/01/21	JD	Correspondence with Davis Polk and PJT re: initial NOAT distribution in the governance agreements.	0.40
07/02/21	JD	Review lower priority additional Bates White reliance materials and suggestions for redactions and production.	0.60
07/02/21	JD	Correspondence with Purdue management, Davis Polk and PJT re: comments to the latest NewCo operating agreement draft.	0.70
07/02/21	RC	Review documentation related to cash distributions.	1.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/02/21	RC	Review documentation related to cash transfer of value categories.	1.70
07/02/21	JD	Call with J. Lowne (Purdue) re: governance agreement comments.	0.30
07/02/21	HSB	Review Purdue plan-related analysis and correspondence from Davis Polk.	0.40
07/02/21	HSB	Review Purdue shareholder settlement-related materials obtained from Davis Polk.	0.30
07/02/21	HSB	Review Purdue work transfer-related correspondence and comments from J.Lowne and R.Aleali (both Purdue).	0.80
07/02/21	HSB	Continue reviewing Purdue plan-related analysis and underlying financial projections.	1.30
07/02/21	HSB	Review Purdue plan related analysis prepared by PJT in connection with plan-related communications with Davis Polk and Purdue management.	0.60
07/03/21	HSB	Review Purdue plan-related analysis and projections in connection with question from J.Lowne (Purdue).	0.20
07/03/21	HSB	Review Purdue plan-related excel analysis in connection with question from E.Voggegut (Davis Polk).	0.20
07/04/21	GJK	Review of recent model draft for potential illustrative scenarios.	1.70
07/05/21	GJK	Review updated definitions of Settlement Agreement draft from Davis Polk (ongoing).	2.30
07/05/21	GJK	Review of Settlement Agreement draft (ongoing), including Articles 3 to 8.	2.30
07/05/21	HSB	Review draft of Purdue work transfer related agreement updated by Davis Polk	0.80
07/05/21	HSB	Review Purdue Plan Projections and PJT prepared analysis in connection with plan related email correspondence with	0.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
		J.Lowne (Purdue), Davis Polk and PJT	
07/06/21	HSB	Attended part of the call among G. Koch, L. Nguyen (both AlixPartners), A. Libby (Davis Polk), J. Ball (Debevoise), G. Coutts, H. Schenk, A. Benjamin (all Houlihan), M. Atkinson (Province), R. Ringer (Kramer Levin), S. Gilbert (Gilbert), M. Diaz (FTI) re: shareholder settlement agreement	0.90
07/06/21	HSB	Review Purdue prepared financial forecasts	0.90
07/06/21	HSB	Review Purdue Plan related analysis in connection with Purdue plan supplement to be filed by Davis Polk	2.30
07/06/21	HSB	Review draft versions of Purdue Plan related analysis and forecasts prepared by PJT	0.80
07/06/21	HSB	Multiple calls with S.Lemack (AlixPartners) to discuss Purdue plan related matters	0.20
07/06/21	RC	Review support documentation related to quantification of cash transfer of value analysis.	1.30
07/06/21	RC	Additional review of support documentation in connection with Plan Confirmation.	0.70
07/06/21	GJK	Call with J. DelConte and G. Koch (both AlixPartners) re: shareholder agreement.	0.20
07/06/21	SKL	Multiple calls with H. Bhattal (AlixPartners) to discuss various plan-related matters	0.20
07/06/21	SKL	Finalize latest updates to the liquidation analysis reliance documents and finalize approval process to provide documents accordingly.	2.60
07/06/21	SKL	Finalize updates to the liquidation analysis reliance document listing and circulate updated feedback to D. Mazer (Davis Polk)	2.10
07/06/21	JD	Call with J. Lowne (Purdue) re: supplemental plan	0.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
		agreements.	
07/06/21	JD	Call with R. Aleali, J. Lowne (Purdue), E. Vonnegut, C. Robertson, S. Massman, Z. Levine, W. Taylor (all Davis Polk), J. DelConte, H. Bhattal (both AlixPartners), J. Turner, T. Melvin, J. Arsic (all PJT) re: supplemental plan documents.	0.80
07/06/21	JD	Call with J. DelConte and G. Koch (both AlixPartners) re: shareholder agreement.	0.20
07/06/21	JD	Call with J. Turner (PJT) re: governance term sheet.	0.20
07/06/21	JD	Call with J. Lowne (Purdue), J. Turner (PJT), W. Taylor (Davis Polk) re: governance term sheet.	0.70
07/06/21	JD	Follow-up call with J. Turner (PJT) re: open governance document issues.	0.50
07/06/21	JD	Call with T. Melvin (PJT) re: open plan documents.	0.20
07/06/21	JD	Correspondence with Davis Polk and PJT re: changes to the governance term sheet and plan documents.	0.80
07/06/21	JD	Review the latest NewCo and TopCo governance term sheet and issues list	1.30
07/06/21	JD	Correspondence with Davis Polk, Purdue management and PJT re: discussions with the AHC on changes to the plan documents.	0.50
07/07/21	JD	Call with E. Vonnegut and S. Massman (both Davis Polk) re: plan document negotiations.	0.20
07/07/21	JD	Call with R. Aleali (Purdue) re: latest plan term sheet discussions.	0.30
07/07/21	JD	Call with J. Turner (PJT) re: distribution amounts in the governance term sheet.	0.30
07/07/21	JD	Call with J. Lowne (Purdue) re: latest plan document discussion updates.	0.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/07/21	JD	Review and provide comments on updated plan documents.	1.10
07/07/21	JD	Correspondence with Davis Polk and PJT re: proposed revisions to the plan language from the AHC.	0.70
07/07/21	JD	Correspondence with Davis Polk and PJT re: potential changes to plan document language.	0.30
07/07/21	SKL	Prepare updated outline of liquidation analysis recovery rates and underlying assumptions.	2.40
07/07/21	SKL	Call with H. Bhattal (AlixPartners) to discuss Purdue plan related matters	0.30
07/07/21	RC	Review materials related to Plan confirmation	1.10
07/07/21	HSB	Call with S.Lemack (AlixPartners) to discuss Purdue plan related matters	0.30
07/07/21	HSB	Review Purdue Plan related analysis and underlying financial amounts	1.30
07/07/21	HSB	Review drafts of NewCo related agreement and related comments	1.50
07/07/21	HSB	Review multiple emails received in connection with discussion of plan related analysis	0.40
07/07/21	HSB	Review shareholder settlement related documents received from Davis Polk	0.60
07/07/21	HSB	Review select sections of Purdue Plan and DS in connection with discussion of plan related issues	0.80
07/08/21	HSB	Review Purdue Mediator's report	0.30
07/08/21	HSB	Review draft versions of Purdue work transfer related documents	2.30
07/08/21	HSB	Review Purdue financial analysis and related underlying amount in connection with Plan related analysis	0.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/08/21	HSB	Review Purdue Plan related analysis and underlying financial amounts	1.50
07/08/21	HSB	Call with S.Lemack (AlixPartners) to discuss Purdue plan related matters	0.60
07/08/21	RC	Review information contained in expert reports re: distributions.	1.10
07/08/21	SKL	Finalize updates to the liquidation analysis reliance materials based on the latest feedback provided by D. Mazer (Davis Polk).	1.20
07/08/21	SKL	Continue to update the high-level outline of the liquidation analysis.	0.90
07/08/21	SKL	Call with H. Bhattal (AlixPartners) to discuss contract analysis process and other case related matters.	0.60
07/09/21	SKL	Continue to update the high-level outline of the liquidation analysis.	0.80
07/09/21	RC	Review documents related to Plan Confirmation.	1.30
07/09/21	RC	Review press coverage re: updated settlement and support from additional states.	0.30
07/09/21	RC	Review information included in the Sackler Family's submitted expert reports.	1.40
07/09/21	JD	Review mediators report filed with the court.	0.30
07/09/21	HSB	Review draft versions of Purdue work transfer related documents	1.40
07/09/21	HSB	Review Purdue plan related documents in connection with ongoing discussions	1.60
07/09/21	HSB	Review Purdue financial projections in connection with plan related discussions	0.70
07/09/21	HSB	Review shareholder settlement related documents received from Davis Polk	0.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/12/21	HSB	Call with M.Kesselman, J.Lowne, R.Aleali (all Purdue), C. Robertson, E.Vonnegut, A.Lele, W.Taylor, S.Massman (all Davis Polk), J.Turner,T. Melvin (PJT), J.DelConte (AlixPartners) re: Purdue plan related discussion	0.80
07/12/21	HSB	Review Purdue forecasts and related analysis in connection with due diligence request	1.40
07/12/21	HSB	Prepare draft responses in connection with due diligence request	0.60
07/12/21	HSB	Review PJT prepared analysis in connection with ongoing Purdue plan related discussions	0.80
07/12/21	HSB	Review excel files prepared by Purdue team with due diligence info	0.70
07/12/21	HSB	Review shareholder settlement related materials obtained from Debevoise	1.20
07/12/21	HSB	Multiple calls with S.Lemack (AlixPartners) to discuss Purdue plan related matters	0.50
07/12/21	HSB	Call with L.Nguyen (AlixPartners) to discuss Purdue plan related matters	0.30
07/12/21	HSB	Review draft of Plan related materials in connection with ongoing negotiations	0.90
07/12/21	LTN	Call with H. Bhattal, L. Nguyen (both AlixPartners) to discuss queries about plan projection	0.30
07/12/21	LTN	Call among G. Koch, L. Nguyen (AlixPartners), A. Libby, J. Weiner (Davis Polk) and other advisors / creditors to discuss open items on the settlement agreement	1.00
07/12/21	JD	Call with M.Kesselman, J.Lowne, R.Aleali (all Purdue), C. Robertson, E.Vonnegut, A.Lele, W.Taylor, S.Massman (all Davis Polk), J.Turner,T. Melvin (PJT), H. Bhattal (AlixPartners) re: Purdue plan related discussion	0.80

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/12/21	RC	Review documentation in connection preparation for plan confirmation.	1.20
07/12/21	GJK	Call among G. Koch, L. Nguyen (AlixPartners), A. Libby, J. Weiner (Davis Polk) and other advisors / creditors to discuss open items on the settlement agreement	1.00
07/12/21	SKL	Multiple calls with H. Bhattal (AlixPartners) to discuss plan related matters	0.50
07/13/21	SKL	Finalize updates related to the reliance materials for the liquidation analysis and circulate update accordingly.	0.50
07/13/21	MFR	Call with R. Collura (AlixPartners) and Davis Polk (D. Mazer, K. Benedict and J. Shinbrot) to discuss the supporting documentation for the cash and non-cash transfer of value reports	0.30
07/13/21	RC	Call with M. Rule (AlixPartners) and Davis Polk (D. Mazer, K. Benedict and J. Shinbrot) to discuss the supporting documentation for the cash and non-cash transfer of value reports.	0.30
07/13/21	RC	Review documents related to the cash transfers of value report in response to requests from Davis Polk.	1.60
07/13/21	RC	Continue to review support documents in preparation for Plan Confirmation.	1.40
07/13/21	JD	Correspondence with Davis Polk and S. Lemack (AlixPartners) re: expert report reliance documents.	0.30
07/13/21	JD	Correspondence with Davis Polk and M. Rule, A. DePalma (both AlixPartners) re: M. Rule expert report reliance material review.	0.50
07/13/21	JD	Review latest NewCo operating agreement draft.	0.40
07/13/21	JD	Provide comments on draft summary presentation from PJT on the AHC operating agreements.	0.80

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/13/21	ADD	Review and compile 1a/1b report reliance documents.	2.30
07/13/21	HSB	Review expert report reliance materials list	0.20
07/13/21	HSB	Review select sections of Purdue plan and DS in connection with ongoing plan discussions	1.10
07/13/21	HSB	Multiple calls with S.Lemack (AlixPartners) to discuss Purdue plan related matters	0.40
07/13/21	HSB	Review Purdue plan related documents in connection with ongoing negotiations	1.80
07/14/21	HSB	Review Purdue plan related analysis in connection with ongoing plan negotiations	1.70
07/14/21	HSB	Review Purdue supporting documents in connection with request from Davis Polk and provided comments to AlixPartners team.	2.90
07/14/21	HSB	Review Purdue financial analysis in connection with due diligence request	1.30
07/14/21	ADD	Review and compile 1a/1b report reliance documents.	3.10
07/14/21	JD	Correspondence with Davis Polk re: initial NOAT distribution discussions with the AHC.	0.20
07/14/21	RC	Review documents related to cash transfers of value report.	1.10
07/14/21	RC	Review documents related to expert discovery.	1.30
07/15/21	RC	Review supporting documents related to expert reports.	1.40
07/15/21	RC	Call with J. DelConte and R. Collura (both AlixPartners) re: confirmation timeline.	0.20
07/15/21	RC	Additional review of supporting documentation related to the expert report.	1.00
07/15/21	RC	Review documents re: Plan Confirmation and related preparation.	0.80

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/15/21	JD	Call with J. DelConte and R. Collura (both AlixPartners) re: confirmation timeline.	0.20
07/15/21	JD	Review and provide comments to N. Simon and L. Nguyen (both AlixPartners) on analysis of S. Miller (Purdue board member) historical compensation for the examiner.	0.40
07/15/21	HSB	Review Purdue contract related files in connection with plan filings	0.80
07/15/21	HSB	Review Plan related analysis in connection with ongoing Purdue plan negotiations	1.40
07/15/21	HSB	Review Purdue prepared analysis in connection with due diligence request	0.20
07/15/21	HSB	Review Purdue prepared analysis in connection with due diligence request related to sales	1.50
07/15/21	HSB	Review Purdue financial projections and updated related excel files	1.30
07/16/21	HSB	Review Purdue contract related files in connection with plan filings	1.60
07/16/21	HSB	Review Purdue financial projections in connection with Plan related due diligence request	1.20
07/16/21	JD	Review confirmation prep update from Davis Polk litigation team.	0.20
07/16/21	RC	Review materials related to expert report and prepare for Plan Confirmation.	1.20
07/16/21	RC	Review expert report support documentation produced by in connection with Plan Confirmation.	0.80
07/16/21	GJK	Review draft edits to Scenario 1 from B Kennedy (Milbank).	0.30
07/19/21	RC	Review expert report materials in preparation for meeting with Davis Polk re: Plan Confirmation.	1.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/19/21	RC	Review document related to information included in the cash transfers of value report.	1.40
07/19/21	SKL	Call with H. Bhattal (AlixPartners) to discuss Purdue plan related matters	0.10
07/19/21	JD	Call with J. DelConte, L. Nguyen (both AlixPartners) re: MOR	0.20
07/19/21	HSB	Call with S.Lemack (AlixPartners) to discuss Purdue plan related matters	0.10
07/19/21	HSB	Review Purdue cash forecasts related input obtained from E.Ruiz (Purdue)	0.20
07/19/21	HSB	Review relevant sections of Purdue plan and disclosure statement in connection with ongoing plan discussions	1.40
07/19/21	HSB	Review relevant sections of shareholder settlement agreement in connection	0.40
07/19/21	HSB	Call with H. Bhattal, L. Nguyen (AlixPartners) to discuss Newco cash flows	0.40
07/19/21	HSB	Continued reviewing Purdue monthly board deck with financial results	1.30
07/19/21	HSB	Review multiple versions of contract assumption related files prepared by S.Lemack (AlixPartners)	1.20
07/19/21	HSB	Review plan related analysis obtained from Purdue in response to due diligence request	0.60
07/19/21	HSB	Review Purdue sales related analysis in connection with due diligence request	0.50
07/19/21	LTN	Call among H. Bhattal, L. Nguyen (AlixPartners), J. Lowne, E. Ruiz (Purdue), T. Melvin (PJT) to discuss Newco Cashflow breakdown	0.20
07/19/21	LTN	Call with J. DelConte, L. Nguyen (both AlixPartners) re: MOR	0.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/20/21	LTN	Revise the NewCo cash flow breakdown by product level based on the internal feedback	1.50
07/20/21	LTN	Call among H. Bhattal, L. Nguyen (AlixPartners), L. Scheinbach (Purdue) to discuss Newco Cashflow breakdown	0.40
07/20/21	LTN	Prepare the NewCo cash flow breakdown by product level requested by UCC	1.70
07/20/21	LTN	Call with H. Bhattal (AlixPartners) to discuss Purdue plan related matters	0.20
07/20/21	HSB	Call with J.DelConte (AlixPartners), J.O'Connell, J.Turner, T.Melvin (both PJT), K.Benedict, M.Tobak, E.Townes, G.Cardillo (all Davis Polk) re: plan related discussions	0.80
07/20/21	HSB	Call among H. Bhattal, L. Nguyen (AlixPartners), L. Scheinbach (Purdue) to discuss Newco Cashflow breakdown	0.40
07/20/21	HSB	Call with L.Nguyen (AlixPartners) to discuss Purdue plan related matters	0.20
07/20/21	HSB	Call with S.Lemack (AlixPartners) to discuss Purdue plan related matters	0.10
07/20/21	HSB	Review multiple versions of Purdue business plan related materials in connection with request from Davis Polk	0.70
07/20/21	HSB	Review Davis Polk's comments in connection with plan related analysis prepared by PJT and related email correspondence	0.60
07/20/21	HSB	Review PJT prepared plan analysis to prepare for meeting with Davis Polk team to discuss plan related issues	0.50
07/20/21	HSB	Review Purdue forecasts in connection with plan related analysis	1.20
07/20/21	HSB	Review relevant sections of Purdue mediator's report	0.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/20/21	HSB	Review updated Purdue plan materials prepared by Davis Polk in connection with review of financial information to be updated	1.80
07/20/21	JD	Correspondence with Purdue management re: governance term sheet and L/C and surety bond needs.	0.40
07/20/21	JD	Review latest updated draft NewCo operating and governance agreements and DOJ edits.	0.70
07/20/21	JD	Call with M. Toback, K. Benedict, E. Townes (all Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT), J. DelConte, H. Bhattal (both AlixPartners) re: confirmation process.	0.80
07/20/21	JD	Correspondence with Davis Polk and Purdue management re: NewCo operating agreement and governance docs negotiations.	0.50
07/20/21	MFR	Call with R. Collura (AlixPartners) and Davis Polk (M. Clarens, E. Kim and A. Whisenant) to discuss upcoming Plan Confirmation trial hearing and related follow-up	0.80
07/20/21	RC	Review Examiner's report.	0.50
07/20/21	RC	Review documentation in preparation for meeting with Davis Polk re: Plan Confirmation.	1.20
07/20/21	RC	Call with M. Rule (AlixPartners) and Davis Polk (M. Clarens, E. Kim and A. Whisenant) to discuss upcoming Plan Confirmation trial hearing and related follow-up.	0.80
07/20/21	RC	Review expert report materials issues in connection with Plan Confirmation.	1.40
07/21/21	RC	Review materials related to Plan Confirmation.	1.30
07/21/21	RC	Review support documentation related to expert reports.	1.50
07/21/21	HSB	Review analysis prepared by L.Nguyen (AlixPartners) and supporting excel files in connection with due diligence	1.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/21/21	HSB	request Review Purdue financial forecasts in connection with analysis prepared by L.Nguyen (AlixPartners)	0.80
07/21/21	HSB	Call with S.Lemack (AlixPartners) to discuss Purdue plan related matters	0.40
07/21/21	HSB	Continue reviewing Purdue plan materials prepared by Davis Polk	2.20
07/21/21	HSB	Made revisions to plan related analysis prepared by L.Nguyen (AlixPartners)	1.20
07/21/21	LTN	Finalize Newco cash flow breakdown by product level and circulate to CFO review	0.40
07/22/21	LTN	Call with H. Bhattal (AlixPartners) to discuss Purdue plan related matters	0.30
07/22/21	LTN	Meeting with S. Lemack (AlixPartners) to discuss MOR format and preparation.	0.50
07/22/21	HSB	Review relevant sections of latest drafts of plan documents obtained from Davis Polk	1.30
07/22/21	HSB	Review Purdue long term financial projections model in connection with due diligence request	1.10
07/22/21	HSB	Call with L.Nguyen (AlixPartners) to discuss Purdue plan related matters	0.30
07/22/21	HSB	Call with S.Lemack (AlixPartners) to discuss Purdue plan related matters	0.20
07/22/21	HSB	Review Purdue business plan materials in connection with plan related analysis	1.10
07/22/21	HSB	Review Purdue revenues related analysis prepared by S.Lemack (AlixPartners) in connection with due diligence request	0.20
07/22/21	JD	Review latest draft NewCo and TopCo operating	0.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
		agreements.	
07/22/21	RC	Review documents related to information included in the cash transfers of value report.	1.60
07/22/21	SKL	Call with H. Bhattal (AlixPartners) to discuss latest diligence requests.	0.20
07/23/21	SKL	Call with H. Bhattal (AlixPartners) to discuss plan related matters.	0.30
07/23/21	RC	Review documentation in connection with Plan Confirmation.	1.60
07/23/21	RC	Additional review of documents related to cash transfers of value report.	1.30
07/23/21	JD	Create summary prescription trend chart for Davis Polk discovery data room.	0.30
07/23/21	HSB	Review Purdue financial projections in connection with financial analysis prepared by L.Nguyen (AlixPartners)	0.70
07/23/21	HSB	Review Purdue financial analysis prepared by L.Nguyen (AlixPartners) in connection with Plan related due diligence request	1.40
07/23/21	HSB	Updated Purdue financial analysis prepared by L.Nguyen (AlixPartners) in connection with Plan related due diligence request	2.50
07/23/21	HSB	Call with S.Lemack (AlixPartners) to discuss Purdue plan related matters	0.30
07/23/21	HSB	Call with L.Nguyen (AlixPartners) to discuss Purdue plan related matters	0.50
07/23/21	HSB	Review select sections of Purdue plan objections filed by various parties	0.80
07/23/21	LTN	Finalize the NewCo cashflow by product level based internal feedback and circulate to Purdue/ PJT for review	1.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/23/21	LTN	Revise the NewCo cashflow by product level based on CFO feedback and circulate for internal review	2.20
07/23/21	LTN	Reconcile Rhodes profit margin vs the long term consolidated plan and update product margin	1.20
07/23/21	LTN	Call with H. Bhattal, L. Nguyen (AlixPartners) to discuss cash schedule for POR	0.50
07/26/21	LTN	Review the changes on NewCo cash flow made by H. Bhattal (AlixPartners)	0.40
07/26/21	LTN	Call among H. Bhattal, L. Nguyen (all AlixPartners), T. Melvin (PJT) to discuss long-term plan versions.	0.30
07/26/21	LTN	Multiple calls with H. Bhattal, L. Nguyen (AlixPartners) re: plan projection matters	0.30
07/26/21	HSB	Call with S.Lemack (AlixPartners) to discuss Purdue plan related matters	0.20
07/26/21	HSB	Updated excel file prepared by L.Nguyen (AlixPartners) in connection with request for Plan related exhibits	0.80
07/26/21	HSB	Review multiple versions of excel files and compared versions in connection with request for Plan related exhibits	1.60
07/26/21	HSB	Call among H. Bhattal, L. Nguyen (all AlixPartners), T. Melvin (PJT) to discuss long-term plan versions.	0.30
07/26/21	HSB	Call with S.Lemack (AlixPartners) re: Purdue due diligence requests	0.40
07/26/21	HSB	Review Purdue board materials in connection with due diligence request for info.	1.10
07/26/21	HSB	Prepared draft excel summary with due diligence info in connection with Purdue due diligence request	0.40
07/26/21	HSB	Review Purdue prepared documents with financial forecasts and financial results in connection with due	1.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
		diligence requests	
07/26/21	HSB	Review Purdue contracts and related info in connection with due diligence request	1.50
07/26/21	HSB	Call with A.DePalma (AlixPartners) to discuss Purdue due diligence	0.20
07/26/21	HSB	Multiple calls with H. Bhattal, L. Nguyen (AlixPartners) re: plan projection matters	0.30
07/26/21	ADD	Call with H. Bhattal (AlixPartners) to discuss Purdue due diligence	0.20
07/26/21	JD	Review latest draft Company operations agreement.	0.30
07/26/21	JD	Review final business plan files to be shared via the confirmation discovery process.	0.40
07/26/21	JD	Review latest NewCo and TopCo operating agreement drafts from Kramer.	0.50
07/26/21	JD	Review potential discovery documents per Davis Polk request for business plan materials.	0.50
07/26/21	RC	Research request from UCC's advisors and coordinate with team re: follow-up steps.	1.00
07/26/21	RC	Review documents related to information request by the UCC's advisors and provide follow-up responses to such requests.	1.10
07/26/21	RC	Review materials in connection with preparing for Plan Confirmation.	1.80
07/26/21	RC	Research information related to requests from Davis Polk and prepare communications with counsel.	1.60
07/26/21	SKL	Call with H. Bhattal (AlixPartners) to discuss plan related matters	0.20
07/26/21	SKL	Meeting with H. Bhattal (AlixPartners) to discuss Purdue operations info request.	0.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/27/21	RC	Review materials provided by Davis Polk in connection with Plan Confirmation.	1.40
07/27/21	RC	Additional review of Plan Confirmation related materials.	1.30
07/27/21	RC	Review documentation re: the cash transfers of value report.	1.50
07/27/21	JD	Call with C. Robertson (Davis Polk) re: confirmation process timeline.	0.20
07/27/21	HSB	Review draft of Purdue plan related materials prepared by Davis Polk	1.80
07/27/21	HSB	Review selection sections of Purdue plan & DS in connection with ongoing analysis	0.60
07/27/21	HSB	Review PJT prepared analysis in connection with analysis supporting ongoing Plan negotiations	1.30
07/27/21	HSB	Review open items on various Purdue plan related issues and prepared list	0.40
07/28/21	HSB	Review Purdue Plan related materials in connection with ongoing Plan negotiations	1.20
07/28/21	HSB	Review draft declarations prepared by Davis Polk in connection with Purdue confirmation hearing	0.50
07/28/21	HSB	Review multiple files prepared by S.Lemack (AlixPartners) in response to due diligence requests	1.50
07/28/21	HSB	Multiple calls with S.Lemack (AlixPartners) to discuss Purdue due diligence related analysis	2.00
07/28/21	HSB	Call with A.DePalma (AlixPartners) to discuss Purdue due diligence	0.10
07/28/21	ADD	Call with H. Bhattal (AlixPartners) to discuss Purdue due diligence	0.10
07/28/21	RC	Review information related to Plan Confirmation.	1.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/29/21	HSB	Review updated draft of declaration prepared by Davis Polk in connection with Purdue confirmation hearing and provided comments	2.30
07/29/21	HSB	Review relevant sections of Plan documents in connection with review of updated draft of declaration prepared by Davis Polk	1.70
07/29/21	JD	Correspondence with Davis Polk re: diligence project and NewCo operating agreements.	0.50
07/29/21	LTN	Call with H. Bhattal, L. Nguyen (AlixPartners) re: new MOR format update	0.20
07/29/21	LTN	Call with D. Consla (DavisPolk) re: new MOR format update	0.40
07/30/21	LTN	Call among G. Koch, L. Nguyen (AlixPartners), A. Libby, J. Weiner (Davis Polk) and other advisors to discuss Settlement agreement	2.70
07/30/21	HSB	Review draft of declaration prepared by Davis Polk and related comments from multiple individuals and sent list of comments to Davis Polk for review and update	1.30
07/30/21	HSB	Review relevant sections of Plan documents in connection with review of updated draft of declaration prepared by Davis Polk	1.70
07/30/21	HSB	Review diligence requests list and reviewed files prepared by S.Lemack (AlixPartners)	2.30
07/30/21	JD	Review and provide comments on latest draft declaration.	1.10
07/30/21	SKL	Review latest draft declaration document and provide updates to the Alix team accordingly.	1.60
07/30/21	GJK	Call among G. Koch, L. Nguyen (AlixPartners), A. Libby, J. Weiner (Davis Polk) and other advisors to discuss Settlement agreement	2.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/31/21	HSB	Review two updated drafts of declarations prepared by Davis Polk and documented comments and edits	1.80
07/31/21	HSB	Review Purdue Plan documents in connection with review of ongoing plan related document drafts	0.70
		Total	240.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice #

2138238-2

POR Development 012589.00107

Fee Recap:

Client/Matter #

Consultant	Hours	Rate	Amount
Lan T Nguyen	17.20	530.00	9,116.00
Andrew D DePalma	5.70	625.00	3,562.50
Sam K Lemack	15.30	665.00	10,174.50
HS Bhattal	115.40	865.00	99,821.00
Gabe J Koch	10.90	865.00	9,428.50
Mark F Rule	1.10	980.00	1,078.00
Jesse DelConte	24.20	1,055.00	25,531.00
Richard Collura	50.60	1,125.00	56,925.00
Total Hours & Fees	240.40		215,636.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/01/21	ADD	Analyze invoice level A/P data to identify vendor spend trends.	2.80
07/01/21	JD	Provide comments on a list of potential contracts to reject and assume in advance of call with management.	0.50
07/01/21	JD	Review list of potential surety bonds to assume in comparison with prepetition list.	0.10
07/01/21	SKL	Continue to finalize review of latest contract rejection feedback and circulate updated analysis prior to afternoon meeting.	2.40
07/01/21	SKL	Meeting with S. Daniel and C. Russo (both Purdue) re: contract rejection analysis.	0.70
07/01/21	SKL	Meeting with S. Daniel and C. Russo (both Purdue) to provide additional update re: contract rejection analysis.	0.40
07/01/21	SKL	Meeting with J. Lowne, S. Daniel, C. Russo (all Purdue), J. DelConte and H. Bhattal (both AlixPartners) to discuss contract rejection exhibit.	0.50
07/01/21	JD	Correspondence with Davis Polk and Purdue management re:list of potential surety bonds to assume in comparison with prepetition list.	0.20
07/01/21	JD	Call with J. Lowne, C. Russo, S. Daniel, R. Aleali (all Purdue), J. DelConte, S. Lemack, H. Bhattal (all AlixPartners) re: contract assumption and rejection lists.	0.50
07/02/21	SKL	Finalize review of contract rejection analysis and circulate update to Davis Polk team accordingly.	1.10
07/02/21	JD	Correspondence with S. Lemack (AlixPartners) and Purdue management re: potential contract rejections.	0.30
07/03/21	GJK	Review IP contract review documents from H Smith (Davis Polk).	0.30
07/06/21	SKL	Review latest notes and feedback provided on the	1.00

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
		contract assumption/rejection analysis and prepare updates to the consolidated contracts tracker accordingly.	
07/07/21	SKL	Multiple calls with C. Robertson (Davis Polk) to discuss contract rejection/assumption analysis.	0.30
07/07/21	SKL	Multiple calls with S. Daniel (Purdue) to discuss contract rejection/assumption analysis.	0.50
07/07/21	SKL	Call with S. Daniel (Purdue) to discuss contract assumption process.	0.30
07/07/21	JD	Call with C. Robertson (Davis Polk), J. DelConte, S. Lemack, H. Bhattal (all AlixPartners), J. Lowne, S. Daniel, J. Lauriat, C. Russo (all Purdue) re: contract rejection and assumption.	0.80
07/07/21	HSB	Call with C. Robertson (Davis Polk), J. DelConte, S. Lemack, H. Bhattal (all AlixPartners), J. Lowne, S. Daniel, J. Lauriat, C. Russo (all Purdue) re: contract rejection and assumption.	0.80
07/08/21	HSB	Meeting with S. Daniel (Purdue), C. Russo (Purdue), J. Doyle (Purdue), C. Robertson (Davis Polk) and S. Lemack (AlixPartners) to discuss open questions re: contract assumption/rejection process.	0.30
07/08/21	SKL	Calls with C. Robertson (Davis Polk) to discuss contract rejection/assumption analysis.	0.20
07/08/21	SKL	Meeting with S. Daniel (Purdue), C. Russo (Purdue), J. Doyle (Purdue), C. Robertson (Davis Polk) and H. Bhattal (AlixPartners) to discuss open questions re: contract assumption/rejection process.	0.30
07/08/21	SKL	Meeting with R. Aleali (Purdue), S. Hoffman (Purdue), S. Brecher (Davis Polk) and C. Chandler (Wiggins Dana) to discuss employee agreements.	0.30
07/08/21	SKL	Call with K. McCarthy, S. Hoffman, Z. Haseeb, B. Koch, R.	1.00

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
		Kreppel, J. Doyle, R. Inz (all Purdue) and G. Koch (AlixPartners) to discuss IP contract review process.	
07/08/21	SKL	Review latest notes and feedback provided by R. Inz (Purdue) and the IP team and updated the consolidated contract tracker accordingly.	2.20
07/08/21	SKL	Finalize review of latest contracts provided by IP and prepare for discussion with C. Robertson (Davis Polk) recontract assumptions.	0.90
07/08/21	GJK	Call with K. McCarthy, S. Hoffman, Z. Haseeb, B. Koch, R. Kreppel, J. Doyle, R. Inz (all Purdue) and S. Lemack (AlixPartners) to discuss IP contract review process.	1.00
07/09/21	SKL	Finalize review of latest notes and feedback provided in IP contracts from R. Kreppel and R. Inz (both Purdue) and circulate updated analysis to C. Robertson (Davis Polk) accordingly.	1.70
07/09/21	SKL	Continue to review latest notes and feedback provided by S. Daniel (Purdue) and the procurement team re: contract analysis and prepare updates to the latest contracts tracker accordingly.	2.00
07/09/21	SKL	Call with S. Daniel (Purdue) to discuss contract assumption process.	0.20
07/12/21	SKL	Call with S. Daniel (Purdue) to discuss contract assumption process.	0.30
07/12/21	SKL	Continue to review latest notes and feedback provided by the various subgroup teams and prepare updates to the contract analysis tracker accordingly.	2.40
07/12/21	SKL	Continue to finalize updates to the latest contract assumption schedule.	1.40
07/13/21	SKL	Continue to review latest feedback received re: contract assumption analysis, and updated the master contract	2.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/13/21	SKL	tracker accordingly. Call with C. Robertson (Davis Polk) to discuss contract cure analysis.	0.10
07/13/21	SKL	Call with S. Daniel (Purdue) to discuss contract assumption process.	0.20
07/14/21	SKL	Call with H. Bhattal (AlixPartners) to discuss latest feedback provided re: contract assumptions.	0.20
07/14/21	SKL	Prepare for and participate in contract cure meeting with J. Doyle, K. McCarthy, E. Ruta (all Purdue), and C. Robertson (Davis Polk)	0.40
07/14/21	SKL	Call with J. DelConte (AlixPartners) to discuss contract cure process.	0.20
07/14/21	SKL	Finalize review of Rhodes and IP feedback re: contract assumption analysis and prepare updates to the latest contract tracker accordingly.	2.70
07/14/21	SKL	Continue review of assumed contracts with cures and begin preparing updated contract assumption schedule accordingly.	2.50
07/14/21	SKL	Finalize review and reconciliation of newly identified contracts for the contract assumption schedule and updated and circulate and master contract tracker accordingly for additional review.	2.50
07/14/21	JD	Call with S. Lemack (AlixPartners) to discuss contract cure process.	0.20
07/14/21	HSB	Call with S. Lemack (AlixPartners) to discuss latest feedback provided re: contract assumptions.	0.20
07/15/21	SKL	Finalize reconciliation of contract cure exhibit against OCPs, Critical Vendors and law firms and circulate updated feedback accordingly.	2.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/15/21	SKL	Finalize review of contract analysis feedback from E. Ruta (Rhodes) and S. Daniel (Purdue) and updated contract analysis accordingly for additional review and sign-off.	2.30
07/15/21	SKL	Call with A. DePalma (AlixPartners) to discuss contract cure analysis and OCP reconcilation.	0.10
07/15/21	SKL	Meeting with J. Lowne, S. Daniel and J. Lauriat (all Purdue) to discuss contract cure costs.	0.40
07/15/21	SKL	Meeting with R. Aleali (Purdue), C. Robertson (Davis Polk), and D. Consla (Davis Polk) to discuss contract assumption process and other change of control matters.	0.40
07/15/21	SKL	Multiple calls with C. Robertson (Davis Polk) to discuss the contract assumption process and open items.	0.40
07/15/21	SKL	Multiple calls with S. Daniel (Purdue) to discuss the contract assumption process and open items.	0.70
07/15/21	SKL	Review latest contract assumption feedback provided by J. Lauriat (Purdue) prior to morning meeting with Procurement.	1.30
07/15/21	SKL	Meeting with S. Daniel, N. McQuilkin, and J. Lauriat (all Purdue) to discuss latest subgroup feedback re: contract assumption process.	1.70
07/15/21	ADD	Review contract list and identify OCP vendors and retained professionals.	1.10
07/15/21	ADD	Call with S. Lemeck (AlixPartners) to discuss contract cure analysis and OCP reconcilation.	0.10
07/16/21	JD	Review latest contract assumption and cure amount list prior to filing on Monday.	0.50
07/16/21	SKL	Call with K. McCarthy (Purdue) to discuss contract assumption/rejection process.	0.20
07/16/21	SKL	Review latest notes and feedback provided by IP re:	0.80

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
		contract assumptions, and update the contract exhibit accordingly.	
07/16/21	SKL	Call with J. Lowne and S. Daniel (both Purdue) to discuss latest contract assumption feedback.	0.80
07/16/21	SKL	Prepare for upcoming cash flow projection meeting.	0.50
07/16/21	SKL	Finalize updated contract analysis tracker for S. Daniel and J. Lowne (both Purdue) review and sign-off.	1.30
07/16/21	SKL	Reconcile contract master to IP high-priority contracts and prepare follow-up on various contracts.	0.60
07/16/21	SKL	Finalize updates to the contract assumption exhibit and contract notice file following update meeting with J. Lowne (Purdue) and S. Daniel (Purdue).	2.10
07/16/21	SKL	Multiple calls with C. MacDonald (Purdue) to discuss latest contract analysis and legal vendors.	0.60
07/16/21	SKL	Multiple calls with S. Daniel (Purdue) to discuss latest feedback provided re: contract assumptions.	0.40
07/16/21	GJK	Review update contract information and comment and questions from S Daniel and J Lowne (Purdue).	0.30
07/17/21	GJK	Review contract assumption and cure information for Purdue.	0.50
07/17/21	SKL	Review latest contract assumption feedback provided and circulated updated analysis to FTI and Province accordingly.	1.60
07/17/21	SKL	Finalize review of latest contracts provided by S. Daniel (Purdue) and prepare updates to the contract master accordingly.	1.30
07/17/21	SKL	Call with C. Robertson (Davis Polk) to discuss latest contract cure inquiry.	0.10
07/17/21	JD	Review contract list updates from S. Lemack	0.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
		(AlixPartners) for the filing on Monday.	
07/18/21	GJK	Follow-up on communication between S Lemack (AlixPartners) and D Consla (Davis Polk) re: Prime Clerk and filings on contract assumption notification.	0.10
07/19/21	SKL	Multiple calls with D. Consla (Davis Polk) to discuss contract assumption schedules.	0.40
07/19/21	SKL	Multiple calls with S. Daniel (Purdue) to discuss contract assumption schedule.	0.50
07/19/21	SKL	Continue to review latest company feedback and notes re: contract assumptions, and update the contract exhibits accordingly.	2.60
07/19/21	SKL	Finalize review of latest newly identified prepetition contracts and prepare updates to the contract exhibits accordingly.	2.20
07/19/21	SKL	Review latest contract assumption exhibits and reconcile against the counterparty notice file to provide update to the Prime Clerk team accordingly.	2.50
07/19/21	SKL	Call with J. Lowne and E. Nowakowski (both Purdue) to discuss counterparty cure inquiry.	0.30
07/19/21	JD	Review vendor cure cost build up from S. Lemack (AlixPartners).	0.20
07/19/21	JD	Review final list of contract assumptions and associated cure amounts.	0.70
07/19/21	JD	Correspondence with Purdue management re: contract assumption list follow up questions.	0.20
07/20/21	SKL	Finalize review of contract cure exhibit and ensure all updates are captured accordingly.	1.80
07/20/21	SKL	Call with D. Consla (Davis Polk) to discuss co-defendant contract inquiry.	0.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/21/21	SKL	Review latest Prime Clerk file re: assumption/rejection notices and prepare and provide update accordingly.	2.10
07/21/21	SKL	Review latest co-defendant contract indemnity chart provided by Davis Polk and prepare updates accordingly.	1.70
07/21/21	SKL	Call with S. Daniel (Purdue) to discuss latest contract cure inquiry.	0.10
07/21/21	SKL	Finalize contract schedule provided by Davis Polk team and provide updated reconciliation accordingly.	0.80
07/21/21	JD	Review SAP contract assumption and cure amount correspondence from SAP.	0.40
07/22/21	JD	Review contract noticing list and process for finding missing addresses from Prime Clerk.	0.20
07/22/21	SKL	Finalize latest counterparty contract/invoice inquiry and provide update accordingly.	1.00
07/23/21	SKL	Review latest counterparty feedback provided by H. Benson (Purdue) and finalize counterparty inquiry accordingly.	0.80
07/26/21	SKL	Finalize review of latest contract cure cost inquiry and circulate feedback accordingly.	0.60
07/26/21	SKL	Call with E. Nowakowski (Purdue) to discuss contract cure inquiries.	0.10
07/26/21	JD	Review questions from a specific vendor on the assumption and cure list filed with the court and correspond with Davis Polk and S. Lemack re: same.	0.40
07/27/21	SKL	Call with E. Turay (Davis Polk) to discuss latest contract reconciliation matter.	0.20
07/27/21	SKL	Review latest Davis Polk contract inquiry and provided updated reconciliation and documents accordingly.	2.10
07/28/21	SKL	Finalize latest vendor cure cost reconciliation and circulate	0.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services to Davis Polk team.	Hours
07/28/21	SKL	Call with S. Daniel (Purdue) to discuss contract cure inquiries.	0.20
07/28/21	SKL	Multiple calls with E. Nowakowski (Purdue) to discuss contraact cure inquiries.	0.30
07/28/21	SKL	Multiple calls with C. Robertson (Davis Polk) to discuss contract cure inquiries.	0.30
07/29/21	SKL	Review latest contract cure inquiry and prepare updates to the tracker and follow-up with the company accordingly.	1.00
07/30/21	SKL	Call with C. Robertson (Davis Polk) to discuss contract cure inquiries.	0.10
		Total	86.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Executory Contracts Client/Matter # 012589.00108

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	4.00	625.00	2,500.00
Sam K Lemack	73.70	665.00	49,010.50
Gabe J Koch	2.20	865.00	1,903.00
HS Bhattal	1.30	865.00	1,124.50
Jesse DelConte	5.50	1,055.00	5,802.50
Total Hours & Fees	86.70		60,340.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Claims Process Re: Client/Matter # 012589.00109

Date	Consultant	Description of Services	Hours
07/13/21	SKL	Review latest POC breakdown provided by the Davis Polk team and prepare updates accordingly.	0.40
07/14/21	JD	Correspondence with Davis Polk re: convenience class claims analysis.	0.30
07/30/21	SKL	Prepare updates to the trade claims in the Alix claims database	1.60
07/30/21	SKL	Continue to finalize updates to the prepetition contracts database and prepare updated contracts breakdown per AHC request.	1.40
		Total	3.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Claims Process Client/Matter # 012589.00109

Fee Recap:

Consultant	Hours	Rate	Amount
Sam K Lemack	3.40	665.00	2,261.00
Jesse DelConte	0.30	1,055.00	316.50
Total Hours & Fees	3.70		2,577.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/01/21	JG	Update reserve data sets in preparation of launch at request of C. Oluwole (Davis Polk).	2.70
07/01/21	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	0.40
07/01/21	JH	Correspondence with J. Hamilton, J. Hardy (both AlixPartners) and J. Wagner (Kramer) re: downloading issues.	0.20
07/01/21	JH	Correspondence with J. Hamilton (AlixPartners) and C. Oluwole (Davis Polk) re reserve reporting.	0.20
07/01/21	JHH	Call with K. McCafferty, A. DePalma, J. Hyun and C. Nweke (all AlixPartners) re: morning meeting to review project deliverables and activities.	1.10
07/01/21	JHH	Review company diligence materials	2.10
07/01/21	JHH	Wilson manufacturing operations overview.	1.70
07/01/21	JHH	Review of existing diligence files re: diligence project.	1.30
07/01/21	JHH	Review Purdue diligence materials.	0.60
07/01/21	JHH	Weekly flash report update re: manufacturing and third- party spend.	0.50
07/01/21	JHH	Preparation for first weekly stand-up meeting with J. Lowne (Purdue).	1.90
07/01/21	KM	Call with C. Nweke (AlixPartners) re: CPP data and analysis.	0.80
07/01/21	KM	Call with C. Nweke (AlixPartners) re: CPP data review.	0.20
07/01/21	ADD	Call with C. Nweke (AlixPartners) re: profitability data requests.	0.20
07/01/21	ADD	Call with K. McCafferty, A. DePalma, J. Hyun and C. Nweke (all AlixPartners) re: morning meeting to review project deliverables and activities.	1.10

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/01/21	KM	Analyze company overview for report.	1.00
07/01/21	KM	Analyze comparable companies for diligence project.	2.00
07/01/21	KM	Analyze Rhodes product profitability for diligence project.	0.90
07/01/21	KM	Analyze development pipeline for diligence project.	0.80
07/01/21	KM	Call with K. McCafferty, A. DePalma, J. Hyun and C. Nweke (all AlixPartners) re: morning meeting to review project deliverables and activities.	1.10
07/01/21	ADD	Compile and clean vendor spend data.	2.70
07/01/21	CCN	Call with K. McCafferty, A. DePalma, J. Hyun and C. Nweke (all AlixPartners) re: morning meeting to review project deliverables and activities.	1.10
07/01/21	CCN	Call with K. McCafferty (AlixPartners) re: CPP data and analysis.	0.80
07/01/21	CCN	Call with K. McCafferty (AlixPartners) re: CPP data review.	0.20
07/01/21	CCN	Call with A. DePalma (AlixPartners) re: profitability data requests.	0.20
07/01/21	CCN	Review company detail files and prepare summary analysis.	1.90
07/01/21	CCN	Develop customer product profitability analysis hypothesis.	1.80
07/01/21	CCN	Review cost and revenue details on Avrio.	1.70
07/01/21	CCN	Review cost and revenue details on Adhansia.	1.40
07/02/21	CCN	Meeting with J. Lowne (Purdue), C. Nweke, A. DePalma, J. DelConte, K. McCafferty (AlixPartners) re: weekly stand-up meeting.	0.50
07/02/21	CCN	Call with K. McCafferty (AlixPartners) re: Avrio margin analysis.	0.20
07/02/21	CCN	Being preparing the initial Tableau CPP Analysis.	1.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/02/21	CCN	Review and analyze various cost files uploaded into the dataroom.	1.80
07/02/21	CCN	Begin preparation of R&D and IT Data overview.	0.30
07/02/21	KM	Call with C. Nweke (AlixPartners) re: Avrio margin analysis.	0.20
07/02/21	KM	Meeting with J. Lowne (Purdue), C. Nweke, A. DePalma, J. DelConte, K. McCafferty (AlixPartners) re: weekly stand-up meeting.	0.50
07/02/21	KM	Analysis and reporting re: company overview.	2.10
07/02/21	ADD	Meeting with J. Lowne (Purdue), C. Nweke, A. DePalma, J. DelConte, K. McCafferty (AlixPartners) re: weekly stand-up meeting.	0.50
07/02/21	ADD	Compile and clean vendor spend data.	2.70
07/02/21	ADD	Review materials for diligence project.	1.70
07/02/21	JHH	Meeting with J. Lowne (Purdue), J. Hyun ,C. Nweke, A. DePalma, J. DelConte, K. McCafferty (AlixPartners) re: weekly stand-up meeting.	0.50
07/02/21	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	0.50
07/02/21	JH	Correspondence with J. Hamilton (AlixPartners), K. Chau and C. Oluwole (both Davis Polk) re: new diligence productions.	0.20
07/02/21	JH	Correspondence with J. Hamilton (AlixPartners) and A. Guo (Davis Polk) re: user access.	0.80
07/02/21	JH	Correspondence with J. Hamilton (AlixPartners), P. Astras (KLD), and C. Oluwole (Davis Polk) re: new data for reserve.	0.20
07/02/21	JH	Correspondence with J. Hamilton (AlixPartners) and R. Atkinson (Cobra) re: reserve access.	0.10

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/02/21	JH	Correspondence with J. Hamilton and D. Reynolds (both AlixPartners) re new media shipment from TCDI.	0.10
07/02/21	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	0.20
07/06/21	JH	Correspondence with J. Hamilton (AlixPartners), and M. Puiggari (Law Offices of Paul Rothstein) re reserve access.	0.50
07/06/21	JH	Correspondence with J. Hamilton (AlixPartners), and J. Kleinman (FGLLP) re password reset.	0.20
07/06/21	JH	Correspondence with J. Hamilton (AlixPartners) and A. Guo (Davis Polk) re new user access.	0.30
07/06/21	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.00
07/06/21	JHH	Spend file review (based on Accounts Payables data from Jan. 2019 to June 2021).	1.70
07/06/21	JHH	Data cleansing of Accounts Payables file, including simplifcation and starndardization of key fields.	1.70
07/06/21	JHH	Existing inventory file review, snapshot in December 2020.	1.60
07/06/21	ADD	Compile and clean vendor spend data.	2.10
07/06/21	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.00
07/06/21	ADD	Review and categorize vendors for spend analysis.	2.40
07/06/21	ADD	Analyze invoice level A/P data to identify vendor spend trends.	2.80
07/06/21	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.00

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/06/21	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: preliminary review of IT and CPP analysis.	0.80
07/06/21	KM	Analyze company details for diligence project.	2.20
07/06/21	KM	Analyze company comparables for diligence project.	1.50
07/06/21	KM	Analyze customer profitability for diligence project.	1.40
07/06/21	KM	Analyze third party spend for diligence project.	1.90
07/06/21	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.00
07/06/21	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: preliminary review of IT and CPP analysis.	0.80
07/06/21	CCN	Analyze Avrio profitability by customer	1.90
07/06/21	CCN	Analyze research and development project spending.	1.80
07/06/21	CCN	Analyze research and development project net present values.	1.90
07/06/21	CCN	Review detailed Avrio spend and revenue files.	1.70
07/07/21	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.70
07/07/21	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: R&D analysis for diligence project.	0.80
07/07/21	CCN	Call with Neal Davis (Purdue), K. McCafferty and C. Nweke (both AlixPartners) re: Rhodes product pipeline tracking.	0.80
07/07/21	CCN	Develop consolidated research and development analysis.	1.90
07/07/21	CCN	Work on brand allocations for the customer product profitability analysis for Avrio.	1.80
07/07/21	CCN	Analysis of Rhodes research and development projects	1.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services and underlying timelines.	Hours
07/07/21	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.70
07/07/21	ADD	Call with J. Hyun, A. DePalma (both AlixPartners) re: Purdue spend analysis.	0.70
07/07/21	KM	Analyze expenses breakdown for diligence project.	1.90
07/07/21	KM	Analyze company details for summary diligence.	2.10
07/07/21	KM	Call with Neal Davis (Purdue), K. McCafferty and C. Nweke (both AlixPartners) re: Rhodes product pipeline tracking.	0.80
07/07/21	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.70
07/07/21	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: R&D analysis for diligence project.	0.80
07/07/21	KM	Analyze product profitability for diligence project.	1.90
07/07/21	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.70
07/07/21	JHH	Call with J. Hyun, A. DePalma (both AlixPartners) re: Purdue spend analysis.	0.70
07/07/21	JHH	Data cleansing of Accounts Payables file, including simplifcation and starndardization of key fields.	1.90
07/07/21	JHH	Preliminary analysis of vendor spend, summary by company code and spend type.	1.80
07/07/21	JHH	Prepare diligence questions re: vendor spend data.	0.70
07/07/21	JHH	Cross-referencing of third party spend with company departments.	1.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/07/21	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	0.40
07/07/21	JH	Correspondence with J. Hamilton (AlixPartners) and J. Chen (Davis Polk) re content of reserve.	0.40
07/07/21	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	0.40
07/08/21	JH	Correspondence with J. Hamilton (AlixPartners) and A. Guo (Davis Polk) re new user access.	0.20
07/08/21	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.90
07/08/21	JHH	Call with Jon Carlisle (Purdue) re: Wilson inventory data request.	0.60
07/08/21	JHH	Meeting with S. Daniel (Purdue), A. DePalma and J. Hyun (AlixPartners) re: Purdue vendor review and categorization.	1.20
07/08/21	JHH	Review of new third party spend data.	1.90
07/08/21	JHH	Mapping of key fields: cost centers, company codes.	1.80
07/08/21	JHH	Consolidation and simplification of key fields for the diligence report.	1.20
07/08/21	KM	Call with Ron Haberlin (Purdue), and K. McCafferty and C. Nweke (AlixPartners) re: Rhodes financial diligence data request.	0.50
07/08/21	KM	Meeting with H. Ghnaimeh and E. Liesmann (Purdue), and K. McCafferty, C. Nweke and A. DePalma (all AlixPartners) re: re: IT diligence interview and data request.	1.70
07/08/21	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/08/21	KM	Document creation re: weekly diligence project stand-up meeting with J. Lowne.	0.80
07/08/21	KM	Meeting with C. Nweke (AlixPartners) re: Avrio CPP preliminary findings.	1.00
07/08/21	KM	Presentation and reporting re: company overview for diligence project.	2.30
07/08/21	KM	Presentation and reporting re: product profitability for diligence project.	1.10
07/08/21	KM	Analyze manufacturing operations for diligence project.	1.80
07/08/21	ADD	Meeting with H. Ghnaimeh and E. Liesmann (Purdue), and K. McCafferty, C. Nweke and A. DePalma (AlixPartners) re: re: IT diligence interview and data request.	1.70
07/08/21	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.90
07/08/21	ADD	Download G&A account data including vendor mapping.	1.80
07/08/21	ADD	Compile and analyze updated G&A data.	2.30
07/08/21	ADD	Meeting with S. Daniel (Purdue), A. DePalma and J. Hyun (AlixPartners) re: Purdue vendor review and categorization.	1.20
07/08/21	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.90
07/08/21	CCN	Call with Ron Haberlin (Purdue), and K. McCafferty and C. Nweke (AlixPartners) re: Rhodes financial diligence data request.	0.50
07/08/21	CCN	Meeting with H. Ghnaimeh and E. Liesmann (Purdue), and K. McCafferty, C. Nweke and A. DePalma (AlixPartners) re: re: IT diligence interview and data request.	1.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/08/21	CCN	Meeting with K. McCafferty (AlixPartners) re: Avrio CPP preliminary findings.	1.00
07/08/21	CCN	Analyze customer profitability by form of product for diligence project.	1.90
07/08/21	CCN	Analyze product profitability by customer for diligence report.	1.80
07/09/21	CCN	Meeting with J. Lowne (Purdue); J.DelConte, K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence project weekly stand-up meeting.	0.80
07/09/21	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.10
07/09/21	CCN	Meeting with T. Au (Purdue); K. McCafferty and C. Nweke (AlixPartners) re: R&D analyiss for diligence project.	0.40
07/09/21	CCN	Meeting with J. Tran (Purdue); K. McCafferty, A. DePalma and C. Nweke (AlixPartners) re: Avrio customer and product profitability data request.	0.50
07/09/21	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: customer and product profitability analysis.	0.80
07/09/21	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: Avrio CPP data review for diligence project.	0.20
07/09/21	CCN	Call with C. Nweke and A. DePalma (AlixPartners) re: profitability data requests.	0.20
07/09/21	CCN	Analyze Avrio CPP.	1.90
07/09/21	CCN	Analysis and hypothesis generation re: CPP for Avrio.	1.80
07/09/21	CCN	Review diligence data re: Avrio customers, sales and margins data.	1.70
07/09/21	CCN	Dilegence data review re: Adhansia revenue and spend	1.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services files.	Hours
07/09/21	ADD	Meeting with J. Lowne (Purdue); J.DelConte, K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence project weekly stand-up meeting.	0.80
07/09/21	ADD	Call with J. Hyun, A. DePalma (both AlixPartners) re: Purdue analysis status.	0.10
07/09/21	ADD	Meeting with J. Tran (Purdue); K. McCafferty, A. DePalma and C. Nweke (AlixPartners) re: Avrio customer and product profitability data request.	0.50
07/09/21	ADD	Review and categorize vendors for analysis.	1.60
07/09/21	ADD	Analyze invoice level A/P data to identify vendor trends.	1.30
07/09/21	ADD	Reconcile data from SAP accounting system and files provided by the client.	2.00
07/09/21	KM	Slide preparation re: diligence project stand-up meeting with J. Lowne.	0.70
07/09/21	KM	Meeting with J. Lowne (Purdue); J.DelConte, K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence project weekly stand-up meeting.	0.80
07/09/21	KM	Meeting with T. Au (Purdue); K. McCafferty and C. Nweke (AlixPartners) re: R&D expenses analysis for diligence project.	0.40
07/09/21	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.10
07/09/21	KM	Meeting with J. Tran (Purdue); K. McCafferty, A. DePalma and C. Nweke (AlixPartners) re: Avrio customer and product profitability data request.	0.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/09/21	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: customer and product profitability analysis.	0.80
07/09/21	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: Avrio CPP data review for diligence project.	0.20
07/09/21	KM	Presentation and reporting re: product profitability for diligence project.	1.20
07/09/21	KM	Analyze third party spend categorization for diligence project.	1.90
07/09/21	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities	1.10
07/09/21	ADD	Call with C. Nweke and A. DePalma (both AlixPartners) re: profitability data requests.	0.20
07/09/21	JHH	Meeting with J. Lowne (Purdue); J.DelConte, K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence project weekly stand-up meeting.	0.80
07/09/21	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.10
07/09/21	JHH	Call with J. Hyun, A. DePalma (both AlixPartners) re: Purdue analysis status.	0.10
07/09/21	JHH	Review of new vendor activity data.	1.50
07/09/21	JHH	Standardization of company codes in vendor activity data.	1.40
07/09/21	JHH	Preliminary summary of vendor activity by businesses: Purdue, Rhodes, Avrio, etc.	1.50
07/09/21	JHH	Standardization of elements by cross reference original Accounts Payable file.	1.90
07/10/21	JH	Correspondence with A. Guo (Davis Polk) re new user	0.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
		access.	
07/11/21	JH	Correspondence with A. Guo (Davis Polk) re content of reserve.	0.20
07/12/21	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	0.50
07/12/21	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.30
07/12/21	JHH	Vendor file: identification of bankruptcy related vendors.	1.60
07/12/21	JHH	Call with J. Hyun and A. DePalma (AlixPartners) re: to review and analyze vendor data.	0.80
07/12/21	JHH	Review historical Wilson operational performance, e.g. OEE, production volume and financial absorption.	1.70
07/12/21	JHH	Mapping cost centers to department roll-up hierarchy for spend summaries.	1.20
07/12/21	JHH	Sales file consolidation of 2020 and 2021 monthly data for analysis preparation.	1.90
07/12/21	JHH	Preparation of multiple client meetings on July 13, list of questions and final data requests.	0.60
07/12/21	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	2.80
07/12/21	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.30
07/12/21	KM	Analyze company information for diligence project.	2.30
07/12/21	KM	Continue to review company diligence details.	1.40
07/12/21	KM	Review comparable company details for diligence projection.	1.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/12/21	KM	Analyze Avrio customer profitability and coop spend analysis.	1.80
07/12/21	KM	Analyze R&D vendor spend for diligence project.	0.80
07/12/21	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.30
07/12/21	ADD	Call with J. Hyun and A. DePalma (AlixPartners) re: to review and analyze vendor data.	0.80
07/12/21	ADD	Review and analyze vendor data.	2.40
07/12/21	ADD	Compile cost center mapping file using data from client's SAP centers.	2.70
07/12/21	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.30
07/12/21	CCN	Prepare analysis of the net present value of various research and development projects	1.70
07/12/21	CCN	Analyze Rhodes R&D pipeline	1.60
07/12/21	CCN	Analyze Avrio profitability by customer, brand - allocation.	1.90
07/12/21	CCN	Analyze profitability analysis and graphs.	1.90
07/12/21	CCN	Analyze Avrio brand analysis and comparison.	1.80
07/13/21	CCN	Analyze overview of IT & R&D.	1.40
07/13/21	CCN	Continue the review of customer profitability by form in the CPP analysis.	1.30
07/13/21	CCN	Continued analysis of Rhodes research and development projects.	1.50
07/13/21	CCN	Analyze medical expenses in various research and development projects.	1.60
07/13/21	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A.	1.00

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
		DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	
07/13/21	CCN	Meeting with R. Haberlin, D. Fogel, J. Carlisle, N. Davis, E. Flath (Purdue); K. McCafferty, C. Nweke, A. DePalma and J. Hyun (AlixPartners) re: due diligence game plan.	0.50
07/13/21	CCN	Meeting with E. Liesman (Purdue); K. McCafferty, C. Nweke, A. DePalma and J. Hyun (AlixPartners) re: cost center mapping.	0.30
07/13/21	CCN	Meeting with J. Lowne (Purdue); K. McCafferty and C. Nweke (AlixPartners) re: diligence project.	1.20
07/13/21	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: Avrio pricing by customer and SKU analysis.	1.00
07/13/21	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.00
07/13/21	ADD	Meeting with W. Sielert (Purdue); J. Hyun and A. DePalma (AlixPartners) re: SAP A/P data.	0.60
07/13/21	ADD	Meeting with R. Haberlin, D. Fogel, J. Carlisle, N. Davis, E. Flath (Purdue); K. McCafferty, C. Nweke, A. DePalma and J. Hyun (AlixPartners) re: due diligence game plan.	0.50
07/13/21	ADD	Meeting with E. Liesman (Purdue); K. McCafferty, C. Nweke, A. DePalma and J. Hyun (AlixPartners) re: cost center mapping.	0.30
07/13/21	ADD	Call with J. Hyun and A. DePalma (AlixPartners) re: status update on vendor analysis.	0.10
07/13/21	ADD	Review and analyze vendor data.	2.80
07/13/21	KM	Meeting with R. Haberlin, D. Fogel, J. Carlisle, N. Davis, E. Flath (Purdue); K. McCafferty, C. Nweke, A. DePalma and J. Hyun (AlixPartners) re: due diligence game plan.	0.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/13/21	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.00
07/13/21	KM	Meeting with J. Lowne (Purdue); K. McCafferty and C. Nweke (AlixPartners) re: diligence project.	1.20
07/13/21	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: Avrio pricing by customer and SKU analysis.	1.00
07/13/21	KM	Company analysis re: margin analysis for diligence project.	2.30
07/13/21	KM	Reporting re: sales analysis for diligence project.	0.80
07/13/21	KM	Analyze Medical Affairs vendors for diligence project.	0.70
07/13/21	KM	Review manufacturing operations overview.	1.80
07/13/21	ADD	Compile cost center mapping file using data from client's SAP centers.	1.60
07/13/21	KM	Meeting with E. Liesman (Purdue); K. McCafferty, C. Nweke, A. DePalma and J. Hyun (AlixPartners) re: cost center mapping.	0.30
07/13/21	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	0.50
07/13/21	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.00
07/13/21	JHH	Meeting with W. Sielert (Purdue); J. Hyun and A. DePalma (AlixPartners) re: SAP A/P data.	0.60
07/13/21	ЈНН	Meeting with R. Haberlin, D. Fogel, J. Carlisle, N. Davis, E. Flath (Purdue); K. McCafferty, C. Nweke, A. DePalma and J. Hyun (AlixPartners) re: due diligence game plan.	0.50
07/13/21	ЈНН	Meeting with E. Liesman (Purdue); K. McCafferty, C. Nweke, A. DePalma and J. Hyun (AlixPartners) re: cost	0.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
		center mapping.	
07/13/21	JHH	Call with J. Hyun and A. DePalma (AlixPartners) re: to provide status update on vendor analysis.	0.10
07/13/21	JHH	2020FY and 2021 June YTD historical sales analysis by SKU and product grouping.	1.90
07/13/21	JHH	Vendor analysis without bankruptcy / non-recurring costs: summary charts and key insights.	1.60
07/13/21	JHH	Preliminary Purdue inventory analysis by units and dollars.	1.80
07/13/21	JHH	Preparation of multiple client meetings on July 14, list of questions/clarifications and final data requests.	0.60
07/13/21	JH	Correspondence with B. Bias (Davis Polk) re potential new data for reserve.	0.20
07/13/21	JH	Correspondence with A. Tsier (White & Case) re password link.	0.20
07/13/21	JH	Correspondence with A. Guo (Davis Polk) re new user access.	0.20
07/13/21	JH	Correspondence with S. Tonnesen (OAG) re new user link.	0.50
07/13/21	JH	Correspondence with K. Arendsen (SPB) re searching reserve.	0.20
07/13/21	JH	Correspondence with A. Guo, and C. Oluwole (both Davis Polk) re re: reserve structure and notification.	0.30
07/14/21	JH	Correspondence with L. Kelleher (OAD MD) re access.	0.30
07/14/21	JH	Correspondence with A. DePalma (AlixPartners) re new productions for reserve.	0.20
07/14/21	JH	Correspondence with P. Astras (KLD) re new data for reserve.	0.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/14/21	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	0.70
07/14/21	ЈНН	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.90
07/14/21	ЈНН	Meeting with J. Carlisle (Purdue); K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: Wilson production plan and COGS vendors.	1.30
07/14/21	JHH	Meeting with R. Brown (Purdue); A. DePalma and J. Hyun (AlixPartners) re: bankruptcy costs (non-reccurring).	0.30
07/14/21	JHH	Meeting with D. McGuire, J. Carlisle (Purdue); K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: Wilson operations.	0.90
07/14/21	JHH	Meeting with D. McGuire (Purdue); K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: manufacturing overview.	1.00
07/14/21	JHH	Call with J. Hyun and A. DePalma (AlixPartners) re: to provide status update on vendor analysis.	0.20
07/14/21	JHH	Vendor summaries by all major categories without bankruptcy/non-recurring costs.	1.80
07/14/21	JHH	Mapping of company codes, cost centers and cost elements.	1.10
07/14/21	JHH	Manufacturing review: conversion cost reductions driven by plant consolidation.	1.70
07/14/21	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	1.80
07/14/21	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/14/21	KM	Meeting with J. Carlisle (Purdue); K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: Wilson production plan and COGS vendors.	1.30
07/14/21	KM	Meeting with J. Lowne (Purdue); J. DelConte, K. McCafferty and C. Nweke (AlixPartners) re: diligence project.	1.00
07/14/21	KM	Meeting with D. McGuire, J. Carlisle (Purdue); K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: Wilson operations.	0.90
07/14/21	KM	Meeting with D. McGuire (Purdue); K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: manufacturing overview.	1.00
07/14/21	KM	Analyze Wilson OEE and asset productivity.	1.90
07/14/21	KM	Analyze Inventory levels and gap analysis.	2.00
07/14/21	ADD	Meeting with J. Carlisle (Purdue); K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: Wilson production plan and COGS vendors.	1.30
07/14/21	ADD	Meeting with R. Brown (Purdue); A. DePalma and J. Hyun (AlixPartners) re: bankruptcy costs (non-reccurring).	0.30
07/14/21	ADD	Meeting with D. McGuire, J. Carlisle (Purdue); K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: Wilson operations.	0.90
07/14/21	ADD	Meeting with D. McGuire (Purdue); K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: manufacturing overview.	1.00
07/14/21	ADD	Call with J. Hyun and A. DePalma (AlixPartners) re: status update on vendor analysis.	0.20
07/14/21	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review	0.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
		project deliverables and activities.	
07/14/21	CCN	Review and analyze Rhodes pipeline timelines and spend.	1.90
07/14/21	CCN	Continue analysis of product profitability by customer for Rhodes.	1.50
07/14/21	CCN	Analyze product profitability by customer for Rhodes.	1.80
07/14/21	CCN	Analyze Rhodes research and development net present value analyses by project.	1.70
07/14/21	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.90
07/14/21	CCN	Meeting with J. Lowne (Purdue); J. DelConte, K. McCafferty and C. Nweke (AlixPartners) re: diligence project.	1.00
07/15/21	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.40
07/15/21	CCN	Meeting with T. Au (Purdue); A. DePalma, C. Nweke and J. Hyun (AlixPartners) re: Opioid claims processing vendors.	0.40
07/15/21	CCN	Meeting with N. Davis (Purdue); K. McCafferty, and C. Nweke (both AlixPartners) re: Rhodes product pipeline valuation.	1.00
07/15/21	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: Rhodes pipeline analysis and sldies for weekly update.	1.90
07/15/21	CCN	Avrio customer and product profitability data review for diligence project.	1.60
07/15/21	CCN	Conduct IT diligence interviews and update analysis.	1.70
07/15/21	ADD	Compile and analyze company performance.	2.70
07/15/21	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A.	1.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
		DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	
07/15/21	ADD	Meeting with T. Au (Purdue); A. DePalma, C. Nweke and J. Hyun (AlixPartners) re: Opioid claims processing vendors.	0.40
07/15/21	ADD	Call with J. Hyun and A. DePalma (AlixPartners) re: to review inventory analysis.	0.40
07/15/21	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.40
07/15/21	KM	Meeting with N. Davis (Purdue); K. McCafferty, and C. Nweke (both AlixPartners) re: Rhodes product pipeline valuation.	1.00
07/15/21	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: Rhodes pipeline analysis and slides for weekly update.	1.90
07/15/21	KM	Presentation and reporting re: manufacturing overview for diligence project.	2.30
07/15/21	KM	Presentation and reporting re: product profitability for diligence project.	1.10
07/15/21	KM	Analyze performance data for diligence project.	1.80
07/15/21	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	0.20
07/15/21	JG	Update reserve data sets in preparation of launch at request of C. Oluwole (Davis Polk).	1.60
07/15/21	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.40
07/15/21	JHH	Meeting with T. Au (Purdue); A. DePalma, C. Nweke and J. Hyun (AlixPartners) re: Opioid claims processing	0.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services vendors.	Hours
07/15/21	JHH	Call with J. Hyun and A. DePalma (AlixPartners) re: to review inventory analysis.	0.40
07/15/21	JHH	Monthly sales analysis by SKU and by sales units.	1.30
07/15/21	JHH	Monthly sales analysis by SKU and by sales dollars, gross and net.	1.60
07/15/21	JHH	Month to month sales trends and fluctuations for proper inventory considerations.	1.30
07/15/21	JHH	Purdue inventory analysis: obsolescence risk and potential shortages by SKU.	1.90
07/15/21	JHH	Preparation for weekly update discussion with client on July 16.	0.70
07/15/21	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	0.20
07/15/21	JH	Correspondence with L. Readinger (Potter Anderson) re updated reporting.	0.80
07/15/21	JH	Correspondence with P. Astras (KLD) re new data for reserve.	0.10
07/15/21	JH	Correspondence with M. O'Neil (Taft) re access.	0.20
07/16/21	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	0.40
07/16/21	JHH	Meeting with J. Lowne (Purdue); K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence project weekly stand-up meeting.	0.90
07/16/21	ЈНН	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.50
07/16/21	JHH	Call with S. Vangavolu, N. Janysek, K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: vendor review.	1.00

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

	Date	Consultant	Description of Services	Hours
	07/16/21	JHH	Call with J. Hyun and A. DePalma (AlixPartners) re: to review updated inventory analysis.	0.30
	07/16/21	JHH	Manufacturing overview summary.	1.80
	07/16/21	JHH	Process bottleneck (packaging line) overview with current shift patterns.	1.20
	07/16/21	JHH	Accounts payable data review by vendors and spend categories.	1.10
	07/16/21	JHH	Preliminary inventory savings potentials for Purdue managed finished goods.	1.90
	07/16/21	JG	Update reserve data sets in preparation of launch at request of C. Oluwole (Davis Polk).	1.70
	07/16/21	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	0.50
	07/16/21	KM	Slide preparation re: diligence project stand-up meeting with J. Lowne.	0.80
	07/16/21	KM	Meeting with J. Lowne (Purdue); K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence project weekly stand-up meeting.	0.90
	07/16/21	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.50
	07/16/21	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: Rhodes pipeline NPV analysis and slippage.	0.80
	07/16/21	KM	Call with S. Vangavolu, N. Janysek, K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: vendor analysis.	1.00
	07/16/21	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: pipeline NPV breakdown.	0.50
	07/16/21	KM	Report creation re: company overview.	1.70
	07/16/21	KM	Analyze Rhodes pipeline value and performance.	1.50
4	C	T 24 4 6 4 7 7 5		

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/16/21	ADD	Call with J. Hyun and A. DePalma (AlixPartners) re: to review updated inventory analysis.	0.30
07/16/21	ADD	Meeting with J. Lowne (Purdue); K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence project weekly stand-up meeting.	0.90
07/16/21	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.50
07/16/21	ADD	Call with S. Vangavolu, N. Janysek, K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: vendor analysis.	1.00
07/16/21	CCN	Continue to work on customer and product profitability analysis by customer.	1.90
07/16/21	CCN	Review change in NPVs due to slippage in research and development projects.	1.70
07/16/21	CCN	Analyze Rhodes profitability by customer and product.	1.80
07/16/21	CCN	Meeting with J. Lowne (Purdue); K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence project weekly stand-up meeting.	0.90
07/16/21	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.50
07/16/21	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: Rhodes pipeline NPV analysis and slippage.	0.80
07/16/21	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: pipeline NPV breakdown.	0.50
07/16/21	NPJ	Call with S. Vangavolu, N. Janysek, K. McCafferty, A. DePalma and J. Hyun (AlixPartners) re: third party spend opportunity.	1.00
07/16/21	NPJ	Researching 3rd party spend suppliers.	0.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/19/21	NPJ	Review suppliers for Purdue and estimated type of work performed for categorization and savings benchmarking.	3.20
07/19/21	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.70
07/19/21	CCN	Meeting with J. Ducharme (Purdue); K. McCafferty and C. Nweke (AlixPartners) re: R&D diligence discussion.	1.00
07/19/21	CCN	Diligence data re: Avrio customers and brand, sales and margins data.	1.90
07/19/21	CCN	Analyze Avrio profitability by customer /brand	1.80
07/19/21	CCN	Avrio customer and product profitability analysis and slide creation.	1.80
07/19/21	CCN	Analyze Avrio vendor data.	1.70
07/19/21	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.70
07/19/21	KM	Meeting with J. Ducharme (Purdue); K. McCafferty and C. Nweke (AlixPartners) re: R&D diligence discussion and opportunity review.	1.00
07/19/21	KM	Analyze company overview for diligence project.	2.20
07/19/21	KM	Analyze R&D and Medical Affairs vendors.	2.40
07/19/21	KM	Analyze Rhodes Pharma product pipeline for diligence project.	1.80
07/19/21	KM	Analyze vendor details for diligence project.	1.70
07/19/21	KM	Prepare slides and visualization re: R&D and Medical overviews.	2.00
07/19/21	ADD	Review diligence project action items and compile necessary data.	0.80

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/19/21	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.70
07/19/21	ADD	Review and analyze new vendor data and incorporate it into the model.	2.20
07/19/21	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.70
07/19/21	JHH	Call with J. Hyun and A. DePalma (AlixPartners) re: to review and analyze vendor data.	0.40
07/19/21	JHH	Categories for vendor data analyses.	1.60
07/19/21	JHH	Vendor data analyses and summary for client review and feedback.	1.90
07/19/21	JHH	Comparison of Accounts Payable data to SAP download for 2020.	1.30
07/19/21	JHH	Incorporation of departments derived from cost centers into spend cube and summaries.	0.90
07/19/21	JHH	Update of vendor summaries to reflect latest spend cube.	1.80
07/19/21	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	0.40
07/20/21	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.30
07/20/21	JHH	Call with N. Janysek, J. Hyun and A. DePalma (AlixPartners) re: vendor overview by category.	0.70
07/20/21	JHH	Call with J. Hyun and A. DePalma (AlixPartners) re: to review and analyze vendor data.	0.50
07/20/21	JHH	Summary of vendor data based on discussion with internal pharma procurement expert.	1.40

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/20/21	JHH	Preparation for client reviews: key points, questions and clarifications.	0.60
07/20/21	JHH	Review of operations data and monthly reports to provide comprehensive manufacturing overview.	1.90
07/20/21	JHH	Review of Purdue Pharma inventory information by material type and SKU.	1.80
07/20/21	JHH	Review of Rhodes Pharma inventory information by material type - SKU detail not yet provided.	1.60
07/20/21	ADD	Review manufacturing operation overview.	2.70
07/20/21	ADD	Review and update vendor analysis to reflect updated data.	2.40
07/20/21	ADD	Call with J. Hyun and A. DePalma (AlixPartners) re: to review and analyze vendor data.	0.50
07/20/21	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.30
07/20/21	ADD	Call with N. Janysek, J. Hyun and A. DePalma (AlixPartners) re: vendor overview by category.	0.70
07/20/21	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.30
07/20/21	KM	Meeting with H. Ghnaimeh (Purdue); K. McCafferty and C. Nweke (AlixPartners) re: IT overview and reporting responsibilities.	0.70
07/20/21	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: Avrio CPP analysis for diligence.	0.80
07/20/21	KM	Meeting with V. Mancinelli, D. Fogel (both Purdue); K. McCafferty and C. Nweke (both AlixPartners) re: Rhodes Pharma P&L and pipeline interview and discussion.	1.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/20/21	KM	Review IT vendor details.	2.20
07/20/21	KM	Analyze Avrio profitability by brand and customer.	1.50
07/20/21	KM	Prepare slides and visualities re: IT overview.	0.80
07/20/21	KM	Prepare slides and visualition re: Rhodes Pharma pipeline.	0.60
07/20/21	CCN	CPP analysis re: Avrio product profitability by customer.	1.90
07/20/21	CCN	CPP analysis re: Rhodes product profitability by customer.	1.90
07/20/21	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.30
07/20/21	CCN	CPP analysis re: Avrio customer profitability by form.	1.80
07/20/21	CCN	Meeting with H. Ghnaimeh (Purdue); K. McCafferty and C. Nweke (AlixPartners) re: IT overview.	0.70
07/20/21	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: Avrio CPP analysis for diligence.	0.80
07/20/21	CCN	Meeting with V. Mancinelli, D. Fogel (both Purdue); K. McCafferty and C. Nweke (both AlixPartners) re: Rhodes Pharma P&L and pipeline interview and discussion.	1.30
07/20/21	NPJ	Review suppliers for Purdue and estimated type of work performed for categorization and savings benchmarking.	3.80
07/20/21	NPJ	Call with N. Janysek, J. Hyun and A. DePalma (AlixPartners) re: Purdue Third Party Spend potential savings estimates by category.	0.70
07/21/21	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.90
07/21/21	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: Rhodes Pharma CPP analysis for diligence.	0.80
07/21/21	CCN	Update analysis of Rhodes pipeline asset NPVs.	1.90

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/21/21	CCN	R&D analysis re: Rhodes current and plan of emergence analysis.	1.80
07/21/21	CCN	Continue building analysis of Rhodes research and development pipeline.	1.80
07/21/21	CCN	CPP analysis re: Rhodes customer profitability by form.	1.80
07/21/21	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.90
07/21/21	ADD	Reconcile data provided by the client to the general ledger.	2.40
07/21/21	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.90
07/21/21	ADD	Meeting with J. Carlisle (Purdue): J. Hyun and A. DePalma (AlixPartners) re: vendor analysis to gather client feedback.	1.00
07/21/21	ADD	Call with J. Hyun and A. DePalma (AlixPartners) re: review and analyze vendor data.	0.20
07/21/21	ADD	Call with J. Hyun and A. DePalma (AlixPartners) re: to review and analyze manufacturing data.	0.60
07/21/21	ADD	Review and analyze new vendor data and incorporate it into the model.	2.70
07/21/21	KM	Continue analysis of manufacturing operational structure.	1.00
07/21/21	KM	Meeting with J. Lowne (Purdue); J. DelConte and K. McCafferty (AlixPartners) re: 2022 planning.	0.50
07/21/21	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: Rhodes Pharma CPP analysis for diligence.	0.80
07/21/21	KM	Review 2022 budgeting assumptions.	2.40
07/21/21	KM	Prepare slides re: 2022 budgeting assumptions and	1.10

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services planning.	Hours
07/21/21	KM	Prepare overview deck re: diligence project.	1.20
07/21/21	KM	Analyze Rhodes Pharma pipeline NPV and discount rates for diligence project.	2.30
07/21/21	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.90
07/21/21	ЈНН	Meeting with J. Carlisle (Purdue): J. Hyun and A. DePalma (AlixPartners) re: vendor analysis to gather client feedback.	1.00
07/21/21	JHH	Call with J. Hyun and A. DePalma (AlixPartners) re: to review and analyze vendor data.	0.20
07/21/21	JHH	Review manufacturing operations.	1.70
07/21/21	JHH	Modifications to vendor analysis based on client feedback.	0.30
07/21/21	JHH	Monthly sales / demand evaluation by SKU and product groups.	1.80
07/21/21	JHH	Month on hand assessment of finished goods inventory at Purdue, including purchased items.	1.30
07/21/21	JHH	Month on hand assessment and graphical summary of finished goods inventory at Rhodes, including purchased items.	1.20
07/21/21	JH	Correspondence with J. Chen (Davis Polk) re updated report.	0.20
07/21/21	JHH	Call with J. Hyun and A. DePalma (AlixPartners) re: to review and analyze manufacturing data.	0.60
07/21/21	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	0.90
07/21/21	JCH	Correspondence with J. Hardy (AlixPartners) and T. O'Neill (WA Attorney General) re reserve access.	0.10

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/22/21	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	0.40
07/22/21	JH	Correspondence with A. DePalma (AlixPartners) re search functionality.	0.10
07/22/21	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.30
07/22/21	ЈНН	Meeting with S. Daniel (Purdue): J. Hyun and A. DePalma (AlixPartners) re: vendor analysis to gather client feedback.	0.60
07/22/21	JHH	Call with J. Hyun and A. DePalma (AlixPartners) re: diligence project.	0.50
07/22/21	JHH	Modifications to vendor analysis based on client feedback.	0.20
07/22/21	JHH	Overall inventory analysis by material type and SKU where available.	1.80
07/22/21	JHH	Sales data clean-up for roll-up and SKU level deviations from month to month.	1.70
07/22/21	JHH	SKU sales velocity vs. month-to-month sales deviation chart.	1.90
07/22/21	JHH	Month on Hand chart by Purdue SKUs by product groups.	1.80
07/22/21	JHH	Weekly client update meeting preparation.	0.40
07/22/21	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.30
07/22/21	KM	Call with S. Daniel, S. Daniel (Purdue); K. McCafferty and C. Nweke (AlixPartners) re: Purdue discussion around CRO cost and what is base business (e.g. in DSP) vs non-recurrent cost.	0.50
07/22/21	KM	Call with V. Mancinelli, D. Fogel (Purdue); K. McCafferty	1.00

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
		and C. Nweke (both AlixPartners) re: Rhodes pharma CPP and revenue analysis review and update.	
07/22/21	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: Avrio CPP analysis and improvement opportunities.	1.60
07/22/21	KM	Analyze Rhodes Pharma pipeline projects and costs.	2.60
07/22/21	KM	Prepare slides re: Rhodes Pharma pipeline projects and costs.	1.20
07/22/21	KM	Analysis review re: Rhodes customer and product profitability.	1.90
07/22/21	KM	Analyze Avrio profitability overview.	1.90
07/22/21	ADD	Reconcile data provided by the client to the general ledger.	1.90
07/22/21	ADD	Update diligence project presentation slides to reflect updated analysis.	1.80
07/22/21	ADD	Analyze manufacturing processes.	1.80
07/22/21	ADD	Review and analyze new vendor data and incorporate it into the model.	1.70
07/22/21	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.30
07/22/21	ADD	Call with J. Hyun and A. DePalma (AlixPartners) re: review company details.	0.50
07/22/21	ADD	Meeting with S. Daniel (Purdue): J. Hyun and A. DePalma (AlixPartners) re: vendor analysis to gather client feedback.	0.60
07/22/21	CCN	Analyze Rhodes R&D pipeline	1.90
07/22/21	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/22/21	CCN	Call with V. Mancinelli, D. Fogel (Purdue); K. McCafferty and C. Nweke (both AlixPartners) re: Rhodes pharma CPP and revenue analysis review and update.	1.00
07/22/21	CCN	Call with S. Daniel, and S. Daniel (Purdue); K. McCafferty and C. Nweke (AlixPartners) re: Purdue discussion around CRO cost and what is base business (e.g. in DSP) vs non-recurrent cost.	0.50
07/22/21	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: Avrio CPP analysis and improvement opportunities.	1.60
07/22/21	CCN	Analyze Rhodes R&D NPV	1.80
07/22/21	CCN	Rhodes CPP analysis re: product profitability by customer.	1.70
07/23/21	CCN	Update Avrio customer and product profitability analysis focused on various customers.	1.90
07/23/21	CCN	Update Rhodes customer and product profitability analysis focused on various customers.	1.10
07/23/21	CCN	Update Avrio customer and product profitability analysis based on product form.	1.80
07/23/21	CCN	Update Rhodes customer and product profitability analysis based on product form.	1.70
07/23/21	CCN	Meeting with J. Lowne (Purdue); K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence project weekly stand-up meeting.	1.10
07/23/21	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.50
07/23/21	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: Rhodes R&D pipeline NPV analysis.	1.00
07/23/21	ADD	Meeting with J. Lowne (Purdue); K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence	1.10

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
		project weekly stand-up meeting.	
07/23/21	ADD	Review draft slides to include in the final presentation.	0.30
07/23/21	ADD	Call with J. Hyun and A. DePalma (AlixPartners) re: to align on remaining tasks for project closure.	0.50
07/23/21	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.50
07/23/21	ADD	Prepare overview of manufacturing operations.	2.20
07/23/21	ADD	Update diligence project presentation slides to reflect updated overview.	1.70
07/23/21	ADD	Review and update vendor analysis to reflect updated data.	2.50
07/23/21	KM	Meeting with J. Lowne (Purdue); K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence project weekly stand-up meeting.	1.10
07/23/21	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.50
07/23/21	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: Rhodes R&D pipeline NPV analysis.	1.00
07/23/21	KM	Presentation and reporting re: diligence project flash report.	1.20
07/23/21	KM	Analyze Rhodes pipeline valuation.	2.40
07/23/21	KM	Prepare company overview for diligence project.	2.10
07/23/21	KM	Continue preparing company overview for diligence project.	0.90
07/23/21	JHH	Meeting with J. Lowne (Purdue); K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: diligence project weekly stand-up meeting.	1.10

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/23/21	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.50
07/23/21	JHH	Call with J. Hyun and A. DePalma (AlixPartners) re: to align on remaining tasks for project closure.	0.50
07/23/21	JHH	Modifications to vendor analysis based on client feedback.	0.40
07/23/21	JHH	Operational overview re: SIOP (Sales, Inventory and Operations Planning).	1.90
07/23/21	JHH	Manufacturing section executive summary - draft version.	1.20
07/23/21	JHH	Review Betadine rationalization plan.	0.70
07/23/21	JHH	Revision of potential inventory reduction assessment.	1.90
07/23/21	JH	Correspondence with A. Guo (Davis Polk) re new user access.	0.10
07/23/21	JH	Correspondence with R. Tuchman (KKWC) re volume encryption.	0.40
07/26/21	JH	Correspondence with L. Readinger (Potter) re user access.	0.20
07/26/21	JHH	Meeting with J. Carlisle, D. Fogel (Purdue); J. Hyun and A. DePalma (AlixPartners) re: inventory opportunities at Purdue and Rhodes pharma.	1.20
07/26/21	JHH	Incorporation of feedback re: month on hand inventory for Rhodes pharma product groups and SKUs.	1.70
07/26/21	JHH	Incorporation of feedback re: month on hand inventory for Purdue product groups and SKUs.	1.40
07/26/21	JHH	Finalization of vendor data section with updated figures.	1.60
07/26/21	JHH	Monthly sales trend assessment completion.	1.80
07/26/21	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review	1.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services project deliverables and activities.	Hours
07/26/21	JCH	Update reserve data sets at request of C. Oluwole (Davis Polk).	0.50
07/26/21	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.20
07/26/21	KM	Call with D. Fogel, J. Carlisle (Purdue) re: Rhodes overview for diligence project.	1.20
07/26/21	KM	Call with K. McCafferty and C. Nweke (AlixPartners) re: CPP analysis for Rhodes Pharma and Avrio for diligence project.	2.90
07/26/21	KM	Summarize company details for diligence project.	2.40
07/26/21	KM	Prepare slides re: Avrio CPP review and assessment.	1.80
07/26/21	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.20
07/26/21	ADD	Meeting with J. Carlisle, D. Fogel (Purdue); J. Hyun and A. DePalma (AlixPartners) re: inventory opportunities at Purdue and Rhodes pharma.	1.20
07/26/21	CCN	Review diligence data re: Avrio customers, sales and margins data.	1.90
07/26/21	CCN	Revise Avrio analysis of customer profitability.	1.80
07/26/21	CCN	Call with K. McCafferty and C. Nweke (AlixPartners) re: CPP analysis for Rhodes Pharma and Avrio for diligence project.	2.90
07/26/21	CCN	Continue working on Rhodes product profitability breakdowns.	1.90
07/26/21	CCN	Revise slides for Rhodes research and development analysis.	1.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/26/21	CCN	Update Avrio customer and product profitability analysis based on brand allocations.	1.50
07/26/21	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.20
07/27/21	CCN	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.60
07/27/21	CCN	Meeting with T. Garvey, J. Tran (Purdue); K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: Avrio CPP analysis.	1.10
07/27/21	CCN	Update analysis for Rhodes customer profitability.	1.90
07/27/21	CCN	Continue work on Avrio customer profitability analysis.	1.90
07/27/21	CCN	Analyze Rhodes R&D pipeline	1.80
07/27/21	CCN	Update slides for Rhodes customer profitability.	1.90
07/27/21	ADD	Call with J. Hyun and A. DePalma (AlixPartners) re: vendor data status discussion.	0.30
07/27/21	ADD	Meeting with P. Shafer, S. Bingham, G. Baron, A. Johnson (FTI); K. McCafferty, J. Hyun and A. DePalma (AlixPartners) re: vendor analysis and spend cube.	1.20
07/27/21	ADD	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.60
07/27/21	ADD	Meeting with T. Garvey, J. Tran (Purdue); K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: Avrio CPP analysis.	1.10
07/27/21	KM	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.60

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/27/21	KM	Meeting with P. Shafer, S. Bingham, G. Baron, A. Johnson (FTI); K. McCafferty, J. Hyun and A. DePalma (AlixPartners) re: vendor data and spend cube.	1.20
07/27/21	KM	Meeting with T. Garvey, J. Tran (Purdue); K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: Avrio CPP analysis.	1.10
07/27/21	KM	Analyze Rhodes product pipeline for diligence project.	1.50
07/27/21	KM	Slide and analysis prep re: diligence project discussion with FTI.	2.20
07/27/21	KM	Analyze company overview diligence materials.	0.70
07/27/21	JHH	Call with K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	0.60
07/27/21	JHH	Call with J. Hyun and A. DePalma (AlixPartners) re: vendor data discussion.	0.30
07/27/21	JHH	Meeting #1 with P. Shafer, S. Bingham, G. Baron, A. Johnson (FTI); K. McCafferty, J. Hyun and A. DePalma (AlixPartners) re: vendor data and spend cube.	1.20
07/27/21	JHH	Meeting with T. Garvey, J. Tran (Purdue); K. McCafferty, J. Hyun, C. Nweke and A. DePalma (AlixPartners) re: Avrio CPP analysis.	1.10
07/27/21	JHH	Separation of Avrio products from various charts: MOH and sales velocity vs variation.	0.60
07/27/21	JHH	Review of company diligence materials.	1.70
07/27/21	JHH	Review of company diligence materials (continued).	1.80
07/27/21	JHH	Create write-up and presentation slides for the diligence project.	1.90
07/27/21	JH	Correspondence with L. Readinger (Potter) re reporting.	0.20
07/27/21	JH	Correspondence with A. Guo (Davis Polk) re user access.	0.30
1 Codar Springs I	Poad T 214 647 7	500	

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/27/21	JH	Correspondence with K. Giampaolo (Milbank) re new data for reserve.	0.20
07/27/21	JH	Correspondence with C. Oluwole and D. Consla (both Davis Polk) re reserve reporting.	0.90
07/28/21	JH	Update data sets in reserve at request of K. Giampaolo (Milbank).	0.40
07/28/21	JH	Update data sets in reserve at request of C. Oluwole (Davis Polk).	0.60
07/28/21	ЈНН	Call with K. McCafferty, J. Hyun and C. Nweke (AlixPartners) re: morning meeting to review project deliverables and activities.	1.00
07/28/21	JHH	Revision of average monthly sales vs variation analysis and charts.	1.80
07/28/21	JHH	Compare MOH vs margin and gross sales for Avrio product groups.	1.70
07/28/21	JHH	Revision of company overview presentation slides.	1.40
07/28/21	JHH	Finalize manufacturing operational overview.	1.50
07/28/21	JHH	Manufacturing, packaging and distribution/supply chain analyses.	1.40
07/28/21	KM	Call with K. McCafferty, J. Hyun and C. Nweke (AlixPartners) re: morning meeting to review project deliverables and activities.	1.00
07/28/21	KM	Analysis and slide preparation re: Avrio CPP for diligence project.	1.90
07/28/21	KM	Analysis and slide preparation re: Rhodes CPP for diligence project.	2.10
07/28/21	KM	Analyze G&A details.	1.90
07/28/21	KM	Research and analysis re: pharma benchmarking.	2.30

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/28/21	CCN	Call with K. McCafferty, J. Hyun and C. Nweke (AlixPartners) re: morning meeting to review project deliverables and activities.	1.00
07/29/21	KM	Call with K. McCafferty, J. Hyun and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.60
07/29/21	KM	Presentation and reporting re: company overview for diligence project.	2.30
07/29/21	KM	Analyze company comparables for diligence project.	1.90
07/29/21	KM	Presentation and reporting re: product profitability for Rhodes Pharma.	1.30
07/29/21	KM	Presentation and reporting re: company overview for CEO/CFO meeting.	2.10
07/29/21	ADD	Call with K. McCafferty, J. Hyun and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.60
07/29/21	JHH	Call with K. McCafferty, J. Hyun and A. DePalma (AlixPartners) re: morning meeting to review project deliverables and activities.	1.60
07/29/21	JHH	Review of Wilson plant operations data and performance.	1.70
07/29/21	JHH	2020 actuals and 2021 budget volumes and expenses for Wilson plant.	0.90
07/29/21	JHH	Labor and overhead cost trend and resulting conversion cost per tablet.	1.30
07/29/21	JHH	Wilson plant summary and overview.	1.80
07/29/21	JHH	Distribution and supply chain related overviews.	1.50
07/30/21	JHH	Meeting with J. Lowne (Purdue); J. DelConte, K. McCafferty and J. Hyun (AlixPartners) re: diligence project weekly stand-up meeting.	0.80

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Date	Consultant	Description of Services	Hours
07/30/21	JHH	Call with K. McCafferty and J. Hyun (both AlixPartners) re: morning meeting to review project deliverables and activities.	0.70
07/30/21	JHH	Meeting with C. Landau, J. Lowne and M. Kesselman (Purdue); J. DelConte, K. McCafferty and J. Hyun (AlixPartners) re: review of draft diligence project.	0.90
07/30/21	JHH	Meeting with P. Shafer, G. Baron, A. Johnson (FTI); K. McCafferty and J. Hyun (AlixPartners) re: Avrio CPP.	1.10
07/30/21	JHH	Distribution and supply chain overview analyses.	1.70
07/30/21	JHH	Draft of manufacturing section executive summary.	1.90
07/30/21	JHH	Continue working on the manufacturing section overview.	1.80
07/30/21	JH	Correspondence with C. Oluwole (Davis Polk) and L. Readinger (Potter) re new user access.	0.20
07/30/21	KM	Meeting with J. Lowne (Purdue); J. DelConte, K. McCafferty and J. Hyun (AlixPartners) re: diligence project weekly stand-up meeting.	0.80
07/30/21	KM	Call with K. McCafferty and J. Hyun (both AlixPartners) re: morning meeting to review project deliverables and activities.	0.70
07/30/21	KM	Meeting with C. Landau, J. Lowne and M. Kesselman (Purdue); J. DelConte, K. McCafferty and J. Hyun (AlixPartners) re: diligence project.	0.90
07/30/21	KM	Meeting with P. Shafer, G. Baron, A. Johnson (FTI); K. McCafferty and J. Hyun (AlixPartners) re: Avrio CPP.	1.10
07/30/21	KM	Create company overview slides for diligence project.	2.70
07/30/21	KM	Slide and analysis prep re: diligence review with FTI.	1.70
		Total	665.70

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice #

2138238-2

Special Projects 012589.00110

Client/Matter #

Consultant	Hours	Rate	Amount
Julia Caitlin Hardy	8.70	530.00	4,611.00
Andrew D DePalma	105.10	625.00	65,687.50
Julia Gutierrez	6.00	625.00	3,750.00
Charles C Nweke	163.50	650.00	106,275.00
Jamey Hamilton	14.20	865.00	12,283.00
Nate P Janysek	9.20	865.00	7,958.00
Joon H Hyun	173.90	980.00	170,422.00
Kevin M McCafferty	185.10	980.00	181,398.00
Total Hours & Fees	665.70	_	552,384.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Fee Statements and Fee Applications Re:

Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
07/01/21	JD	Review final draft May fee application to be filed with the court.	0.30
07/01/21	ТВ	Update monthly fee statement and exhibits for May 2021 per J. DelConte (AlixPartners).	0.30
07/02/21	ТВ	Update twenty-first monthly fee statement and exhibits per the request of J. Hamilton (AlixPartners)	0.60
07/06/21	LMB	Update fee application summary status chart	0.50
07/06/21	TB	Update May monthly fee statement.	0.20
07/06/21	JD	Review updated May fee statement	0.20
07/08/21	LMB	Prepare Fifth Interim Fee Application	3.80
07/08/21	LMB	Prepare schedules to Fifth Interim Fee Application	1.20
07/09/21	LMB	Prepare fifth interim fee application, supporting exhibits and schedules	2.20
07/09/21	LMB	Prepare professional fees for June 2021 monthly fee statement	1.00
07/09/21	JD	Begin review of 5th interim fee application to be filed with the court.	0.50
07/12/21	LMB	Prepare professional fees for June 2021 monthly fee statement	3.00
07/12/21	LMB	Continue to prepare professional fees for June 2021 monthly fee statement	2.80
07/13/21	LMB	Prepare professional fees for June 2021 monthly fee statement	2.50
07/13/21	LMB	Emails to/from C. Nweke (AlixPartners) re: June 2021 professional fees	0.20
07/14/21	LMB	Revise fifth interim fee application and compile exhibits	1.20
07/14/21	JD	Finalize review and edit of 5th interim fee application to be filed with the court.	2.20

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Fee Statements and Fee Applications Re:

Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
07/15/21	JD	Call with E. Kardos, H. Saydah, L. Bonito, J. DelConte (all AlixPartners) re: 5th interim fee application.	0.30
07/15/21	LMB	Prepare professional fees for June 2021 monthly fee statement	3.10
07/15/21	LMB	Call with E. Kardos, L. Bonito, J. DelConte (all AlixPartners) re: 5th interim fee application.	0.30
07/16/21	LMB	Email to M. Pera (Davis Polk) attaching the fifth interim fee application for filing on the Court docket	0.20
07/16/21	LMB	Finalize fifth interim fee application	0.80
07/21/21	LMB	Prepare professional fees for June 2021 monthly fee statement	1.80
07/22/21	LMB	Prepare professional fees for June 2021 monthly fee statement	3.20
07/23/21	LMB	Prepare professional fees for June 2021 monthly fee statement	1.30
07/27/21	JD	Continue review of draft June fee application to be filed with the court.	2.00
07/27/21	JD	Begin review of draft June fee application.	2.50
07/28/21	JD	Finalize review of draft June fee application.	1.70
07/28/21	LMB	Prepare professional fees for June 2021 monthly fee statement	1.70
07/29/21	LMB	Prepare professional fees for June 2021 monthly fee statement	1.50
07/30/21	JD	Review latest draft version of the June fee application to be filed with the court.	0.40
		Total	43.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Fee Statements and Fee Applications Re:

Client/Matter # 012589.00113

Consultant	Hours	Rate	Amount
Tammy Brewer	1.10	465.00	511.50
Lisa Marie Bonito	32.30	465.00	15,019.50
Jesse DelConte	10.10	1,055.00	10,655.50
Total Hours & Fees	43.50	_	26,186.50

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Court Hearings Re: Client/Matter # 012589.00114

Date	Consultant	Description of Services		Hours
07/29/21	JD	Participate in court hearing re: KEIP/KERP.		2.00
07/29/21	HSB	Attended Purdue Ch11 b/k court hearing re: Kerp		2.00
			Total	4.00

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Court Hearings Client/Matter # 012589.00114

Consultant	Hours	Rate	Amount
HS Bhattal	2.00	865.00	1,730.00
Jesse DelConte	2.00	1,055.00	2,110.00
Total Hours & Fees	4.00		3,840.00

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Forensic Analysis Re: Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
07/02/21	MFR	Review of Rule Expert Report, Report 1B and supporting documents in preparation for deposition and/or confirmation hearing testimony.	2.90
07/06/21	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for deposition and/or confirmation hearing testimony.	3.20
07/07/21	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for deposition and/or confirmation hearing testimony.	2.90
07/08/21	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for deposition and/or confirmation hearing testimony.	3.10
07/09/21	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for deposition and/or confirmation hearing testimony.	3.30
07/12/21	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for deposition and/or confirmation hearing testimony.	3.00
07/13/21	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for deposition and/or confirmation hearing testimony.	2.80
07/13/21	MFR	Preparation for call with Davis Polk on the Rule Report and Collura Report and pending confirmation hearing testimony.	2.40
07/14/21	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for deposition and/or confirmation hearing testimony.	3.30
07/15/21	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for deposition and/or confirmation hearing testimony.	3.10

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Forensic Analysis Re: Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
07/16/21	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for confirmation hearing testimony.	3.40
07/19/21	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for confirmation hearing testimony.	2.80
07/20/21	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for confirmation hearing testimony.	2.40
07/21/21	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for confirmation hearing testimony.	2.90
07/22/21	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for confirmation hearing testimony.	3.00
07/23/21	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for confirmation hearing testimony.	2.60
07/26/21	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for confirmation hearing testimony.	2.80
07/27/21	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for confirmation hearing testimony.	3.10
07/28/21	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for confirmation hearing testimony.	2.70
07/29/21	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for confirmation hearing testimony.	2.80

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Forensic Analysis Re: Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
07/30/21	MFR	Review of Rule Expert Report, Report 1B and supporting documents/materials/analyses in preparation for confirmation hearing testimony.	3.10
		Total	61.60

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2138238-2

Forensic Analysis Client/Matter # 012589.00115

Consultant	Hours	Rate	Amount
Mark F Rule	61.60	980.00	60,368.00
Total Hours & Fees	61.60		60,368.00

Exhibit B

AlixPartners, LLP

Summary and Detailed Description of AlixPartners' Expenses

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel **Rhodes Technologies** Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice # 2137966-2

Data Processing Fees Re:

Client/Matter # 012589.Other

Date	Disbursement Description		Amount
07/31/21	Hosting Fees (GB)		64,512.00
		Total Disbursements	64,512.00

Mr. Jon Lowne Chief Financial Officer Purdue Pharma L.P. One Stamford Forum 201 Tresser Boulevard Stamford, CT 06901-3431

Mr. James P. Doyle Vice President & General Counsel Rhodes Technologies Rhodes Pharmaceuticals L.P. 498 Washington Street Coventry, RI 02816

Invoice #

2137966-2

Re:

Processing & Hosting

Client/Matter #

012589.01004

Disbursement Recap:

Description Amount Hosting Fees (GB) 64,512.00

Total Disbursements 64,512.00